World Patents in Skin Care Actives Published in 2011
WORLD PATENTS IN ACTIVES FOR SKIN CARE GRANTED IN  2011
This list includes patent documents published by the World Intellectual Property Organization (WIPO). The list was retrieved by searching the claims section of all patent applications
published. Salient search terms include skin care active ingredients having properties such as anti-ageing, anti-wrinkle, antioxidant, acne control benefits, skin whitening or lightening,
blemish removal, etc. This category includes technology related to the synthesis and delivery of actives such as peptides, exfoliants, α-hydroxy acids, herbals, free radical scavenger, "green"
derived molecules, etc.

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

PCT - WORLD PATENTS IN SKIN CARE ACTIVES PUBLISHED IN 2011



Publication No.: WO2011000218A1  Published: 06/Jan/2011

Title: COMPOSITIONS CONTAINING BERBERINE OR ANALOGS THEREOF FOR TREATING ROSACEA OR RED FACE RELATED SKIN DISORDERS

Applicant/Assignee:

Application No.: CN2010/000983   Filing Date: 30/Jun/2010

Abstract:The present invention discloses topical pharmaceutical formulations of berberine and its biologically equivalent analogues, such as palmatine and coptisine, for the treatment of rosacea and other red face-related skin disorders. The topical pharmaceutical formulations of this invention contain purified berberine as the primary active drug ingredient at concentrations higher than 0.1%. The invention also discloses methods of treating rosacea and other red face related skin disorders, such as steroid-induced rosacea-like dermatitis, comprising the administration of topical pharmaceutical formulations that contain berberine or its biologically equivalent analogues, such as palmatine.

Priority: US20090221725P Applic. Date: 2009-06-30

Inventor: HUANG SHUEN-LU [CN]; CHUNG WEN-HUNG [CN]; CHANG TSE-WEN [CN]


Publication No.: WO2011000765A1  Published: 06/Jan/2011

Title: NEW MEDICAL USE

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: EP2010/058979   Filing Date: 24/Jun/2010

Abstract:The prepsent invention relates to 3-(4-{[4-(4-{[3-(3,3-dimethyl-1 -piperidinyl)propyl]oxy} phenyl)- 1-piperidinyl]carbonyl}-1-naphthalenyl)propanoic acid, or a pharmaceutically acceptable salt thereof for use in the treatment of urticaria.

Priority: US20090221213P Applic. Date: 2009-06-29

Inventor: CLARK KENNETH LYLE [GB]; PHILPOT EDWARD EARL [US]


Publication No.: WO2011000767A1  Published: 06/Jan/2011

Title: NEW MEDICAL USE

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: EP2010/058981   Filing Date: 24/Jun/2010

Abstract:The prepsent invention relates to 34-[(4-chlorophenyl)methyl]-2-({(2R)-1-[4-(4-{[3-(hexahydro- 1 H-azepin-1 -yl)propyl]oxy}phenyl)butyl]-2-pyrrolidinyl}methyl)-1 (2H)-phthalazinone, or a pharmaceutically acceptable salt thereof for use in the treatment of urticaria.

Priority: US20090221218P Applic. Date: 2009-06-29

Inventor: CLARK KENNETH LYLE [GB]; PHILPOT EDWARD EARL [US]


Publication No.: WO2011000863A1  Published: 06/Jan/2011

Title: SULFONAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF SKIN CONDITIONS

Applicant/Assignee: DSM IP ASSETS B.V

Application No.: EP2010/059273   Filing Date: 30/Jun/2010

Abstract:The invention relates to novel sulfonamide derivatives, their preparation as well as to their use as BK 1 antagonists. Furthermore, the invention relates to topical compositions comprising such novel sulfonamide derivatives and their use for the treatment of painful skin sensations as well as sensitive skin and the symptoms associated therewith. Formula (I).

Priority: EP20090008610 Applic. Date: 2009-07-01

Inventor: IMFELD DOMINIK [CH]; WIKSTROEM PETER [CH]; ZIEGLER HUGO [CH]


Publication No.: WO2011000930A1  Published: 06/Jan/2011

Title: L-SERINE TO BE USED AS A DRUG FOR PREVENTING AND/OR TREATING AN INFLAMMATORY RESPONSE OF THE SKIN

Applicant/Assignee: PIERRE FABRE DERMO-COSMETIQUE

Application No.: EP2010/059401   Filing Date: 01/Jul/2010

Abstract:The invention relates to the use of L-serine as a drug for preventing and/or treating an inflammatory response of the skin caused by the overexpression and/or the overactivation of PAR2 receptors.

Priority: FR20090054497 Applic. Date: 2009-07-01

Inventor: DECHELETTE CORINNE [FR]; CASTEX RIZZI NATHALIE [FR]; BONZOM LAETITIA [FR]


Publication No.: WO2011002033A1  Published: 06/Jan/2011

Title: GLUCOSE METABOLISM-IMPROVING AGENT AND GLUCOSE METABOLISM-IMPROVING COMPOSITION

Applicant/Assignee: LION CORPORATION

Application No.: JP2010/061180   Filing Date: 30/Jun/2010

Abstract:A glucose metabolism-improving agent having an activity of suppressing the increase in an after-meal glucose level, an activity of decreasing a fasting glucose level, an activity of regulating a glucose metabolism-related measure in serum, an activity of enhancing the intake of glucose into a muscle cell, and an activity of enhancing a meal-related glucose metabolism, which comprises at least one of a compound represented by structural formula (1) and a compound represented by structural formula (2)

a glucose metabolism-improving composition, an agent for suppressing the increase in an after-meal glucose level, an agent for reducing a fasting glucose level, and an agent for enhancing the intake of glucose, each of which comprises the glucose metabolism-improving agent

and a food or beverage.

Priority: JP20090155914 Applic. Date: 2009-06-30; JP20090155957 Applic. Date: 2009-06-30

Inventor: IWASAKI HIDEAKI [JP]; KAMBAYASHI HIROAKI [JP]; NOMURA MITSURU [JP]; SUZUKI NAHO [JP]; KITAMURA KUMIKO [JP]


Publication No.: WO2011002814A2  Published: 06/Jan/2011

Title: BIARYL OXYACETIC ACID COMPOUNDS

Applicant/Assignee: LIGAND PHARMACEUTICALS INC, SMITHKLINE BEECHAM CORPORATION

Application No.: US2010/040482   Filing Date: 29/Jun/2010

Abstract:Some embodiments of the present invention include novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin. Some compounds provided include those of the general formula (I), and compounds of general formula (Ia).

Priority: US20090221899P Applic. Date: 2009-06-30

Inventor: MCGUINNESS BRIAN F [US]; HO KOC-KAN [US]; BABU SURESH [US]; DONG GUIZHEN [US]; DUO JINGQI [US]; LE THUY X H [US]; SAIONZ KURT W [US]; NEEB MICHAEL J [US]


Publication No.: WO2011003062A2  Published: 06/Jan/2011

Title: PROBIOTIC COMPOSITIONS AND PROCESSES THEREOF

Applicant/Assignee: JAMES MADISON UNIVERSITY

Application No.: US2010/040898   Filing Date: 02/Jul/2010

Abstract:Probiotic composition(s) and/or process(es) thereof. Processes may include applying Janthinobacterium, for example Janthinobacterium Lividum, over a host and/or host area(s) to minimize microbe(s) and/or maximize therapeutic effects. A process to minimize a microbe may include applying to skin a composition including isolated Janthinobacterium Lividum and a pharmaceutically acceptable carrier. Probiotic composition(s) and/or process(es) thereof may include relatively heat tolerant Janthinobacterium Lividum which may produce metabolites, for example violacein up to approximately 29 DEG C, Probiotic composition(s) and/or process(es) thereof may include Janthinobacterium Lividum between approximately 25x106 and 6.4x107 cells.

Probiotic composition(s) and/or process(es) thereof may include Janthinobacterium Lividum which has and/or produces between approximately 18 [mu]M and 129 [mu]M of violacein. Probiotic composition(s) and/or process(es) thereof may include a stimulant to maximize metabolites. A process to minimize a microbe may include removing a portion of resident microbes with a sanitizer. Janthinobacterium Lividum may be in lysed form.

Priority: US2010-829520 Applic. Date: 2010-07-02; US20090222964P Applic. Date: 2009-07-03

Inventor: MINBIOLE KEVIN P C [US]; HARRIS REID [US]


Publication No.: WO2011003172A1  Published: 13/Jan/2011

Title: CONTROLLED NITRIC OXIDE DELIVERY FROM AQUEOUS S-NITROSOTHIOL CONJUGATED POLYMERS AND THEIR COMPLEXES

Applicant/Assignee: UNIVERSITY OF TORONTO

Application No.: CA2010/000270   Filing Date: 26/Feb/2010

Abstract:A method of making an aqueous solution of a bio-adhesive, supramacromoIecular nitric oxide generatable polymer complex of the general formula (I): wherein R1 is independently selected from the group consisting of an alkane unsubstituted or substituted with alkoxy groups

R2 is independently selected from the group consisting of C 1-6 alkyl

R3 and R4 are independently selected from the group consisting of optionally substituted aliphatic or aromatic alkyl

W is a hydrogen-bond accepting ftractional group-containing entity

Y is a carboxylic acid ester or amide linkage

R is independently selected peptide linking group

T1, T2, T3 and T4 are independently selected polymer residues

and m1, m2, m3, n1, and n2 are integers greater than 25

and wherein P has a molecular weight of about 1 x 103 to 1 x 107 and Q has a molecular weight of about 1 x 103to 1 x 107

the method comprising (a) covalently linking a S-nitrosothiol compound having an amino linking group with a bio-adhesive, hydrophobic polyanhydride compound to form a nitric oxide donor polymeric conjugate carrier

comprising (i) treating the polyanhydride compound dissolved in an aprotic solvent with an aqueous solution of said S-nitrosothiol compound for an effective period of time and protected from light

(ii) removing the aprotic solvent to produce an essentially aqueous solution of the conjugate carrier

and (b) mixing the solution of the conjugate carrier with an intermolecular hydrogen bond acceptable polymer to produce an aqueous solution of the complex. Solutions are to be used in the treatment of healing wounds. Also provided is the polymeric conjugate carrier for use in the treatment of healing wounds through the release of nitric oxide. The invention is also of value through use of photo irradiation of the conjugate carrier and complex containing systems, to enhance the healing of skin wounds.

Priority: CA20092671595 Applic. Date: 2009-07-09

Inventor: LEE PING I [CA]; LI YAN [CN]


Publication No.: WO2011003236A1  Published: 13/Jan/2011

Title: THE PREPARATION AND USES OF A LONGAN SEED EXTRACT

Applicant/Assignee: JOJIA BIO-TECH CO., LTD

Application No.: CN2009/072687   Filing Date: 08/Jul/2009

Abstract:The invention provides a method for preparing a longan seed extract and uses thereof. The method includes the following steps: (1) formulating an extracting solution with a specific concentration

(2) heating the extracting solution to a specific temperature

(3) adding powdered longan seeds to the solution and extracting

(4) filtering the extract and concentrating

(5) lyophilizing the concentrated solution

(6) obtaining a longan seed extract. It is demonstrated that the longan seed extract prepared by the invention method can be used in organisms to produce an anti-inflammatory response, reduce the generation of uric acid, inhibit bacterial activity, improve the growth of skin keratinocytes, and promote wound healing without damaging internal organs or increasing the burden of internal organs.

Priority:

Inventor: HUANG WEN-TIEN [CN]; HOU CHIEN-WEI [CN]; LEE YING-CHUNG [CN]; TSENG HUANG-CHUNG [CN]; LIAO JER-YI [CN]; HUANG GIAO-ZHI [CN]; HUANG CHIEH-WEI [CN]; KENG CHUN-LAN [CN]


Publication No.: WO2011003858A2  Published: 13/Jan/2011

Title: PHARMACEUTICAL COMPOSITIONS AND SOLID FORMS

Applicant/Assignee: NOVARTIS AG

Application No.: EP2010/059553   Filing Date: 05/Jul/2010

Abstract:The present invention relates to pharmaceutical compositions of 6-(6-hydroxymethyl- pyrimidin-4-yloxy)-naphthalene-1-carboxyfic acid (3-trifluoromethyl-phenyl)-amide, to the use of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthatene-1-carboxylic acid (3-trifluoromethyI- phenyl)-amide and compositions of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1- carboxylic acid (3-trifluoromethyi-phenyi)-amide in therapeutic applications, especially indications with a dysregulation/overexpression of VEFG, (neo)-vascularisation and VEGF driven angiogenesis and to methods for manufacturing such compositions, the invention further relates to specific forms of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-paphthalene-1- carboxyiic acid (3-trifluaromethyl-phenyl)-amide and to the manufacturing and use of such forms.

The present invention also relates to a new process to produce 6-{6-hydroxymethyl- pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide.

Priority: US20090223269P Applic. Date: 2009-07-06

Inventor: BERGHAUSEN JOERG [CH]; HAUG CLAIRE [CH]; HERBIG MICHAEL [CH]; HU BIN [US]; JONAT STEPHANE [CH]; LELETI RAJENDER [US]; MEINGASSNER JOSEF GOTTFRIED [AT]; MONNIER STEPHANIE [FR]; NAPP MATTHIAS [CH]; PRASHAD MAHAVIR [US]; STUETZ ANTON [AT]; THAKUR RANJIT [CH]


Publication No.: WO2011004733A1  Published: 13/Jan/2011

Title: ACTIVITY ENHANCER FOR OXIDIZED PROTEIN HYDROLASE

Applicant/Assignee: ARKRAY, INC

Application No.: JP2010/061062   Filing Date: 29/Jun/2010

Abstract:Disclosed is an activity enhancer for oxidized protein hydrolase. The activity enhancer for oxidized protein hydrolase is characterized by comprising an extract of at least one plant selected from the group consisting of plants belonging to Compositae Anthemis (Chamaemelum), Saururaceae Houttuynia, Rosaceae Crataegus and Vitaceae Vitis. It is preferable that the activity enhancer for oxidized protein hydrolase comprises an extract of a plant belonging to Compositae Anthemis (Chamaemelum), an extract of a plant belonging to Saururaceae Houttuynia, an extract of a plant belonging to Rosaceae Crataegus and an extract of a plant belonging to Vitaceae Vitis. It is also preferable that the plant belonging to Compositae Anthemis (Chamaemelum) is Anthemis nobilis L., the plant belonging to Saururaceae Houttuynia is Houttuynia cordata Thunberg, the plant belonging to Rosaceae Crataegus is Crataegus oxyacantha L. and the plant belonging to Vitaceae Vitis is Vitis vinifera L.

Priority: JP20090162188 Applic. Date: 2009-07-08

Inventor: YAGI MASAYUKI; TAKAHASHI TOMOKO


Publication No.: WO2011005290A1  Published: 13/Jan/2011

Title: DISUBSTITUTED OXADIAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

Applicant/Assignee: ARENA PHARMACEUTICALS, INC

Application No.: US2010/001787   Filing Date: 22/Jun/2010

Abstract:The present invention relates to certain disubstituted oxadiazole derivatives of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer.

Priority: US20090269269P Applic. Date: 2009-06-23

Inventor: JONES ROBERT M [US]; BUZARD DANIEL J [US]; HAN SANGDON [US]; LEHMANN JUERG [US]; LOPEZ LUIS A [US]; ULLMAN BRETT [US]; KAWASAKI ANDREW M [US]; THORESEN LARS [US]; ZHU XIUWEN [US]


Publication No.: WO2011005380A2  Published: 13/Jan/2011

Title: ARG-GLY-ASP-CONJUGATED ALPHA-MELANOCYTE STIMULATING HORMONE HYBRID PEPTIDE FOR USE IN DIAGNOSING AND TREATING MELANOMA, INCLUDING METASTATIC MELANOMA AND METHODS RELATED TO SAME

Applicant/Assignee: STC. UNM

Application No.: US2010/036686   Filing Date: 28/May/2010

Abstract:The present invention is directed to novel non-invasive diagnostic and therapeutic tools/compounds comprising a hybride cyclic peptide which utilizes a cyclic peptide chelating group wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques.

The novel probes of the present invention will also be useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compound according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

Priority: US20090268409P Applic. Date: 2009-06-12

Inventor: MIAO YUBIN [US]; YANG JIANQUAN [US]


Publication No.: WO2011005406A2  Published: 13/Jan/2011

Title: SKIN REPAIR COMPOSITIONS COMPRISING CIRCADIAN GENE ACTIVATORS AND A SYNERGISTIC COMBINATION OF SIRT1 GENE ACTIVATORS

Applicant/Assignee: ELC MANAGEMENT LLC

Application No.: US2010/037871   Filing Date: 09/Jun/2010

Abstract:Compositions and methods for enhancing repair of damaged DNA in skin cells. Topical compositions comprising at least one agent that upregulates circadian gene expression in skin cells and at least one non-circadian agent that delays mitosis in skin cells. Preferably, such compositions comprise one or more keratinocyte clock and per1 gene activators, along with SIRT1 or one or more sirt1 activators. More preferably, the sirt1 activator is a synergistic combination of specific peptidic sirt1 activators and resveratrol. Preferably, such compositions are easy to use, efficacious, cosmetically acceptable, chemically, thermodynamically and light stable, safe for topical use, have little or no side effects, and commercially feasible in a personal care marketplace.

Priority: US2009-489619 Applic. Date: 2009-06-23

Inventor: MAES DANIEL H [US]; PERNODET NADINE A [US]; MAMMONE THOMAS [US]; COLLINS DONALD F [US]; SLUTSKY LENNEY [US]; GOLDGRABEN KERRI [US]; MCCARTHY JAMES TIMOTHY [US]


Publication No.: WO2011005749A2  Published: 13/Jan/2011

Title: TOPICAL ANTIFUNGAL COMPOSITION

Applicant/Assignee: ONIKOLABS LLC

Application No.: US2010/041050   Filing Date: 06/Jul/2010

Abstract:A composition obtained primarily from plant materials provides antimicrobial activity for use as an anti-fungal agent. The anti-fungal agent is effective in inhibiting the growth of Trichophyton rubrum, the fungus that is the most common cause of Tinea pedis. The composition includes selective mixtures of the origanum oil, menthol, and Atlantic cedarwood oil, thuja oil, cedarwood oil, cinnamon oil, clove oil, cumin oil, fennel oil, peppermint oil, or rosemary oil.

Priority: US20090223870P Applic. Date: 2009-07-08

Inventor: BOEGLI CHARLES J [US]


Publication No.: WO2011007633A1  Published: 20/Jan/2011

Title: CRYSTALS OF PYRROLOQUINOLINEQUINONE SODIUM SALTS

Applicant/Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC

Application No.: JP2010/059761   Filing Date: 09/Jun/2010

Abstract:Crystals of a disodium salt of pyrroloquinolinequinone which, in analysis by X-ray powder diffractometry with a CuKa line, have peaks of 2? at 9.1 , 10.3 , 13.8 , 17.7 , 18.3 , 24.0 , 27.4 , 31.2 , and 39.5 (+-0.2 each)

and crystals of a trisodium salt of pyrroloquinolinequinone which, in analysis by X-ray powder diffractometry with a CuKa line, have peaks of 2? at 6.6 , 11.4 , 13.0 , 22.6 , 26.9 , 27.9 , 37.0 , 38.9 , and 43.4 (+-0.2 each).

Priority: JP20090168087 Applic. Date: 2009-07-16

Inventor: EDAHIRO JUNICHI [JP]; SAKAMOTO HITOSHI [JP]; IKEMOTO KAZUTO [JP]; SHIMIZU HAJIME [JP]; HASEGAWA TATSUYA [JP]; NAKANO MASAHIKO [JP]


Publication No.: WO2011007794A1  Published: 20/Jan/2011

Title: ZEOLITE AND SERICITE-CONTAINING COMPOSITION FOR MEDICAL OR MEDICAL ASSISTING USES

Applicant/Assignee: RAPAS CORPORATION

Application No.: JP2010/061879   Filing Date: 14/Jul/2010

Abstract:The present invention is directed to improve the usefulness of zeolite and sericite in various medical fields. To achieve this purpose, a composition for medical or medical assisting uses, which contains zeolite and sericite, is provided based on, as the most important characteristic, the finding that zeolite and sericite can exert a synergistic effect when used in combination. It is confirmed that the aforesaid composition containing zeolite and sericite exerts an advantageous synergistic effect in the following cases. When externally applied, the aforesaid composition is particularly efficacious in, for example, treating skin itching, sore and pain caused by burn injury, skin diseases, miliaria, etc., atopic dermatitis, cut, scratch, nail slipping, inflammatory diseases, sunburn inflammation, muscle fragmentation, muscular pain, contusion, bruise, sprain, athlete's foot, urticaria and cancerous pain, as a substitute for ice in cooling, as an additive to hair dyes and perming agents for preventing itching and sore, and so on. When orally administered, the aforesaid composition is particularly efficacious in, for example, healing bronchitis, asthma, stomach ulcer, duodenal ulcer, gastritis, stomatitis, chronic gastritis, periodontal disease, chronic liver disease, pollen allergy, oral dysodia, cancer, etc., overcoming fatigue and exhaustion, and so on.

Priority: JP20090168531 Applic. Date: 2009-07-17; JP20090235118 Applic. Date: 2009-10-09; JP20090270208 Applic. Date: 2009-11-27

Inventor: ISHIDUKA HIROKO [JP]


Publication No.: WO2011007807A1  Published: 20/Jan/2011

Title: METHOD FOR MANUFACTURING SPILANTHOL AND INTERMEDIATE MANUFACTURING PRODUCT THEREFOR

Applicant/Assignee: TAKASAGO INTERNATIONAL CORPORATION

Application No.: JP2010/061912   Filing Date: 14/Jul/2010

Abstract:Provided is an amide ester that is useful as an intermediate manufacturing product for an aroma compound such as spilanthol or the like. Also provided is a spilanthol manufacturing method using said amide ester. High-purity spilanthol can be manufactured by reacting an amide ester represented by general formula (1) with a basic compound. (1) (In the formula, R1 represents a phenyl group that may be substituted with a C1-6 alkyl group and either a C1-4 alkyl group, a C1-4 alkoxy group, or a halogen atom

R2 represents a C1-8 hydrocarbon group

and the wavy lines represent cis configurations, trans configurations, or a mixture of the two configurations.)

Priority: JP20090165530 Applic. Date: 2009-07-14

Inventor: TANAKA SHIGERU [JP]; ISHIDA KENYA [JP]; YAGI KENJI [JP]; UJIHARA HIDEO [JP]


Publication No.: WO2011007885A1  Published: 20/Jan/2011

Title: PROTEOGLYCAN-CONTAINING MATERIAL

Applicant/Assignee: SUNSTAR INC, HIROSAKI UNIVERSITY

Application No.: JP2010/062125   Filing Date: 16/Jul/2010

Abstract:Disclosed is a novel proteoglycan-containing material, which has novel use applications and/or an excellent effect. Specifically disclosed is a proteoglycan-containing material which is produced from a fish cartilage and contains an acidic sugar component having a molecular weight of 2000 kDa or more. The proteoglycan-containing material has effects advantageous for skin moisturization and anti-aging, such as an excellent effect of proliferating skin fibroblasts, an excellent effect of enhancing and improving the skin barrier function, an excellent effect of enhancing and improving skin collagen production capability and an excellent effect of inhibiting the thickening of dermises.

Priority: JP20090168123 Applic. Date: 2009-07-16

Inventor: GOTO MASASHI [JP]; YAMAMOTO KAZUSHI [JP]; KATOU YOUJI [JP]; KATAGATA YOHTARO [JP]; ITOU SEIKO [JP]


Publication No.: WO2011008086A1  Published: 20/Jan/2011

Title: MIXTURE OF NON-DIGESTIBLE OLIGOSACCHARIDES FOR STIMULATING THE IMMUNE SYSTEM

Applicant/Assignee: N.V. NUTRICIA

Application No.: NL2010/050446   Filing Date: 12/Jul/2010

Abstract:Nutritional compositions with fucosyllactose and betagalactooligosaccharides for use in stimulation of the immune system. The composition is suitable for infants.

Priority: EP20090165543 Applic. Date: 2009-07-15; US20090255950P Applic. Date: 2009-10-29

Inventor: STAHL BERND [DE]; NAUTA ALMA JILDOU [NL]; GARSSEN JOHAN [NL]; SAMAIN ERIC [FR]; DROUILLARD SOPHIE [FR]


Publication No.: WO2011009757A2  Published: 27/Jan/2011

Title: USE OF HUMAN BETA-DEFENSIN TO INFLUENCE THE NATURAL PIGMENTATION PROCESS

Applicant/Assignee: HENKEL AG & CO. KGAA

Application No.: EP2010/060026   Filing Date: 13/Jul/2010

Abstract:The invention relates to the use of at least one human beta-defensin, the analogues thereof or agents that can stimulate expression of human beta-defensins, in order to influence the natural pigmentation process of skin and/or skin appendages.

Priority: DE200910027953 Applic. Date: 2009-07-23; DE200910044970 Applic. Date: 2009-09-24

Inventor: GIESEN MELANIE [DE]; GRUEDL SABINE [DE]; FUHRMANN GUIDO [DE]


Publication No.: WO2011009899A2  Published: 27/Jan/2011

Title: PHENALENONES AS ANTITUMORAL AGENTS

Applicant/Assignee: INSTITUTO BIOMAR, S.A

Application No.: EP2010/060588   Filing Date: 21/Jul/2010

Abstract:Compounds of general formula (Ia) or (Ib) or (Ic) or (Id), wherein the R groups are each independently selected from the group consisting of hydrogen, acyl, alkyl, alkenyl, alkynyl, aryl, -CONH2, alkali metal, and sugar, and their use for the treatment of cancers.

Priority: EP20090382119 Applic. Date: 2009-07-22

Inventor: SANCHEZ LOPEZ JOSE MARIA [ES]; MARTINEZ INSUA MARTA [ES]; VINUESA-NAVARRO MARIA DE LOS ANGELES [ES]; DE LA FUENTE BLANCO JESUS ANGEL [ES]; FERNANDEZ-MEDARDE ANTONIO [ES]


Publication No.: WO2011010072A1  Published: 27/Jan/2011

Title: SELENOQUINONE-DERIVED ACTIVE ORGANOMETALLIC COMPLEXES, METHODS FOR SYNTHESIZING SAME, AND USES THEREOF

Applicant/Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS

Application No.: FR2010/051555   Filing Date: 22/Jul/2010

Abstract:The present invention relates to the synthesis of novel biologically active selenoquinone-derived organometallic complexes, and to the uses thereof in the context of preventing or treating cancer.

Priority: FR20090003641 Applic. Date: 2009-07-23

Inventor: AMOURI HANI HANIEL [FR]


Publication No.: WO2011010075A1  Published: 27/Jan/2011

Title: USE OF JASMONIC ACID DERIVATIVE AS A SOOTHING AGENT

Applicant/Assignee: L'OREAL

Application No.: FR2010/051566   Filing Date: 23/Jul/2010

Abstract:The present invention relates to the use of a jasmonic acid derivative as a soothing agent and to the use of a jasmonic acid derivative to prepare a composition for reducing and/or treating skin reactions. The invention also relates to a cosmetic treatment method for soothing the skin, mucus membranes, and/or the scalp. The present invention also relates to a composition including a jasmonic acid derivative and, optionally, at least one compound capable of causing skin, mucus membrane, and/or scalp irritation, as well as to a cosmetic or dermatological unit.

Priority: FR20090055214 Applic. Date: 2009-07-24; US20090232804P Applic. Date: 2009-08-11

Inventor: FAGOT DOMINIQUE [FR]


Publication No.: WO2011010090A1  Published: 27/Jan/2011

Title: THERAPEUTIC USES FOR PLANTS OF THE CAPSICUM GENUS

Applicant/Assignee:

Application No.: GB2010/001377   Filing Date: 20/Jul/2010

Abstract:A saponin or a sapogenin, or a saponin or sapogenin derivative, from a plant of the capsicum genus for use in the treatment of a disease other than eczema and dermatitis. A process for preparing a plant of the capsicum genus, extracts, or seeds thereof for use as a medicament suitable for the treatment of diseases other than skin conditions which process comprises storing the plant, extracts or seeds thereof at a temperature of 2O DEG C or below.

Priority: GB20090012587 Applic. Date: 2009-07-20

Inventor: REZAI-FARD ALI [GB]


Publication No.: WO2011010306A1  Published: 27/Jan/2011

Title: A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION

Applicant/Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD

Application No.: IL2010/000576   Filing Date: 20/Jul/2010

Abstract:The present invention relates to compositions and methods for modulating melanin production, secretion and/or accumulation in human skin cells. In particular, the present invention relates to the use of A3 adenosine receptor antagonists in compositions and methods for the treatment and amelioration of hyper-pigmentation conditions and for the lightening of skin, and to the use of A3 adenosine receptor agonists in compositions and methods for the treatment and amelioration of hypo-pigmentation conditions and for the tanning of skin.

Priority: US20090227079P Applic. Date: 2009-07-21

Inventor: MADI LEA LEVANA [IL]; KORENSTEIN RAFI [IL]


Publication No.: WO2011010364A1  Published: 27/Jan/2011

Title: COMPOUND HAVING NEURITE-OUTGROWING ACTIVITY

Applicant/Assignee: LEAD CHEMICAL CO.,LTD

Application No.: JP2009/063063   Filing Date: 21/Jul/2009

Abstract:Disclosed is a novel compound having a neurite-outgrowing activity and is therefore useful for the prevention or treatment of neurodegenerative diseases. Specifically disclosed is a compound represented by formula (I) [wherein X represents OR or NR1R2

Y represents OH, NR3R4, -NHC(=NH)NHR5 or -NHC(=NH)R5

and Z represents a hydrogen atom, a linear or branched alkyl group having 1 to 5 carbon atoms, or a 5- to 6-membered aryl group which may have one or two atoms independently selected from a nitrogen atom, a sulfur atom and an oxygen atom] or a pharmaceutically or veterinarily acceptable salt thereof.

Priority:

Inventor: NEMOTO HIDEO [JP]; MATSUYA YUJI [JP]


Publication No.: WO2011010456A1  Published: 27/Jan/2011

Title: EXTERNAL PREPARATION CONTAINING NSAIDs AND METHOD FOR PRODUCING THE EXTERNAL PREPARATION

Applicant/Assignee: NEXT21 K.K, THE UNIVERSITY OF TOKYO

Application No.: JP2010/004669   Filing Date: 21/Jul/2010

Abstract:Disclosed is an external preparation containing nonsteroidal anti-inflammatory drugs (NSAIDs), which is suppressed in cytotoxicity induced by the NSAIDs. Also disclosed is a method for producing the external preparation. The present invention is based on the finding that skin disorders induced by nonsteroidal anti-inflammatory drugs (NSAIDs) can be suppressed when the NSAIDs form intermolecular compounds together with trehalose, which is an example of disaccharides. A disaccharide other than trehalose may be used therefor.

Priority: JP20090173609 Applic. Date: 2009-07-24

Inventor: TEI YUICHI [JP]; SASAKI NOBUO [JP]; SUZUKI SHIGEKI [JP]


Publication No.: WO2011010732A1  Published: 27/Jan/2011

Title: COMPOSITION FOR EXTERNAL PREPARATION FOR SKIN

Applicant/Assignee: IGISU CO., LTD

Application No.: JP2010/062459   Filing Date: 23/Jul/2010

Abstract:Provided is a therapeutic agent for dermatitis which: is effective and safe for use by dermatitis patients, especially patients with atopic dermatitis

exhibits remarkable effects in severe cases in which a condition was diagnosed to be extremely difficult to treat with conventional external preparations

can be applied to affected sites such as the face or neck

and is extremely safe and effective for patients with sensitive skin and for application on children or women. Also provided is an external preparation which is effective as a skin care cosmetic that exhibits improvements of the skin such as increased firmness and reduced wrinkles, and has moisturizing and hair growth efficacy. A composition for an external preparation for the skin, especially for a therapeutic agent for dermatitis and for a skin quality improver have C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.

Priority: JP20090172589 Applic. Date: 2009-07-23; JP20100134600 Applic. Date: 2010-06-11

Inventor: ENDO KYOKO [JP]


Publication No.: WO2011011506A1  Published: 27/Jan/2011

Title: SPIROCYCLIC OXAZEPINE COMPOUNDS AS STEAROYL-COENZYME A DELTA-9 DESATURASE INHIBITORS

Applicant/Assignee: SCHERING CORPORATION

Application No.: US2010/042732   Filing Date: 21/Jul/2010

Abstract:The present invention relates to certain 4,5-dihydro-3H-spiro[benzo[b]-[1,4]oxazepine compounds of the Formula (I), wherein the compounds are as herein described. In addition, the invention relates to compositions comprising at least one such compound, and methods of using the compounds for treating or preventing disorders such as non-insulin dependent (Type 2) diabetes, insulin resistance, hyperglycemia, a lipid disorder, obesity, fatty liver disease, or a skin disorder.

Priority: US20090227948P Applic. Date: 2009-07-23

Inventor: SHIPPS JR GERALD W [US]; YANG ZHIWEI [US]; WEST ROBERT [US]


Publication No.: WO2011011808A1  Published: 03/Feb/2011

Title: A COSMETIC COMPOSITION COMPRISING SODIUM CHLORIDE IN COMBINATION WITH ONE OR MORE OF PROTEIN, COLLAGEN, GELATIN OR AMINO ACID

Applicant/Assignee:

Application No.: AU2009/000963   Filing Date: 30/Jul/2009

Abstract:A cosmetic composition comprising sodium chloride in combination with one or more of protein, collagen, gelatin or amino acid and its uses thereof.

Priority:

Inventor: BUGA ROMAN [AU]


Publication No.: WO2011012526A1  Published: 03/Feb/2011

Title: FLAVANONES-CONTAINING FOOD COMPOSITIONS

Applicant/Assignee: NESTEC S.A

Application No.: EP2010/060607   Filing Date: 22/Jul/2010

Abstract:The present invention relates to food products comprising flavanones. In particular, it relates to food products comprising hesperidin having improved stability. The present invention also concerns processes for the manufacturing of food products comprising said flavanones, especially hesperidin and to the use of the food products in the manufacture of compositions for the improvement of bone and skin health.

Priority: EP20090166700 Applic. Date: 2009-07-29

Inventor: HOEBLER PASCALINE [CH]


Publication No.: WO2011012612A2  Published: 03/Feb/2011

Title:

Applicant/Assignee: LABORATOIRES EXPANSCIENCE

Application No.: EP2010/060873   Filing Date: 27/Jul/2010

Abstract:The present invention relates to a cosmetic, dermatological or nutraceutical composition comprising a Schisandra sphenanthera fruit extract. Said Schisandra sphenanthera fruit extract is selected from a peptide and sugar extract, a crude oil, a refined oil, a refined oil concentrate or the unsaponifiable fraction of said concentrate. The invention also relates to a method for preparing a peptide and sugar extract, a refined oil, and a concentrate and an unsaponifiable fraction of oil of Schisandra sphenanthera fruit. Finally, the invention relates to the dermatological, cosmetic and nutraceutical uses of said extracts.

Priority: FR20090055344 Applic. Date: 2009-07-30

Inventor: GARNIER SEBASTIEN [FR]; MSIKA PHILIPPE [FR]


Publication No.: WO2011012896A2  Published: 03/Feb/2011

Title: COMPOUNDS - 801

Applicant/Assignee: ASTRAZENECA AB, PULMAGEN THERAPEUTICS (SYNGERY) LIMITED

Application No.: GB2010/051242   Filing Date: 29/Jul/2010

Abstract:Spirocyclic amide derivatives of formula (I) wherein ArCH2CH2NH- represents a ss-adrenoceptor binding group, processes for their preparation, pharmaceutical compositions containing them, a process for preparing such pharmaceutical compositions, their use in therapy, and intermediates for use in their preparation.

Priority: GB20090013342 Applic. Date: 2009-07-31

Inventor: ALCARAZ LILIAN [GB]; BAILEY ANDREW [GB]; KINDON NICHOLAS [GB]


Publication No.: WO2011013494A1  Published: 03/Feb/2011

Title: AQUEOUS COMPOSITION

Applicant/Assignee: ARCH CHEMICALS JAPAN, INC

Application No.: JP2010/061578   Filing Date: 08/Jul/2010

Abstract:Disclosed is an aqueous composition which is prevented from the occurrence of remarkable white turbidity and precipitation even when a polyvalent anionic compound and a polycationic antibacterial agent are contained as components. The aqueous composition additionally contains a phosphoric acid ester of a polyoxyethylene alkyl ether and/or a salt thereof. It is more preferred to add a phosphoric acid ester of a polyoxyethylene alkyl ether or a salt thereof which has a linear alkyl group having a predetermined number or more of carbon atoms and contains a polyoxyethylene in a predetermined repeating number or more. It is also more preferred to add the phosphoric acid ester of the polyoxyethylene alkyl ether or the salt thereof at a predetermined ratio or more relative to the amount of the polycationic antibacterial agent.

Priority: JP20090177172 Applic. Date: 2009-07-30

Inventor: YONEDA RYU [JP]; NEW MAYUMI [JP]; SAKATA KAZUHIKO [JP]


Publication No.: WO2011013496A1  Published: 03/Feb/2011

Title: PROCESS FOR PREPARATION OF APHANOTHECE SACRUM-ORIGINATED POLYSACCHARIDE WITH REDUCED TRIVALENT METAL CONTENT

Applicant/Assignee: JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY, GREEN SCIENCE MATERIAL INC

Application No.: JP2010/061600   Filing Date: 08/Jul/2010

Abstract:A process for the preparation of an Aphanothece sacrum-originated polysaccharide with a reduced trivalent metal content, which includes treating Aphanothece sacrum with an acid

an Aphanothece sacrum-originated polysaccharide with a reduced trivalent metal content, which is obtained by the process

and a wound-protective agent and an anti-allergic dermatitis agent, which each contain the Aphanothece sacrum-originated polysaccharide with a reduced trivalent metal content.

Priority: JP20090178813 Applic. Date: 2009-07-31

Inventor: KANEKO TATSUO; KANEKO MAIKO; NAKAMURA HIROYUKI; KANEKO SHINICHIRO; SUGANUMA NARUFUMI; HIROTA RYOJI


Publication No.: WO2011013729A1  Published: 03/Feb/2011

Title: FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION

Applicant/Assignee: ONCOTHERAPY SCIENCE, INC

Application No.: JP2010/062747   Filing Date: 29/Jul/2010

Abstract:Provided are a compound represented by general formula (I) and having a TTK inhibitory action and a medicine containing the compound. In formula (I), (X, Y, V, W) is (-N=, =CR1-, =N-, -CR7=), (-CR2=, =N-, =N-, -CR7=), etc.

A is an (un)substituted aromatic hydrocarbon ring, etc.

L is a single bond, -C(=O)-NRA-, etc.

Z is a group represented by the formula -NR3R4 or a group represented by the formula -OR5

R1 to R3, R6, and R7 each is a hydrogen atom, etc.

R4 and R5 each is an (un)substituted alkyl, etc.

and R8 is an (un)substituted cycloalkyl, etc.

Priority: JP20090178452 Applic. Date: 2009-07-30; JP20100121045 Applic. Date: 2010-05-26

Inventor: KUSAKABE KEN-ICHI [JP]; YOSHIDA HIROSHI [JP]; NOZU KOHEI [JP]; HASHIZUME HIROSHI [JP]; TADANO GENTA [JP]; SATO JUN [JP]; TAMURA YUUSUKE [JP]; MITSUOKA YASUNORI [JP]


Publication No.: WO2011013735A1  Published: 03/Feb/2011

Title: NOVEL FLAVANONE DERIVATIVE

Applicant/Assignee: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY

Application No.: JP2010/062759   Filing Date: 29/Jul/2010

Abstract:Disclosed is a novel antibacterial agent. Specifically disclosed is a novel antibacterial agent which can exert an effective action on various resistant bacteria such as VSSA, MRSA, VISA, VRE and VRSA. A novel flavanone derivative having a derivative of a 6-membered monosaccharide, in particular a glucose derivative or a galactose derivative, can exert an effective action on the aforesaid various bacteria. More specifically, a compound represented by formula (I) is disclosed. In formula (I), X represents a 6-membered monosaccharide derivative

and Y is substituted by a hydroxyl group.

Priority: JP20090178718 Applic. Date: 2009-07-31

Inventor: SASAKI KENJI [JP]; TSUCHIYA TOMOFUSA [JP]; ABUGAFAR MD LOKMAN HOSSION [JP]; OHTSUKA NAO [JP]; ZAMAMI YOSHITO [JP]; KUROSAKI YUJI [JP]


Publication No.: WO2011013752A1  Published: 03/Feb/2011

Title: PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE

Applicant/Assignee: SHIONOGI & CO. LTD

Application No.: JP2010/062804   Filing Date: 29/Jul/2010

Abstract:Disclosed is a compound having a histamine H4 receptor-regulating activity. Specifically disclosed is a compound represented by formula (I) [wherein ring A represents a ring represented by formula (a-1), (a-2) or (a-3) (wherein R1 represents a substituted or unsubstituted alkyl group, or the like

W represents -O-, or the like

n represents an integer of 0 to 6

X represents -N(R7)- or -O-

R7 represents a hydrogen atom, a substituted or unsubstituted alkyl group, or the like

Y represents -C(R8)= or -N=

and R8 represents a hydrogen atom, a substituted or unsubstituted alkyl group, or the like), or the like

Z represents =O, =S, or the like

and ring B represents a ring represented by formula (b-1), (b-2), (b-3) or (b-4) (wherein R10 independently represents a substituted or unsubstituted alkyl group, a halogen atom, a hydroxy group, a substituted or unsubstituted alkyloxy group, or a substituted or unsubstituted amino group

and R11, R12a and R12b independently represent a hydrogen atom, a substituted or unsubstituted alkyl group, or the like

and p represents an integer of 0 to 4), or the like] or a pharmaceutically acceptable salt thereof, or a solvate of the compound or the pharmaceutically acceptable salt thereof.

Priority: JP20090178508 Applic. Date: 2009-07-31

Inventor: TACHIBANA YUUKI [JP]; MIYAGAWA MASAYOSHI [JP]; MASUDA TSUTOMU [JP]; HASEGAWA TSUYOSHI [JP]


Publication No.: WO2011013785A1  Published: 03/Feb/2011

Title: NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME

Applicant/Assignee: JAPAN TOBACCO INC

Application No.: JP2010/062873   Filing Date: 30/Jul/2010

Abstract:Disclosed are a compound represented by general formula [I], a pharmaceutically acceptable salt thereof or a solvate of the same, and medicinal use thereof for treating rejection in organ transplantation, graft-versus-host reaction after organ transplantation, autoimmune diseases, allergic diseases and chronic myeloproliferative diseases by using these compounds as the active ingredient. In general formula [I], Ra's are the same or different and represent (1) a C1-6 alkyl group, etc.

n1 represents an integer of 0 to 4

Rb's are the same or different and represent (1) a C1-6 alkyl group, etc.

n2 represents an integer of 0 to 4

m1 represents an integer of 0 to 3

m2 represents an integer of 1 to 4

Xa=Xb represents (1) CH=CH, etc.

X represents (1) a nitrogen atom, etc.

and Rc represents (1) a hydrogen atom, etc.

Priority: JP20090179502 Applic. Date: 2009-07-31; US20090274137P Applic. Date: 2009-08-13

Inventor: NOJI SATORU [JP]; SHIOZAKI MAKOTO [JP]; MIURA TOMOYA [JP]; HARA YOSHINORI [JP]; YAMANAKA HIROSHI [JP]; MAEDA KATSUYA [JP]; HORI AKIMI [JP]; INOUE MASAFUMI [JP]; HASE YASUNORI [JP]


Publication No.: WO2011013909A2  Published: 03/Feb/2011

Title: COMPOSITION CONTAINING OLIGO-HYALURONIC ACID FOR PROMOTING THE STEMNESS OF SKIN CELLS AND FOR STIMULATING DIFFERENTIATION

Applicant/Assignee: BIOLAND LTD

Application No.: KR2010/004185   Filing Date: 28/Jun/2010

Abstract:The present invention relates to a composition containing oligo-hyaluronic acid for promoting the stemness of skin cells and for stimulating differentiation, and more specifically, to a composition containing oligo-hyaluronic acid as an active ingredient for promoting the stemness of skin cells and for stimulating differentiation, and to a method for stimulating the differentiation of adult skin stem cells using same. According to the present invention, unlike existing hyaluronic acid, oligo-hyaluronic acid exhibits the effects of stimulating differentiation in epidermal cells and enhancing the function of epidermal cells by increasing the expression of markers of the epidermal stem cells in skin tissue to restore the stemness of the epidermal cells.

Priority: KR20090069624 Applic. Date: 2009-07-29

Inventor: KIM KI HO [KR]; KIM KI SOO [KR]; KIM YOUNG HEUI [KR]; KIM JIN GUK [KR]; PARK SUN HEE [KR]; CHOI HYE RYUNG [KR]


Publication No.: WO2011013979A2  Published: 03/Feb/2011

Title: COMPOSITION CONTAINING BEE VENOM AS AN ACTIVE INGREDIENT FOR PREVENTING AND TREATING ACNE

Applicant/Assignee: REPUBLIC OF KOREA (MANAGEMENT : RURAL DEVELOPMENTADMINISTRATION), DONG SUNG PHARM. CO., LTD

Application No.: KR2010/004912   Filing Date: 27/Jul/2010

Abstract:The present invention relates to a composition for preventing and treating acne, containing a superior material having an excellent antimicrobial activity against Propionibacterium acnes which is known to be an acne-causing bacterium, having an excellent antimicrobial activity against human skin pathogens that expand an inflammatory site to worsen acne, and which aids in the regeneration of skin cells damaged by the acne. The composition of the present invention contains bee venom (liquid from the stings of bees, Apis mellifera), and can be formed into cosmetics, soaps, or external skin medicines such as an ointments, bands, dressings, and the like, in order to be used accordingly as a composition for preventing and treating acne.

Priority: KR20090068925 Applic. Date: 2009-07-28

Inventor: HAN SANG MI [KR]; LEE KWANG GIL [KR]; YEO JU HONG [KR]; LEE YANG GU [KR]; HAN CHUNG SUB [KR]


Publication No.: WO2011014516A1  Published: 03/Feb/2011

Title: ESTROGEN ANTAGONISTS AS TREATMENTS FOR SCLEROSING DISORDERS

Applicant/Assignee: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Application No.: US2010/043418   Filing Date: 27/Jul/2010

Abstract:The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist ("ERANT"), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.

Priority: US20090271965P Applic. Date: 2009-07-28; US20090231899P Applic. Date: 2009-08-06

Inventor: FEGHALI-BOSTWICK CAROL A [US]; HERSHBERGER PAMELA ANNE [US]


Publication No.: WO2011014588A2  Published: 03/Feb/2011

Title: DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS

Applicant/Assignee: AMIRA PHARMACEUTICALS, INC

Application No.: US2010/043599   Filing Date: 28/Jul/2010

Abstract:Described herein are topical formulations for use in the treatment or prevention of dermatological diseases, disorders, or conditions in a mammal. Topical formulations disclosed herein include a DP2 receptor antagonist compound formulated for dermal administration

Priority: US20090230585P Applic. Date: 2009-07-31

Inventor: HUTCHINSON JOHN HOWARD [US]


Publication No.: WO2011014627A1  Published: 03/Feb/2011

Title: COMBINATION OF DAPSONE WITH ADAPALENE

Applicant/Assignee: ALLERGAN, INC

Application No.: US2010/043671   Filing Date: 29/Jul/2010

Abstract:A composition suitable for topical application that contains at least two active ingredients, one of these being dapsone and one selected from the group consisting of adapalene, tazarotene and treinion for the effective treatment of acne and other dermatological conditions.

Priority: US20090229903P Applic. Date: 2009-07-30

Inventor: AHLUWALIA GURPREET [US]; WARNER KEVIN S [US]; CHEN HAIGANG [US]; YANG MEIDONG [US]


Publication No.: WO2011014825A2  Published: 03/Feb/2011

Title: ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE

Applicant/Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC

Application No.: US2010/043998   Filing Date: 30/Jul/2010

Abstract:Methods of inhibiting undesired angiogenesis are provided, which methods include administering to a subject a therapeutically effective amount of at least one of the compounds described herein, or a pharmaceutically acceptable salt thereof.

Priority: US20090230667P Applic. Date: 2009-07-31

Inventor: ZUDAIRE ENRIQUE [US]; APARICIO MARTA [US]; CUTTITTA FRANK [US]


Publication No.: WO2011014883A2  Published: 03/Feb/2011

Title: SKIN REJUVENATION AND WRINKLE TREATMENT BY GINGIVAL FIBROBLAST AND ITS GROWTH FACTOR: ACTIVATION OF EFFECT BY HYLURONIC ACID

Applicant/Assignee: CHIRONCELL INC

Application No.: US2010/044147   Filing Date: 02/Aug/2010

Abstract:Disclosed herein is method a treating UVB-induced wrinkle or photo damaged skin by administering therapeutically effective amount of cultured GF-CM alone or in combination with Hyaluronic Acid subcutaneously via injection.

Priority: US20090230511P Applic. Date: 2009-07-31; US20090230709P Applic. Date: 2009-08-01

Inventor: MINORU UEDA [US]; PATEL AMIT [US]; GOJO SATOSHI [US]


Publication No.: WO2011015629A1  Published: 10/Feb/2011

Title: DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS

Applicant/Assignee: PIERRE FABRE MEDICAMENT

Application No.: EP2010/061426   Filing Date: 05/Aug/2010

Abstract:The present invention concerns compounds of general formula (I) characterized in that (formula 1) wherein, in particular: -R1 represents one or more groups such as: trif luoromethyl, halogen such as F, C1, -when n=m=1, W represents CH then Y represents oxygen, -U represents: DEG either - (C=O) CH2NH- and is branched at position 4 of pyridazinone, then R2 represents H, DEG or -(C=O)NH- and U is branched at positions (4), (5) or (6) of pyridazinone, then R2 represents H, - R3 represents a hydrogen or methyl and the addition salts with pharmaceutically acceptable bases and acids and the different isomers, and their mixtures in any proportion for use as SCD-1 enyzme inhibitors for the treatment of obesitz, tzpe-2 diabetes and lipid disorders.

Priority: FR20090055504 Applic. Date: 2009-08-05

Inventor: DUPONT-PASSELAIGUE ELISABETH [FR]; MIALHE SAMUEL [FR]; RIEU JEAN-PIERRE [FR]; JUNQUERO DIDIER [FR]; VALEILLE KARINE [FR]


Publication No.: WO2011015744A2  Published: 10/Feb/2011

Title: INJECTABLE COMPOSITION COMBINING A FILLING AGENT AND A FIBROBLAST GROWTH MEDIUM

Applicant/Assignee:

Application No.: FR2010/051421   Filing Date: 06/Jul/2010

Abstract:The invention relates a composition that can be subcutaneously or intradermally injected, including: a filling agent

and a fibroblast growth medium.

Priority: FR20090055235 Applic. Date: 2009-07-27

Inventor: THOREL JEAN-NOEL [FR]; GATTO HUGUES [FR]


Publication No.: WO2011016351A1  Published: 10/Feb/2011

Title: DNA SYNTHASE INHIBITORS

Applicant/Assignee: KOBE GAKUIN EDUCATIONAL FOUNDATION

Application No.: JP2010/062439   Filing Date: 23/Jul/2010

Abstract:The purpose of the present invention is to find compounds having a DNA synthase inhibitory effect and provide novel medicinal compositions (DNA synthase inhibitors, anticancer agents and antiinflammatory agents) using said compounds. Disclosed are compounds represented by general formula (1) or (2) or pharmaceutically acceptable salts of the same and medicinal compositions (DNA synthase inhibitors, anticancer agents, antiinflammatory agents and so on) comprising these compounds as the active ingredient. In general formulae (1) and (2), R represents H or an alkyl group.

Priority: JP20090184255 Applic. Date: 2009-08-07

Inventor: MIZUSHINA YOSHIYUKI [JP]; SUGAWARA FUMIO [JP]; TAKEUCHI TOSHIFUMI [JP]; YOSHIDA HIROMI [JP]


Publication No.: WO2011016459A1  Published: 10/Feb/2011

Title: THIENOOXAZEPINE DERIVATIVE

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: JP2010/063120   Filing Date: 03/Aug/2010

Abstract:Disclosed is a compound which has serotonin 5-HT2C receptor activating activity. Specifically disclosed is a compound represented by formula (I) or a salt thereof. (In the formula, the symbols are as defined in the description.)

Priority: JP20090181360 Applic. Date: 2009-08-04

Inventor: MATSUMOTO TAKAHIRO [JP]; NOMURA IZUMI [JP]


Publication No.: WO2011016812A1  Published: 10/Feb/2011

Title: TOPICAL MEDICAMENT FOR THE TREATMENT OF PSORIASIS

Applicant/Assignee: HAHL, ROBERT, W, ALPES PHARMAEUTICALS LIMITADA

Application No.: US2009/053120   Filing Date: 07/Aug/2009

Abstract:A topical medicament for the treatment of psoriasis, comprising: chia oil, metallic iodine, virgin wax, a variety of oils of animal and plant origin, camphor, chlorophyll and benzoic acid, in a pharmaceutically acceptable emollient excipient base.

Priority:

Inventor: VAZQUEZ LIPI RAMON EFRAIN [AR]


Publication No.: WO2011017909A1  Published: 17/Feb/2011

Title: PHARMACEUTICAL SOLUTION OF CETIRIZINE HYDROCHLORIDE

Applicant/Assignee: LUNNAN BETTER PHARMACEUTICAL CO., LTD

Application No.: CN2010/001221   Filing Date: 11/Aug/2010

Abstract:A pharmaceutical solution comprising cetirizine hydrochloride, an alcohol compound with less than 3 carbon atoms, a preservative and urea is disclosed. The cetirizine hydrochloride is in racemic form or in levo form.

Priority: CN20091165840 Applic. Date: 2009-08-12; CN20091211361 Applic. Date: 2009-10-31

Inventor: ZHAO ZHIQUAN [CN]


Publication No.: WO2011017998A1  Published: 17/Feb/2011

Title: GAMBOGIC ACID CYCLIZATION ANALOGUES, PREPARATION METHOD AND APPLICATION THEREOF

Applicant/Assignee: LIAONING LIFENG SCIENTIFIC & TECHNOLOGY DEVELOPMENT COMPANY LTD

Application No.: CN2010/075625   Filing Date: 02/Aug/2010

Abstract:Gambogic acid cyclization analogues with formula I, II and III are disclosed, wherein cycles A, B and C are saturated or unsaturated alicyclic, alicyclic heterocyclic, aromatic ring or aromatic heterocyclic groups containing 4-10 members, and R1-R12 groups contain one or more of glycosyl, poly-hydroxy, amino acid group, acyloxy, phosphoric acid oxygen, sulfonic acid oxygen, alkoxy, aryloxy, heterocyclic oxygen, mercapto, substituted mercapto, chain alkyl, and/or cycle group. The gambogic acid cyclization analogues of the invention are synthesized from extracted and purified gambogic acid. Said gambogic acid cyclization analogues have antitumor, antiviral, antibacterial and antifungal activities and can be used as antitumor, antiviral, immune, antibacterial and antifungal medical agents. The medical agents may also contain other known antitumor, antiviral, immune, antibacterial and antifungal medicines.

Priority: CN20091166738 Applic. Date: 2009-08-12

Inventor: XU LIFENG [CN]


Publication No.: WO2011018510A1  Published: 17/Feb/2011

Title: NEW MACROLIDES AND THEIR USE

Applicant/Assignee: BASILEA PHARMACEUTICA AG

Application No.: EP2010/061822   Filing Date: 13/Aug/2010

Abstract:The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.

Priority: EP20090167830 Applic. Date: 2009-08-13

Inventor: KELLENBERGER JOHANNES LAURENZ [CH]; DREIER JUERG [CH]


Publication No.: WO2011018885A1  Published: 17/Feb/2011

Title: PREPARATION FOR EXTERNAL APPLICATION TO SKIN, SKIN WHITENING AGENT, ANTIOXIDANT AGENT, AND ANTI-AGING AGENT

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: JP2010/004877   Filing Date: 03/Aug/2010

Abstract:Disclosed are: a skin whitening agent which has an excellent skin whitening activity and can exhibit an excellent effect on the reduction in pigment deposition after sunburn, pigmented spots, freckles, chloasma or the like and the whitening of the skin

and an antioxidant agent and an anti-aging agent, both of which can prevent or inhibit the aging in the skin or skin diseases caused by active oxygen (free radical) and therefore have excellent free radical scavenging capability. Each of the skin whitening agent, the antioxidant agent and the anti-aging agent comprises an extract from a plant Polyalthia longifolia.

Priority: JP20090186478 Applic. Date: 2009-08-11

Inventor: SUZUKI RIKAKO [JP]; HASEGAWA KIYOTAKA [JP]; SATO KIYOSHI [JP]; KUSAKARI KEN [JP]; YOKOI TOKIYA [JP]


Publication No.: WO2011019060A1  Published: 17/Feb/2011

Title: HEDGEHOG SIGNAL INHIBITOR

Applicant/Assignee: KYOWA HAKKO KIRIN CO., LTD

Application No.: JP2010/063655   Filing Date: 11/Aug/2010

Abstract:Provided are a hedgehog signal inhibitor and the like that contain, as an active ingredient, either a condensed heterocyclic derivative represented by general formula (I) or a pharmacologically permitted salt thereof. In formula (I), R1 represents a hydrogen atom or the like

R3 represents a lower alkyl or the like that may have a substituent

A represents a cycloalkyl or the like that may have a substituent

B represents a five- or six-membered nonaromatic carbon ring or the like that goes together with the -C=C- of the neighboring pyrrole ring and may have a substituent

L1 represents formula (i) or the like

L2 represents formula (iv) (in which R4 represents a hydrogen atom or the like), formula (v), or the like

and M represents formula (x) (in which R2 represents a hydrogen atom or the like

if L2 represents formula (v) or the like then Q does not exist

and if L2 represents formula (iv) then Q either does not exist or represents an oxygen atom) or the like.

Priority: JP20090187173 Applic. Date: 2009-08-12

Inventor: SUGAWARA MASAMORI [JP]; DANJO TOMOHIRO [JP]; SAWADA TAKASHI [JP]; ISHIDA HIROSHI [JP]; SAKU OSAMU [JP]; ICHIOKA MAKI [JP]; UESAKA NORIAKI [JP]; FUJIWARA KATSUAKI [JP]; FUJIHARA HIROAKI [JP]


Publication No.: WO2011019239A2  Published: 17/Feb/2011

Title: COMPOSITION CONTAINING A NATURAL EXTRACT

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: KR2010/005342   Filing Date: 13/Aug/2010

Abstract:Disclosed is a composition containing an active ingredient or ingredients comprising an extract or extracts of one or more constituents selected from the group consisting of Astragalus membranaceus, Saururus chinensis, Glycyrrhizae radix, rose, rhubarb, Acanthopanax senticosus and cortex Phellodendri. The composition is efficacious in suppressing acneiform pigment deposition and/or pitted scars, and can be used to advantage in various ways in the fields of foods and drugs.

Priority: KR20090075082 Applic. Date: 2009-08-14; KR20090075083 Applic. Date: 2009-08-14; KR20090075084 Applic. Date: 2009-08-14; KR20090075085 Applic. Date: 2009-08-14; KR20090075219 Applic. Date: 2009-08-14; KR20090075242 Applic. Date: 2009-08-14; KR20090075280 Applic. Date: 2009-08-14

Inventor: KIM JEONG-HWAN [KR]; PARK WON SEOK [KR]; KOH HYUN JU [KR]; SHIN HONG-JU [KR]; KIM DO-HOON [KR]; PARK JONG HEE [KR]; YI CHANG-GEUN [KR]; KIM HYOUNG JUN [KR]; SEO JUNG A [KR]


Publication No.: WO2011020167A1  Published: 24/Feb/2011

Title: SKIN CLARIFYING COMPLEX, USE OF SAID COMPLEX, COSMESTIC OR PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPLEX AND METHOD FOR APPLICATION THEREOF

Applicant/Assignee: NATURA COSMETICOS S.A

Application No.: BR2010/000268   Filing Date: 17/Aug/2010

Abstract:It is disclosed a skin clarifying complex comprising gallic acid and linoleic acid. It is further provided that the gallic acid can be obtained from Shinus sp and the linoleic acid can be obtained from passion flower oil. It is further disclosed the cosmetic or pharmaceutical use of the clarifying complex and a cosmetic or pharmaceutical composition comprising 0.25 to 10%, by weight, of said clarifying complex. The clarifying complex exhibits a high skin, spot and sprecke clarifying effect.

Priority: FR20090055693 Applic. Date: 2009-08-17

Inventor: DA LUZ MOREIRA PATRICIA [BR]; FERRARI CINTIA ROSA [BR]; TEIXEIRA TAGE BIAGGIO ROSA MARIA [BR]; SIQUEIRA JORGE ADRIANO TADEU [BR]; ARROTEIA KELEN FABIOLA [BR]


Publication No.: WO2011020311A1  Published: 24/Feb/2011

Title: USE OF PHARMACEUTICAL COMPOSITIONS IN PREPARING PHARMACEUTICALS FOR TREATING DIABETIC ULCER

Applicant/Assignee:

Application No.: CN2010/070263   Filing Date: 20/Jan/2010

Abstract:The use of pharmaceutical compositions in preparing pharmaceuticals for treating diabetic ulcer in limb or on body surface, or in preparing medical dressing. The pharmaceutical compositions consist of (A) 3 to 15% by weight of edible beeswax and (B) 85 to 97% by weight of sesame oil extract of Scutellaria root, Coptis root, Phellodendron bark, earthworm and poppy capsule, based on the total weight of the pharmaceutical compositions. In the sesame oil extract, each of Scutellaria root, Coptis root, Phellodendron bark, earthworm and poppy capsule is in an amount of 2 to 10% by weight of dry raw material based on the total weight of sesame oil. A medical dressing for treating diabetic ulcer and corresponding medicine box enclosing the said dressing are also provided.

Priority: CN20091091355 Applic. Date: 2009-08-20

Inventor: XU RONGXIANG [CN]


Publication No.: WO2011021203A2  Published: 24/Feb/2011

Title: DESFERRIOXAMINE-METAL COMPLEXES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS

Applicant/Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREWUNIVERSITY OF JERUSALEM LTD, HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENTLTD

Application No.: IL2010/000681   Filing Date: 19/Aug/2010

Abstract:The present invention relates to methods kits and combined compositions using DFO-metal complexes, specifically, Zinc-desferrioxamine (Zn-DFO), gallium-desferrioxamine (Ga-DFO) complexes and any combinations thereof for preventing, treating, ameliorating or inhibiting an immune-related disorder, specifically, a skin-related inflammatory disorder such as psoriasis, an inflammatory respiratory condition such as asthma, and an autoimmune disease such as diabetes and any immune-related disorder.

Priority: US20090235062P Applic. Date: 2009-08-19; US20100298596P Applic. Date: 2010-01-27; US20100347617P Applic. Date: 2010-05-24

Inventor: CHEVION MORDECHAI [IL]; VINOKUR VLADIMIR [IL]; BERENSHTEIN EDUARD [IL]; ELIASHAR RON [IL]; BULVIK BARUCH [IL]


Publication No.: WO2011021678A1  Published: 24/Feb/2011

Title: FUSED HETEROCYCLIC COMPOUND

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: JP2010/064042   Filing Date: 20/Aug/2010

Abstract:Disclosed are: a fused heterocyclic compound having excellent medical activities including a p38 MAPK-inhibiting activity and a TNF-a production-inhibiting activity

a medicinal agent comprising the compound

and others. Specifically disclosed is a compound represented by formula (I) [wherein one of Y1 and Y2 represents an N atom and the other represents CH

one of X1 and X2 represents CH and the other represents C-L-R2

L represents a bond, -NH-, -CH2- or -CO-

R1 represents an optionally substituted phenyl group, an optionally substituted heterocyclic group, an optionally substituted C1-6 alkyl group, an optionally substituted C3-6 cycloalkyl group, or an optionally substituted indanyl group

and R2 represents an optionally substituted aryl group, or an optionally substituted bicyclic heteroaryl group] or a salt thereof. The compound is useful as a p38 MAPK inhibitor and/or a TNF-a production inhibitor.

Priority: JP20090192602 Applic. Date: 2009-08-21

Inventor: MIWATASHI SEIJI [JP]; KAIEDA AKIRA [US]; TAKAHASHI MASASHI [US]; INUI HIROMI [JP]; OKAMOTO REI [JP]


Publication No.: WO2011021818A2  Published: 24/Feb/2011

Title: COMPOSITION FOR PROLIFERATING EPIDERMAL KERATINOCYTE STEM CELLS

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: KR2010/005387   Filing Date: 16/Aug/2010

Abstract:Disclosed is a composition for improving skin regeneration or skin elasticity, which contains, as an active ingredient, one or more ortho-dihydroxyisoflavone derivatives selected from a group consisting of 4',7,8-trihydroxyisoflavone, 4',6,7-trihydroxyisoflavone and 3',4',7- trihydroxyisoflavone. The composition promotes the proliferation of epidermal keratinocyte stem cells and exhibits the effects of improving skin regeneration or skin elasticity, and thus can be widely used in the field of cosmetics or pharmaceuticals.

Priority: KR20090075678 Applic. Date: 2009-08-17

Inventor: SHIN DONG WOOK [KR]; PARK JUN SEONG [KR]; KIM DONG HYUN [KR]; NOH MIN SOO [KR]; KIM DUCK HEE [KR]


Publication No.: WO2011021892A2  Published: 24/Feb/2011

Title: COMPOSITION FOR SKIN IMPROVEMENT COMPRISING HEXAMIDINES AND RETINOIDS

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: KR2010/005541   Filing Date: 20/Aug/2010

Abstract:Disclosed is herein a composition comprising hexamidines, derivatives thereof, or pharmaceutically acceptable salts thereof

and retinoids, derivatives thereof, or pharmaceutically acceptable salts thereof, as an active ingredient. The composition of the present invention has effects for preventing, improving or treating acne

controlling sebum

pore-controlling

and preventing, improving or treating skin pigmentation. Also, the composition of the present invention could alleviate skin-irritations caused with retinoids by including ceramides.

Priority: KR20090077158 Applic. Date: 2009-08-20

Inventor: PARK JONG HEE [KR]; PARK SHIN YOUNG [KR]; SHIN HONG-JU [KR]; KIM DO-HOON [KR]; YI CHANG-GEUN [KR]; PARK WON SEOK [KR]; KOH HYUN JU [KR]; KIM JEONG-HWAN [KR]; KIM HYOUNG JUN [KR]


Publication No.: WO2011022389A1  Published: 24/Feb/2011

Title: COMPOSITIONS AND METHODS FOR WOUND HEALING

Applicant/Assignee: UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL

Application No.: US2010/045747   Filing Date: 17/Aug/2010

Abstract:The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osetoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked a-gal epitopes for induction of recruitment of macrophages localized within or surrounding damaged tissue. The recruited macrophages recruit stem cells and promote the repair and regeneration of the treated injured tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects. In some embodiments, the present invention provides treatments for injured tissues such as brain, peripheral nerve, heart muscle, skeletal muscle, cartilage, bone, gastrointestinal tract and dysfunctional endocrine tissues.

Priority: US2009-542377 Applic. Date: 2009-08-17

Inventor: GALILI URI [US]


Publication No.: WO2011022652A1  Published: 24/Feb/2011

Title: TOPICAL GELS

Applicant/Assignee: NOVAN, INC

Application No.: US2010/046173   Filing Date: 20/Aug/2010

Abstract:Provided according to some embodiments of the invention are topical gels that may release nitric oxide. Also provided are methods of using such topical gels in the treatment of wounds and other skin ailments. The topical gels comprise diazeniutndiolate-functionalized polysiloxane macromolecules.

Priority: US20090235933P Applic. Date: 2009-08-21

Inventor: STASKO NATHAN [US]; BAUMAN SUSANNE [US]; JOSHI PRANAV R [US]


Publication No.: WO2011022757A1  Published: 03/Mar/2011

Title: PURINE-TARGETED DIAGNOSIS AND THERAPY OF WOUNDS

Applicant/Assignee: QUEENSLAND UNIVERSITY OF TECHNOLOGY

Application No.: AU2010/001037   Filing Date: 13/Aug/2010

Abstract:Methods of treating a wound, an ulcer and/or a burn responsive to inhibition of xanthine oxidoreductase to thereby reduce uric acid in an animal are provided wherein the methods include topical administration of a therapeutic agent effective for treatment of the wound, the ulcer and/or the burn wherein the therapeutic agent inhibits xanthine oxidoreductase to thereby reduce uric acid in the wound, ulcer and/or burn. Also provided are methods and kits for determining the severity of a wound, a burn and/or an ulcer including the step of detecting one or more of (i) a level of uric acid

(ii) a level of one or more uric acid precursors

and (iii) a presence, or absence of, or level of xanthine oxidoreductase.

Priority: AU20090904013 Applic. Date: 2009-08-24

Inventor: FERNANDEZ MELISSA LAURA [AU]; SHOOTER GARY KEITH [AU]


Publication No.: WO2011023013A1  Published: 03/Mar/2011

Title: MEDICINE FOR DISSOLVING AND ELIMINATING WART AND EXCRESCENCE CONSISTING OF PROTEIN AND ITS USES

Applicant/Assignee:

Application No.: CN2010/073628   Filing Date: 07/Jun/2010

Abstract:A pharmaceutical composition for dissolving and eliminating wart and excrescence consisting of protein is disclosed in the present invention. The pharmaceutical composition comprises (in 100 weight parts) 1.0-60.0 parts of sodium hydroxide and/or potassium hydroxide. The pharmaceutical composition further comprises 0.25-1.0 parts of amethocaine, bufalin, venenum bufonis and/or menthol having local anesthetic effect. The pharmaceutical composition can dissolve and eliminate wart and excrescence consisting of protein immediately and has significant effect and low side effect.

Priority: CN20091042030 Applic. Date: 2009-08-24

Inventor: TAM KUOK LEONG [CN]; TAM IO CHENG [CN]; TAM IO MAN [CN]


Publication No.: WO2011023081A1  Published: 03/Mar/2011

Title: 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS

Applicant/Assignee: ASCEPION PHARMACEUTICALS, INC

Application No.: CN2010/076199   Filing Date: 20/Aug/2010

Abstract:The present invention provides 5,6-bicyclic heteroaryl-containing urea compounds of Formula I or II and use of the same for treating conditions mediated by protein kinase such as VEGFR2, c-Met, PDGFRss c-Kit, CSFlR, or EphA2.

Priority: US20090236274P Applic. Date: 2009-08-24

Inventor: JIANG SHAN [US]; XING XINGLONG [CN]; WANG QISHAN [US]; KONG REN [CN]


Publication No.: WO2011023287A1  Published: 03/Mar/2011

Title: USE OF FAA AND ITS DERIVATIVES IN COSMETICS AND DERMATOLOGY

Applicant/Assignee: MERCK PATENT GMBH

Application No.: EP2010/004875   Filing Date: 10/Aug/2010

Abstract:The invention relates to flavone acetic acid, its derivatives and its use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing flavone acetic acid and/or its derivatives.

Priority: EP20090010961 Applic. Date: 2009-08-27

Inventor: ANZALI SOHEILA [DE]


Publication No.: WO2011023573A1  Published: 03/Mar/2011

Title: ANTIMICROBIAL AMINO-SALICYLIC ACID DERIVATIVES

Applicant/Assignee: BASF SE

Application No.: EP2010/061804   Filing Date: 13/Aug/2010

Abstract:Disclosed is a novel method for achieving an antimicrobial, preservative and/or microorganism adhesion inhibiting effect, for the protection within an article and/or material or on the surface of an article and/or material. The novel method comprises application of a salicylic compound of the formula (I) wherein one of A and A is a residue of the formula (I'): -NH-CO-R1 while the other is hydrogen

R1 is C1-C22alkyl, C3-C12cycloalkyl, C3-C12cycloalkyl interrupted by O and/or NR5, C4-C12aryl, C5-C18arylalkyl

R2 is OR3 or NHR4

R3 and R4 are selected from H, C1-C22alkyl, C3-C12cycloalkyl, C3-C12cycloalkyl interrupted by O and/or NR5, C4-C12aryl, C5-C18arylalkyl

R5 is H or C1-C8alkyl

wherein each aryl moiety is unsubstituted or substituted by C1-C4alkyl, C1-C4alkoxy, C1-C4acyl, C1-C4acyloxy, C1-C4acylamino, CF3, OH, amino, halogen

or an adduct or salt thereof

to said article and/or material.

Priority: EP20090168669 Applic. Date: 2009-08-26

Inventor: HOELZL WERNER [FR]; PURSCHWITZ JANINA [DE]


Publication No.: WO2011024027A1  Published: 03/Mar/2011

Title: PHARMACEUTICAL COMBINATIONS OF DIFLUCORTOLONE AND TERBINAFINE

Applicant/Assignee: ABDI IBRAHIM ILAC SANAYI VE TICARET ANONIM SIRKETI

Application No.: IB2009/053700   Filing Date: 24/Aug/2009

Abstract:This invention relates to pharmaceutical combinations, compositions and kits of diflucortolone and terbinafine and methods of using such combinations in the treatment of skin disease or diseases which respond to topical corticoid therapy where said skin disease or diseases are associated with one or more fungis or to prevent skin disease or diseases which respond to topical corticoid therapy where there is a likelihood of associating with one or more fungal diseases.

Priority:

Inventor: FARSHI FARHAD [TR]; KOC FIKRET [TR]; SOYLEMEZ SERDAR [TR]


Publication No.: WO2011024620A1  Published: 03/Mar/2011

Title: ANTIMYCOTIC PHARMACEUTICAL COMPOSITION

Applicant/Assignee: POLA PHARMA INC, NIHON NOHYAKU CO., LTD

Application No.: JP2010/063230   Filing Date: 29/Jul/2010

Abstract:A pharmaceutical composition which comprises 1) a compound represented by the following general formula (1) and/or a salt thereof

and 2) a ketone such as methyl ethyl ketone. Preferably, the compound represented by the following general formula (1) is luliconazole, where R1=R2=a chlorine atom: where R1 and R2 each independently represents a hydrogen atom or a halogen atom, and at least one of R1 and R2 represents a halogen atom. The present invention provides a preparation excellent in solubilization stability for a compound represented by the general formula (1) and/or a salt thereof in low-temperature or high-temperature storage.

Priority: JP20090194835 Applic. Date: 2009-08-25

Inventor: KOBAYASHI HIROKAZU [JP]; KUBOTA NOBUO [JP]


Publication No.: WO2011024711A1  Published: 03/Mar/2011

Title: NOVEL COMPOUND AMYCOLOSE DERIVATIVE, AND PRODUCTION PROCESS AND USE OF SAME

Applicant/Assignee: MICROBIAL CHEMISTRY RESEARCH FOUNDATION

Application No.: JP2010/064033   Filing Date: 19/Aug/2010

Abstract:A novel compound represented by general formula (1) and salts thereof, which are obtained by subjecting amycolamicin obtained from a microorganism belonging to the genus Amycolatopsis or a salt thereof to decomposition under acid conditions, and which exhibit inhibitory activity against cell proliferation. In general formula (1), R is a hydrogen atom or an alkyl group.

Priority: JP20090194376 Applic. Date: 2009-08-25

Inventor: TOHYAMA SHIGEHIRO [JP]


Publication No.: WO2011024874A1  Published: 03/Mar/2011

Title: BASE ADDITION SALTS

Applicant/Assignee: NIPPON SHINYAKU CO., LTD

Application No.: JP2010/064416   Filing Date: 25/Aug/2010

Abstract:Provided is novel base addition salts of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide (hereinafter referred to as "compound (A)"). As an example of the aforesaid base addition salts, a base addition salt composed of compound (A) and a base selected from the group consisting of (a) to (d) can be cited: (a) t-butylamine

(b) potassium

(c) sodium

and (d) dimethylaminoethanol.

Priority: JP20090196079 Applic. Date: 2009-08-26; JP20090196080 Applic. Date: 2009-08-26; JP20090196081 Applic. Date: 2009-08-26; JP20090196082 Applic. Date: 2009-08-26

Inventor: VICTOR M DIAZ PEREZ [GB]; JENNIFER HILL [GB]


Publication No.: WO2011024918A1  Published: 03/Mar/2011

Title: ANTIANGIOGENIC AGENT AND METHOD FOR INHIBITION OF ANGIOGENESIS

Applicant/Assignee: OSAKA UNIVERSITY

Application No.: JP2010/064523   Filing Date: 26/Aug/2010

Abstract:Disclosed are: an antiangiogenic agent having a higher therapeutic effect than those of conventional antiangiogenic agents

and a method for inhibiting angiogenesis, which utilizes the antiangiogenic agent. The antiangiogenic agent comprises at least one type of miRNA selected from the group consisting of miRNA, pre-miRNA and pri-miRNA each having an miRNA activity on VE-cadherin.

Priority: JP20090195848 Applic. Date: 2009-08-26

Inventor: TAKAKURA NOBUYUKI [JP]; KIDOYA HIROYASU [JP]; MURAMATSU FUMITAKA [JP]


Publication No.: WO2011024942A1  Published: 03/Mar/2011

Title: MATRIX METALLOPROTEASE-2 (MMP-2) INHIBITOR

Applicant/Assignee: FUJIFILM CORPORATION

Application No.: JP2010/064568   Filing Date: 27/Aug/2010

Abstract:For the purpose of developing novel use applications of resveratrol, an inhibitory activity of resveratrol on matrix metalloprotease-2 (MMP-2) is found. A preparation for exhibiting the inhibitory activity of resveratrol on matrix metalloprotease-2 (MMP-2) effectively is provided. Thus, disclosed is a matrix metallo protease-2 (MMP-2)inhibitor comprising resveratrol as an active ingredient.

Priority: JP20090197544 Applic. Date: 2009-08-28

Inventor: MURAGUCHI TAICHI [JP]; AIMI MAKIKO [JP]; KUBO TOSHIAKI [JP]


Publication No.: WO2011024955A1  Published: 03/Mar/2011

Title: NUCLEIC ACID CAPABLE OF BINDING TO TGF-?II-TYPE RECEPTOR, AND USE THEREOF

Applicant/Assignee: THE UNIVERSITY OF TOKYO

Application No.: JP2010/064612   Filing Date: 27/Aug/2010

Abstract:Disclosed is a substance which can be used for the elucidation of the physiological functions of TGF-ss and a TGF-ssII-type receptor and the analysis of mechanism of development of TGF-ss-induced diseases and the diagnosis and treatment of TGF-ss-induced diseases. Specifically disclosed are: an aptamer which is characterized by being capable of binding to a TGF-ssII-type receptor and being capable of inhibiting the binding between TGF-ss and a TGF-ssII-type receptor

a method for detecting a TGF-ssII-type receptor, which is characterized by using the aptamer

a medicinal agent comprising the aptamer

and others.

Priority: JP20090198813 Applic. Date: 2009-08-28

Inventor: NAKAMURA YOSHIKAZU [JP]; YAMAMURA YASUKO [JP]


Publication No.: WO2011024987A1  Published: 03/Mar/2011

Title: AROMATIC FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

Applicant/Assignee: SHIONOGI & CO. LTD

Application No.: JP2010/064665   Filing Date: 30/Aug/2010

Abstract:Disclosed is a compound having an activity of modulating a histamine-H4 receptor. Specifically disclosed is a compound represented by formula (I) [wherein Ra and Rb independently represent a hydrogen atom, a substituted or unsubstituted alkyl group, or the like

X represents -O- or -S(O)p-

p represents an integer of 0 to 2

Y represents =O or =S

R1 represents a halogen atom, a substituted or unsubstituted alkyl group, or the like

n represents an integer of 0 to 4

and R2 represents a hydrogen atom, a substituted or unsubstituted alkyl group, or the like], a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable salt.

Priority: JP20090200094 Applic. Date: 2009-08-31

Inventor: TACHIBANA YUUKI [JP]; MASUDA TSUTOMU [JP]


Publication No.: WO2011025107A1  Published: 03/Mar/2011

Title: COMPOSITION FOR RELIEVING PRURITUS

Applicant/Assignee: INDUSTRIAL COOPERATION FOUNDATION CHONBUK NATIONAL UNIVERSITY

Application No.: KR2010/001375   Filing Date: 05/Mar/2010

Abstract:The present invention relates to a composition for relieving pruritus, and more specifically, to a composition for relieving pruritus containing peptides formed by coupling glutamine and one or more types of amino acids, as an effective ingredient. The composition of the present invention has an excellent relieving effect on all skin diseases accompanied by skin itching.

Priority: KR20090080298 Applic. Date: 2009-08-28; KR20090106620 Applic. Date: 2009-11-05

Inventor: LEE HERN KU [KR]; CHO BAIK HWAN [KR]


Publication No.: WO2011025635A2  Published: 03/Mar/2011

Title: COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED COMPOSITIONS

Applicant/Assignee: AVON PRODUCTS, INC

Application No.: US2010/044360   Filing Date: 04/Aug/2010

Abstract:Cosmetic compositions comprising a metal-complexed peptide fraction of stressed yeast extracts and/or a calcium influx inhibitor are disclosed, as well as methods of using such compositions to impart exfoliating, anti-aging, anti-lipid, anti-inflammatory, and/or lightening benefits to the skin

and/or lightening benefits to the hair. These compositions are believed to have modulatory activity against at least one biochemical pathway implicated in skin aging, inflammation, lipid synthesis, and melanin production.

Priority: US20090238427P Applic. Date: 2009-08-31

Inventor: SANTHANAM UMA [US]; KYROU CHRISTOS D [US]; MAZICH DESIREE [US]; HONG QI [US]; SHAHEEN HUSSAM H [US]


Publication No.: WO2011026076A2  Published: 03/Mar/2011

Title: TOPICAL FORMULATIONS COMPRISING A STEROID

Applicant/Assignee: DR. REDDY'S LABORATORIES LTD, DR. REDDY'S LABORATORIES, INC

Application No.: US2010/047240   Filing Date: 31/Aug/2010

Abstract:The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.

Priority: IN2009CH02111 Applic. Date: 2009-08-31; US20090256554P Applic. Date: 2009-10-30

Inventor: UBAIDULLA UDHUMANSHA [IN]; KANDAVILLI SATEESH [IN]; VAIRALE AJAY SUNIL [IN]; WAYNE JEFFREY A [CA]; NALAMOTHU VIJENDRA [US]; MEGHAL MISTRY [IN]; PAKUNLU REFIKA ISIL [US]


Publication No.: WO2011026094A2  Published: 03/Mar/2011

Title: STABLE AEROSOL TOPICAL FOAMS COMPRISING A HYPOCHLORITE SALT

Applicant/Assignee: COLLEGIUM PHARMACEUTICAL, INC, PRECISION DERMATOLOGY, INC

Application No.: US2010/047296   Filing Date: 31/Aug/2010

Abstract:Described herein are compositions useful in the treatment of atopic dermatitis and other skin conditions, which compositions exhibit enhanced stability. The compositions contain a hypochlorite salt, useful for its antimicrobial properties, and are non-irritating when applied to the skin. The compositions also provide enhanced moisturizing properties. The compositions can be formulated into a topical aerosol foam with inert, non-flammable propellants, such as hydrofluoroalkanes, and may be used in cosmetics or pharmaceuticals.

Priority: US20090238439P Applic. Date: 2009-08-31

Inventor: ABEL DOUGLAS [US]; GURGE RONALD M [US]; TRUMBORE MARK W [US]


Publication No.: WO2011026351A1  Published: 10/Mar/2011

Title: A CYANOVIRIN N MUTANT, MODIFIED DERIVATIVE AND USES THEREOF

Applicant/Assignee: JINAN UNIVERSITY

Application No.: CN2010/073124   Filing Date: 24/May/2010

Abstract:A cyanovirin N (CVN) mutant, its PEG modified derivative and their uses in preparing drugs. The said cyanovirin N mutant is composed of sequence A and sequence B: sequence A is a linker peptide with hydrophilicity and flexibility, sequence B is a codon optimized sequence of cyanovirin N. The cyanoviein N mutant is modified by PEG to obtain derivative. The mutant and the derivative both exhibit good anti-HIV activities, and have prospect of being used in preparing drugs for anti-HIV and other viral microorganism.

Priority: CN20091192063 Applic. Date: 2009-09-04

Inventor: XIONG SHENG [CN]; CHEN WEI [CN]; QIAN CHUIWEN [CN]; WANG YIFEI [CN]; KITAZATO KAIO [CN]


Publication No.: WO2011026781A1  Published: 10/Mar/2011

Title: NOVEL MULTIFUNCTIONAL PEPTIDASE INHIBITORS, ESPECIALLY FOR MEDICAL USE

Applicant/Assignee: IMTM GMBH

Application No.: EP2010/062472   Filing Date: 26/Aug/2010

Abstract:The invention relates to compounds of the general formula (1) or the acid addition salts thereof with organic and/or inorganic acids

as well as to the use of the compounds of the general formula (1) in medicine.

Priority: EP20090169269 Applic. Date: 2009-09-02

Inventor: ANSORGE SIEGFRIED [DE]; BANK UTE [DE]; NORDHOFF KARSTEN [DE]; ROEHNERT PETER [DE]; STEFIN SOFIA [DE]; STRIGGOW FRANK [DE]; TAEGER MICHAEL [DE]


Publication No.: WO2011027048A1  Published: 10/Mar/2011

Title: TRANSGLUTAMINASE-ACTIVATING PEPTIDE, AND COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING SAME

Applicant/Assignee: ISP INVESTMENTS INC

Application No.: FR2010/000595   Filing Date: 31/Aug/2010

Abstract:The present invention relates to a peptide of general formula (I) R1-(AA)n-X1-X2--Arg-Arg-GIy-X3-X4-(AA)P-R2. The present invention also relates to a cosmetic or pharmaceutical composition including at least one peptide of general formula (I) in a physiologically suitable medium. The present invention further relates to the use of a composition containing the peptide of general formula (I) as an active principle activating human transglutaminase in order to reinforce the skin barrier function and stimulate epidermal regeneration and differentiation. The invention also relates to a cosmetic treatment method for preventing and/or controlling external stresses and signs of skin aging.

Priority: FR20090004218 Applic. Date: 2009-09-04

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Publication No.: WO2011027128A1  Published: 10/Mar/2011

Title: USE OF NON-DIGESTIBLE OLIGOSACCHARIDES

Applicant/Assignee: THE UNIVERSITY OF MANCHESTER

Application No.: GB2010/001680   Filing Date: 03/Sep/2010

Abstract:Use of a non-digestible oligosaccharide or salt thereof for producing an anti proliferative effect in a subject wherein the non-digestible oligosaccharide is of formulae (i) [A]-[B]n Formula 1 wherein A and B are each independently a five or six membered saccharide unit and n is 2 to 10.

Priority: GB20090015315 Applic. Date: 2009-09-03

Inventor: PAUS RALF LUDWIG [DE]; O'NEILL CATHERINE ANNE [GB]


Publication No.: WO2011027348A1  Published: 10/Mar/2011

Title: PHARMACEUTICAL COMPOSITION COMPRISING A3 ADENOSINE RECEPTOR AGONIST (IB-MECA/CF-101) FOR TREATMENT OF PSORIASIS

Applicant/Assignee: CAN-FITE BIOPHARMA LTD

Application No.: IL2010/000729   Filing Date: 06/Sep/2010

Abstract:The present invention is based on the clinical finding that twice daily administrations of 2 mg of 1-[N6-(3-iodobenzyl)-adenin-9-yl]-ss-D-ribofuronamide (IB-MECA) (total daily administration of 4mg) to subjects having moderate to severe psoriasis, was significantly more effective in treatment of the psoriatic plaques than treatment of psoriasis at two administration doses of 1 mg or 4 mg (total daily doses of 2 or 8mg, respectively). Thus, the present invention provides a pharmaceutical composition for the treatment of psoriasis comprising as the active ingredient IB-MECA in an amount suitable for a total daily dose administration of about 4 mg. In one preferred embodiment IB-MECA is administered twice a day to a subject in need of psoriasis treatment, the pharmaceutical composition comprising an administration dose of 2mg.

Priority: IL20090200753 Applic. Date: 2009-09-06

Inventor: FISHMAN PNINA [IL]


Publication No.: WO2011027916A1  Published: 10/Mar/2011

Title: THERAPEUTIC AGENT FOR ALLERGIC DISEASES

Applicant/Assignee: NIHON UNIVERSITY

Application No.: JP2010/065689   Filing Date: 07/Sep/2010

Abstract:Disclosed are: an inhibitor of the IgE-dependent activation of mast cells

a method for inhibiting the the IgE-dependent activation of mast cells

a pharmaceutical composition for treating and/or preventing allergic diseases

a method for treating and/or preventing allergic diseases

a phosphorylated peptide which can be used for the inhibitors and the methods

and others. The inhibitor of the IgE-dependent activation of mast cells is characterized by comprising a peptide (a) or (b), a derivative of the peptide, or a salt of the peptide or the derivative: (a) a peptide which comprises the amino acid sequence represented by formula (I): KVPEDRV-Y1-EELNI-Y2-SAT-Y3-SELEDPG

and (b) a peptide which is produced by deleting, substituting or adding one or several amino acid residues in the amino acid sequence represented by formula (I) and which has an inhibitory activity on the IgE-dependent activation of mast cells.

Priority: JP20090206324 Applic. Date: 2009-09-07

Inventor: OKAYAMA YOSHIMICHI [JP]; RA CHISEI [JP]


Publication No.: WO2011028110A1  Published: 10/Mar/2011

Title: COMPOSITION FOR TOPICAL APPLICATION, USES THEREOF, APPLICATOR DEVICE AND KIT OF PARTS

Applicant/Assignee: ZACCO NETHERLANDS B.V

Application No.: NL2010/050549   Filing Date: 01/Sep/2010

Abstract:The invention relates to a composition for topical application. The invention further relates to various uses for the treatment of skin conditions, including acne, warts, corns and calluses, psoriasis, keratosis pilaris and conditions in general involving keratinized skin. The invention further relates to an applicator device and kit of parts comprising such a composition. The composition comprises at least one physiologically acceptable C1 -C4 alkyl ester of a carboxylic acid as a carrier, and an effective amount of salicylic acid, and/or a physiologically acceptable ester of salt thereof.

Priority: NL20092003419 Applic. Date: 2009-09-01

Inventor: CLAPPOSEN MIRIAM [NL]


Publication No.: WO2011028112A1  Published: 10/Mar/2011

Title: IMIDAZOLE-4-CARBOXYLIC ACID FOR USE IN TREATING A DISEASE RELATED TO EXTRACELLULAR REACTIVE OXYGEN SPECIES

Applicant/Assignee: VALLETTA HEALTH B.V

Application No.: NL2010/050551   Filing Date: 02/Sep/2010

Abstract:The invention relates to the field of medicine and in particular to the use of imidazole-4-carboxylic acid or a pharmaceutically acceptable salt thereof for use in treating a disease related to extracellular reactive oxygen species, such as acne, atopic dermatitis, rosacea, pyoderma gangrenosum, necrotizing fasciitis, Sweet's syndrome, Behçet's disease, septic shock, rheumatoid arthritis, or colitis. The present invention also relates to the field of pharmacy and in particular to the pharmaceutical use of imidazole-4-carboxylic acid.

Priority: EP20090169302 Applic. Date: 2009-09-02

Inventor: KAMMEIJER ARTHUR [NL]; BOS JOANNES DOSITHEUS [NL]


Publication No.: WO2011028542A2  Published: 10/Mar/2011

Title: METHODS OF TREATING PAIN ASSOCIATED WITH COMPLEX REGIONAL PAIN SYNDROME

Applicant/Assignee: ZARS PHARMA, INC

Application No.: US2010/046523   Filing Date: 24/Aug/2010

Abstract:The present invention is drawn to methods for treating pain associated with complex regional pain syndrome. Specifically, a method for treating pain associated with complex regional pain syndrome includes the application of an analgesic system to a skin surface of a subject experiencing the pain and maintaining the analgesic system on the skin surface for a period of time of at least 30 minutes. The analgesic system applied to the skin surface can include a heating component and a local anesthetic formulation which includes at least one local anesthetic. The heating component can be capable of heating the skin surface to a temperature of 36 DEG C to 42 DEG C.

Priority: US20090236221P Applic. Date: 2009-08-24

Inventor: ZHANG JIE [US]; CROCKETT ANDREW [GB]; RIGBY LARRY [US]


Publication No.: WO2011028567A2  Published: 10/Mar/2011

Title: COMPOSITION AND METHOD FOR SKIN REPAIR

Applicant/Assignee: ACCESS BUSINESS GROUP INTERNATIONAL LLC

Application No.: US2010/046613   Filing Date: 25/Aug/2010

Abstract:A composition and a method of using the composition is described that is effective to protect or repair oxidative damage to DNA in mammalian skin by up regulating each of SIRT1, Gadd45b, and SOD2. The composition includes at least two of a candle bush extract, noni leaf extract, and melon extract with each present in an amount such that the composition is effective to up regulate each of SIRT1, Gadd45b, and SOD2.

Priority: US20090239240P Applic. Date: 2009-09-02

Inventor: BRUMBAUGH ERNEST H [US]; RAJGOPAL ARUN [US]


Publication No.: WO2011029784A1  Published: 17/Mar/2011

Title: PROBIOTIC LACTOBACILLUS RHAMNOSUS STRAIN AND ORAL AND TOPICAL USES THEREOF

Applicant/Assignee: GIULIANI SPA

Application No.: EP2010/062993   Filing Date: 03/Sep/2010

Abstract:The present invention relates to a selected probiotic strain of Lactobacillus rhamnosus and its uses in the nutritional, cosmetic and/or medical fields. The Lactobacillus rhamnosus strain of the invention has anti-inflammatory activity and is applied mainly in the treatment of the skin inflammatory and/or allergic infections, such as eczema, acne, seborrhoeic, atopic dermatitis and in the treatment of the sensitive skin.

Priority: IT2009MI01547 Applic. Date: 2009-09-08

Inventor: GIULIANI GIAMMARIA [IT]; BENEDUSI ANNA [IT]; MASCOLO ANTONIO [IT]


Publication No.: WO2011029861A1  Published: 17/Mar/2011

Title: PLGF-1 IN HOMODIMERIC FORM

Applicant/Assignee: DOMPE PHA.R.MA S.P.A, GEYMONAT S.P.A

Application No.: EP2010/063217   Filing Date: 09/Sep/2010

Abstract:The present invention relates to a new homodimeric form of recombinant PlGF-1, to a process for its preparation and to compositions containing it.

Priority: EP20090169873 Applic. Date: 2009-09-09

Inventor: D ANNIBALLE GAETANO [IT]; MARTIN FRANCK [IT]; SALVIA GIUSEPPE [IT]


Publication No.: WO2011029996A1  Published: 17/Mar/2011

Title: USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS

Applicant/Assignee: BIOTIE THERAPIES CORP, THE UNIVERSITY OF BIRMINGHAM

Application No.: FI2010/050689   Filing Date: 07/Sep/2010

Abstract:The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.

Priority: US20090240402P Applic. Date: 2009-09-08; US20100323032P Applic. Date: 2010-04-12

Inventor: WESTON CHRISTOPHER [GB]; CLARIDGE LEE CHARLES [GB]; ADAMS DAVID [GB]; SMITH DAVID [FI]; WESTERLUND NINA [FI]; PIHLAVISTO MARJO [FI]; OESTERMAN THUA [FI]


Publication No.: WO2011030727A1  Published: 17/Mar/2011

Title: EXTERNAL PREPARATION CONTAINING PANTETHINE PHOSPHATE ESTER

Applicant/Assignee: DAIICHI FINE CHEMICAL CO., LTD

Application No.: JP2010/065202   Filing Date: 06/Sep/2010

Abstract:A pantethine phosphate ester represented by formula (1) or formula (2) has an excellent inhibitory effect on tyrosinase activity and an excellent inhibitory effect on melanin production.

Priority: JP20090210888 Applic. Date: 2009-09-11

Inventor: WADA KOICHI [JP]; SUMI KOICHI [JP]; SHIMOMURA SHIHOKO [JP]


Publication No.: WO2011030859A1  Published: 17/Mar/2011

Title: SKIN-WHITENING COMPOSITION

Applicant/Assignee: ROHTO PHARMACEUTICAL CO., LTD

Application No.: JP2010/065639   Filing Date: 10/Sep/2010

Abstract:Disclosed is a composition having both a higher skin-whitening activity and a higher cell-activating activity. It is found that a combination of d-tocopherol and an extract from Centella Asiatica has a high inhibitory activity on the production of melanin. The extract from Centella Asiatica preferably contains at least one component selected from the group consisting of asiatic acid, madecassic acid and asiaticoside, particularly preferably contains asiatic acid, madecassic acid and asiaticoside.

Priority: JP20090210444 Applic. Date: 2009-09-11

Inventor: OHTA NORIKO [JP]


Publication No.: WO2011030903A1  Published: 17/Mar/2011

Title: COMPOSITION FOR ALLEVIATING ULTRAVIOLET RADIATION-INDUCED DAMAGE

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: JP2010/065789   Filing Date: 14/Sep/2010

Abstract:Disclosed are a composition for alleviating ultraviolet radiation-induced damage, which is stable and safe and can be used on a day-to-day basis, and a medicinal composition, an external skin preparation, a food composition and a medicine for cataract, each comprising said composition for alleviating ultraviolet radiation-induced damage. Specifically disclosed is a composition for alleviating ultraviolet radiation-induced damage which contains one or more kinds of compounds selected from the group consisting of methionine, D-serine and derivatives and/or salts of the same. The aforesaid composition may be an external skin preparation, an anti-wrinkle agent, a sunscreen agent, a medicinal composition for treating and/or preventing skin diseases, a food composition or a medicine for cataract. In the aforesaid composition for alleviating ultraviolet radiation-induced damage, said methionine may be D-methionine, and said D-serine derivative may be D-cycloserine.

Priority: JP20090211255 Applic. Date: 2009-09-14; JP20090223327 Applic. Date: 2009-09-28

Inventor: ASHIDA YUTAKA [JP]; TOJO YOSUKE [JP]; MIZUMOTO CHIEKO [JP]; MITA MASASHI [JP]


Publication No.: WO2011030927A1  Published: 17/Mar/2011

Title: COMPOUND FOR INHIBITING TYPE-3 17?-HYDROXYSTEROID DEHYDROGENASE

Applicant/Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED

Application No.: JP2010/066115   Filing Date: 13/Sep/2010

Abstract:Use of a compound represented by formula (I), a salt of the compound, or a solvate of the compound or the salt for inhibiting type-3 17ss-hydroxysteroid dehydrogenase

and others.

Priority: JP20090211419 Applic. Date: 2009-09-14

Inventor: HARADA KOICHIRO [JP]; KUBO HIDEKI [JP]; TANAKA AKIO [JP]


Publication No.: WO2011030929A1  Published: 17/Mar/2011

Title: COMPOUND FOR INHIBITING TYPE 3 17?-HYDROXYSTEROID DEHYDROGENASE

Applicant/Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED

Application No.: JP2010/066122   Filing Date: 13/Sep/2010

Abstract:Use of a compound represented by formula (I), a salt thereof or a solvate of the same for inhibiting type 3 17ss-hydroxysteroid dehydrogenase, and so on.

Priority: JP20090211420 Applic. Date: 2009-09-14

Inventor: HARADA KOICHIRO [JP]; KUBO HIDEKI [JP]


Publication No.: WO2011031554A2  Published: 17/Mar/2011

Title: HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS

Applicant/Assignee: BIOCRYST PHARMACEUTICALS, INC

Application No.: US2010/046999   Filing Date: 27/Aug/2010

Abstract:The invention provides compounds of formula (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula (I).

Priority: US20090237546P Applic. Date: 2009-08-27; US20100313583P Applic. Date: 2010-03-12

Inventor: BABU YARLAGADDA S [US]; KOTIAN PRAVIN L [US]; KUMAR V SATISH [US]; WU MINWAN [US]; LIN TSU-HSING [US]


Publication No.: WO2011033207A1  Published: 24/Mar/2011

Title: COSMETIC COMPOSITION INCLUDING LEUCODOPACHROME DERIVATIVE

Applicant/Assignee: CHANEL PARFUMS BEAUTE

Application No.: FR2010/051845   Filing Date: 06/Sep/2010

Abstract:The present invention relates to a cosmetic or dermatological composition characterized in that it contains, in a physiologically acceptable medium, at least one compound from Formula (I). The invention also relates to a method, using said composition, for reducing or preventing pigmenting, and/or whitening and/or lightening of the skin. The invention also relates to novel compounds from Formula (I') that are included in Formula (I).

Priority: FR20090056365 Applic. Date: 2009-09-16

Inventor: DESMURS JEAN-ROGER [FR]; DELAIRE SABINE [FR]


Publication No.: WO2011033361A2  Published: 24/Mar/2011

Title: COMBINATION AND COMPOSITION THAT CONTAINS AN ANTIMICROBIAL, A GLUCOCORTICOID AND AN ANTIMYCOTIC

Applicant/Assignee: LABORATORIOS SENOSIAIN S.A. DE C.V

Application No.: IB2010/002301   Filing Date: 14/Sep/2010

Abstract:The present invention relates to a topical pharmaceutical composition that comprises the combination of an antimicrobial, a glucocorticoid, an antimycotic and pharmaceutically acceptable vehicles or excipients

the method for producing the composition and the use of said composition for treating localized dermatosis ailments.

Priority: MX20090009884 Applic. Date: 2009-09-15

Inventor: GARCIA SALGADO LOPEZ RAUL [MX]; BARRANCO HERNANDEZ GUSTAVO [MX]


Publication No.: WO2011033715A1  Published: 24/Mar/2011

Title: EXTERNAL PREPARATION FOR SKIN

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: JP2010/004889   Filing Date: 03/Aug/2010

Abstract:Provided is an external preparation for the skin which is excellent in terms of promoting production of the extracellular matrix, specifically collagen and hyaluronic acid, and is effective in the prevention and improvement of age-associated wrinkling and sagging. The external preparation for the skin comprises a C5-24 a-ketol or ?-ketol fatty acid as the active ingredient, wherein the number of double bonds between carbon atoms is from 1 to 6, or a derivative thereof.

Priority: JP20090214684 Applic. Date: 2009-09-16

Inventor: YOKOYAMA MINEYUKI [JP]; OCHIAI NOBUHIKO [JP]; AMANO SATOSHI [JP]; KISHIMOTO JIRO [JP]


Publication No.: WO2011034323A2  Published: 24/Mar/2011

Title: TRANSDERMAL DELIVERY SYSTEM, METHOD FOR MANUFACTURING THE SAME, AND TRANSDERMAL DELIVERY METHOD USING THE SYSTEM

Applicant/Assignee: SAMYANG CORPORATION

Application No.: KR2010/006251   Filing Date: 14/Sep/2010

Abstract:Disclosed is a transdermal delivery systemof multiple adhesive layers having a drug-free adhesive layer as an intermediate layer to control drug delivery rate. The transdermal delivery system enhances transdermal delivery rate in the early stage after application on skin and provides sustained control of the drug delivery rate in the intermediate and later stages. Thus, the drug delivery rate effective for treatment can be controlled in a sustained manner.

Priority: US20090242854P Applic. Date: 2009-09-16; KR20090106090 Applic. Date: 2009-11-04

Inventor: LEE HEONHAN [KR]


Publication No.: WO2011034328A2  Published: 24/Mar/2011

Title: COMPOSITION INCLUDING CHLOROPHYLL A AS AN ACTIVE INGREDIENT FOR PREVENTING AND TREATING TH2-MEDIATED IMMUNOLOGICAL DISEASES

Applicant/Assignee: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY

Application No.: KR2010/006268   Filing Date: 14/Sep/2010

Abstract:The present invention relates to a composition including chlorophyll a as an active ingredient for preventing and treating Th2-mediated immunological diseases. The composition of the present invention is very effective for preventing and treating atopic dermatitis which is one of the Th2-mediated immunological diseases. Chlorophyll a is a natural ingredient used to treat atopic dermatitis and is advantageous in that it causes absolutely no side effects in humans. Further, the composition of the present invention may be applied as a medical composition including chlorophyll a, which has preventive and therapeutic effects for atopic dermatitis, as a food composition, as a cosmetic composition, and for various other products using chlorophyll a, and has excellent marketability.

Priority: KR20090087238 Applic. Date: 2009-09-15

Inventor: KIM YONG-CHUL [KR]; PARK ZEE YONG [KR]


Publication No.: WO2011035158A2  Published: 24/Mar/2011

Title: NASAL, WOUND AND SKIN FORMULATIONS AND METHODS FOR CONTROL OF ANTIBIOTIC-RESISTANT STAPHYLOCOCCI AND OTHER GRAM-POSITIVE BACTERIA

Applicant/Assignee:

Application No.: US2010/049336   Filing Date: 17/Sep/2010

Abstract:Formulations and methods are disclosed which are effective to kill or control bacteria in the nares including gram-positive bacteria strains of S. aureus that are antibiotic resistant (MRSA - methicillin-resistant Staphylococcus aureus. A preferred composition comprises one or more medium-chain alcohols (dodecanol), glycerol monoesters (glycerol monocaprylate or glycerol monolaurate), and/or benzoic acid or benzoic acid analog, in a suitable pharmaceutical carrier, preferably an ointment, along with an odorant compound, preferably eucalyptus oil. The formulations and variations of the formulation may also be used on open wounds or lesions as well as intact skin.

Priority: US20090243455P Applic. Date: 2009-09-17; US20090257922P Applic. Date: 2009-11-04

Inventor: GUTHERY B EUGENE [US]


Publication No.: WO2011036304A1  Published: 31/Mar/2011

Title: LEAVEN-BASED MIXTURE

Applicant/Assignee: WORESAN GMBH

Application No.: EP2010/064333   Filing Date: 28/Sep/2010

Abstract:A mixture obtainable by a process comprising the following steps: a) adding a culture comprising sprouted rye grains and water to a rye fine or coarse meal and subjecting the mixture to a process of heating to 30-34 DEG C within 3 to 5 hours, a strong maltose formation being initiated from enzymatic reactions

b) followed by a further addition of rye fine or coarse meal, water and a bacteriological inoculum from the group of heterofermentative lactic-acid bacteria

c) acidifying the mixture until the metabolic activity of the microorganisms ceases, and optionally pasteurizing at 90-95 DEG C

d) separating the mixture by centrifugation into a solution and a precipitate, after which the solution is optionally filtered at least once.

Priority: EP20090171506 Applic. Date: 2009-09-28

Inventor: WOLF GABRIELE [DE]


Publication No.: WO2011036786A1  Published: 31/Mar/2011

Title: STRESS-ALLEVIATING AGENT COMPRISING PLANT-DERIVED POLYAMINE-CONTAINING EXTRACT AS ACTIVE INGREDIENT

Applicant/Assignee: TOYO BOSEKI KABUSHIKI KAISHA

Application No.: JP2009/066744   Filing Date: 28/Sep/2009

Abstract:Disclosed is a composition for preventing or inhibiting stress at the cellular level, which contains a plant-derived polyamine-containing extract and has a stress-alleviating activity, an anti-stress activity, a stress-reducing activity, a stress-preventing activity, a stress-inhibiting activity, a stress-protecting activity and the like. Also disclosed is a cosmetic, a quasi drug, a medical supply, a hygiene product, a medicine, a food or a beverage which comprises the composition. Specifically disclosed is a stress-alleviating agent, which is characterized by comprising a plant-derived polyamine-containing extract as an active ingredient.

Priority:

Inventor: KITAZAWA HIROAKI [JP]; KASUKABE YOSHIHISA [JP]; KITAGAWA MASARU [JP]


Publication No.: WO2011036895A1  Published: 31/Mar/2011

Title: MALEIC ACID SALT AND CRYSTAL THEREOF

Applicant/Assignee: KYORIN PHARMACEUTICAL CO., LTD

Application No.: JP2010/005786   Filing Date: 27/Sep/2010

Abstract:Disclosed is a benz[d][1,3]oxazine derivative having excellent stability when used as an active ingredient for a medicinal agent, and also having excellent solubility and crystallinity. Specifically disclosed is 2-[2-((S)-3- dimethylaminopyrrolidin-1-yl)pyridine-3-yl]-5-ethyl-7- methoxy-4H-benz[d][1,3]oxazin-4-one maleate.

Priority: JP20090220296 Applic. Date: 2009-09-25

Inventor: TSUBUKI TAKESHI [JP]; SAGAWA TETSUYA [JP]; FUNADA KEIKO [JP]; ARAYA ICHIRO [JP]


Publication No.: WO2011038417A2  Published: 31/Mar/2011

Title: METHODS TO ACCELERATE TISSUE AND WOUND HEALING RATES AND REDUCE SWELLING AND SCAR FORMATION

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: US2010/050600   Filing Date: 28/Sep/2010

Abstract:The present disclosure serves to reduce the healing time of tissue wounds, including those formed during surgery, whether necessary or elective (including cosmetic surgery), by providing a therapeutic dose of a pancreatic enzyme inhibitor.

Priority: US20090246527P Applic. Date: 2009-09-28

Inventor: DELANO FRANK A [US]; SCHMID-SCHOENBEIN GEERT W [US]


Publication No.: WO2011040052A1  Published: 07/Apr/2011

Title: THERAPEUTIC AGENT FOR ATOPIC DERMATITIS

Applicant/Assignee: NIHON UNIVERSITY

Application No.: JP2010/052394   Filing Date: 10/Feb/2010

Abstract:Disclosed are: a kit for treating atopic dermatitis in human and an animal

a method for treating atopic dermatitis

and others. Specifically disclosed are: an administration method

and a drug kit in which the monitoring, measurement and evaluation of a TGF-ss1-Th3 biological reaction (a Th3 cell), a Th2 biological reaction (both a Th2 cell and a Th9 cell, or any one of the Th cells), a Th1 biological reaction (a Th1 cell and a Tfh cell or a Th1 cytokine) and a cytokine are carried out sequentially to select the quantity of each of the Th agents and the period of administration of each of the Th agents, thereby formulating a therapeutic agent.

Priority: JP20090230019 Applic. Date: 2009-10-01

Inventor: KUWABARA MASATO [JP]; HONJOH MICHIO [JP]; KAWANABE MIKIKO [JP]


Publication No.: WO2011040070A1  Published: 07/Apr/2011

Title: ORAL COMPOSITION FOR ALLEVIATION OF ULTRAVIOLET RADIATION-INDUCED DAMAGE

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: JP2010/055841   Filing Date: 31/Mar/2010

Abstract:Disclosed are: an oral composition for alleviating ultraviolet radiation-induced damage, which can be used on a daily basis and is stable and safe

and a medicinal agent, an anti-wrinkle agent and a food composition, each of which comprises the oral composition. Specifically disclosed is an oral composition for alleviating ultraviolet radiation-induced damage, which comprises at least one compound selected from the group consisting of methionine and derivatives and/or salts thereof. The composition may be an anti-wrinkle agent, a pharmaceutical composition for treating and/or preventing skin diseases, a food composition, or a pharmaceutical composition for preventing or treating cataract. In the oral composition for alleviating ultraviolet radiation-induced damage, methionine may have a D-form.

Priority: JP20090228267 Applic. Date: 2009-09-30

Inventor: ASHIDA YUTAKA [JP]; TOJO YOSUKE [JP]; MIZUMOTO CHIEKO [JP]; MITA MASASHI [JP]; SHIMADA SHOICHIRO [JP]


Publication No.: WO2011040071A1  Published: 07/Apr/2011

Title: ANTIOXIDANT COMPOSITION

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: JP2010/055842   Filing Date: 31/Mar/2010

Abstract:Disclosed is a stable and safe antioxidant composition which can be used routinely. Specifically disclosed is an antioxidant composition which contains one or more compounds selected from the group consisting of D-aspartic acid, derivatives thereof and/or salts thereof. The composition may be used for the purpose of suppressing and/or improving skin conditions. The skin conditions may include but is not limited to fine wrinkles, rough skin, dry skin, skin cancers, skin allergies, inflammation of the skin and photosensitive dermatosis. The composition may be used for an external preparation for the skin, food and a pharmaceutical product for cataract.

Priority: JP20090224742 Applic. Date: 2009-09-29

Inventor: TOJO YOSUKE [JP]; MIZUMOTO CHIEKO [JP]; ASHIDA YUTAKA [JP]; MITA MASASHI [JP]


Publication No.: WO2011040082A1  Published: 07/Apr/2011

Title: LAMININ-332 PRODUCTION ACCELERATING COMPOSITION

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: JP2010/058219   Filing Date: 14/May/2010

Abstract:Disclosed is a novel composition which has a function of accelerating production of laminin-332. The composition is stable and safe, and can be used routinely. Specifically disclosed is a laminin-332 production accelerating composition which contains one or more compounds selected from the group consisting of D-alanine, D-hydroxyproline, derivatives of D-alanine or D-hydroxyproline and/or salts of D-alanine or D-hydroxyproline. The composition may be used for the purpose of suppressing and/or improving skin conditions. The skin conditions may include but are not limited to photoaging, wrinkles, rough skin, fine wrinkles and dry skin. The composition may be used for an external preparation for the skin or food.

Priority: JP20090225871 Applic. Date: 2009-09-30; JP20090225872 Applic. Date: 2009-09-30

Inventor: TOJO YOSUKE [JP]; HOSOI JUN-ICHI [JP]; MATSUMOTO HANAYO [JP]


Publication No.: WO2011040166A1  Published: 07/Apr/2011

Title: ORAL COMPOSITION FOR REDUCING WRINKLE FORMATION

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: JP2010/064817   Filing Date: 31/Aug/2010

Abstract:Provided is a novel composition that acts to inhibit and/or ameliorate wrinkle formation, does not have adverse effects like those of retinoids, and is highly photostable. An oral composition for reducing wrinkle formation and an oral composition for preventing wrinkle formation are provided, said compositions containing at least one compound selected from a group comprising D-glutamic acid and derivatives and/or salts thereof. Also provided are a pharmaceutical composition and a food composition containing the aforementioned oral composition for reducing wrinkle formation or the aforementioned oral composition for preventing wrinkle formation.

Priority: JP20090226076 Applic. Date: 2009-09-30

Inventor: ASHIDA YUTAKA [JP]; TAKADA KEIKO [JP]; YOKOO MIHOSHI [JP]; TOJO YOSUKE [JP]


Publication No.: WO2011040185A1  Published: 07/Apr/2011

Title: ORAL COMPOSITION FOR REDUCING SKIN ROUGHNESS

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: JP2010/065198   Filing Date: 06/Sep/2010

Abstract:Provided is a stable and safe oral composition that acts on the barrier function of the skin to reduce and/or prevent skin roughness. An oral composition for reducing skin roughness and an oral composition for preventing skin roughness are provided, said compositions containing at least one compound selected from a group comprising D-glutamic acid and derivatives and/or salts thereof. Also provided are a pharmaceutical composition and/or a food composition containing the aforementioned oral composition for reducing skin roughness or the aforementioned oral composition for preventing skin roughness.

Priority: JP20090226075 Applic. Date: 2009-09-30

Inventor: NAKANO YUSUKE [JP]; ASHIDA YUTAKA [JP]; TOJO YOSUKE [JP]


Publication No.: WO2011040363A1  Published: 07/Apr/2011

Title: COLLAGEN PRODUCTION ACCELERATING COMPOSITION

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: JP2010/066672   Filing Date: 27/Sep/2010

Abstract:Disclosed is a novel composition which has a function of accelerating production of collagen. The composition has high light stability and is free from side effects such as those of retinoids. Specifically disclosed is a collagen production accelerating composition which contains one or more compounds selected from the group consisting of D-aspartic acid, D-alanine, derivatives of D-aspartic acid or D-alanine and/or salts of D-aspartic acid or D-alanine. The composition may be used for the purpose of suppressing and/or improving skin conditions. The skin conditions may include but is not limited to photoaging and/or wrinkles. The composition may be used for an external preparation for the skin or food. The composition may be a type I collagen production accelerating composition.

Priority: JP20090224743 Applic. Date: 2009-09-29; JP20090225870 Applic. Date: 2009-09-30

Inventor: ASHIDA YUTAKA [JP]; TOJO YOSUKE [JP]; SHIMADA SHOICHIRO [JP]; MIZUMOTO CHIEKO [JP]; MITA MASASHI [JP]


Publication No.: WO2011040495A1  Published: 07/Apr/2011

Title: HEPARANASE-ACTIVITY INHIBITOR, WRINKLE AMELIORATING AGENT CONTAINING SAME, AND PHARMACEUTICAL COMPOSITION

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: JP2010/066997   Filing Date: 29/Sep/2010

Abstract:Disclosed is a heparanase-activity inhibitor containing as an active ingredient a 4-alkylresorcinol represented by the belowmentioned formula (I) (wherein R represents a straight-chain or branched alkyl group having 1-6 carbon atoms).

Priority: JP20090228209 Applic. Date: 2009-09-30

Inventor: IRIYAMA SHUNSUKE [JP]; FUKUNISHI HIROTADA [JP]; SUETSUGU MASARU [JP]; AMANO SATOSHI [JP]


Publication No.: WO2011040509A1  Published: 07/Apr/2011

Title: 2,3-DIHYDRO-1H-INDENE-2-YLUREA DERIVATIVE AND PHARMACEUTICAL APPLICATION OF SAME

Applicant/Assignee: TORAY INDUSTRIES, INC

Application No.: JP2010/067047   Filing Date: 30/Sep/2010

Abstract:In order to provide a low molecular weight compound that has p38MAPK inhibitory activity and the accompanying TNFa production suppression activity and that has a favorable pharmacokinetic profile as a pharmaceutical and decreased hepatotoxicity, and to provide a pharmaceutical application of same, disclosed is a 2,3-dihydro-1H-indene-2-ylurea derivative represented below, a pharmacologically acceptable salt thereof, and a therapeutic agent or preventative agent that contains same as an active ingredient and that is for allergic dermatitis, inflammatory bowel disease, and pain.

Priority: JP20090227411 Applic. Date: 2009-09-30; JP20100083722 Applic. Date: 2010-03-31

Inventor: KANEKO HIROAKI [JP]; KAWAI HIDEKI [JP]; IURA YOSUKE [JP]; INOUE HIDEKI [JP]; KAINO MIE [JP]; MEGURO HIROYUKI [JP]; UCHIDA TAZURU [JP]


Publication No.: WO2011040651A1  Published: 07/Apr/2011

Title: THERAPEUTIC AGENT FOR ATOPIC DERMATITIS

Applicant/Assignee: NIHON UNIVERSITY

Application No.: JP2010/067701   Filing Date: 01/Oct/2010

Abstract:Disclosed are: a kit for treating atopic dermatitis in human and an animal

a method for treating atopic dermatitis

and others. Specifically disclosed are: an administration method

and a drug kit in which the monitoring, measurement and evaluation of a TGF-ss1-Th3 biological reaction (a Th3 cell), a Th2 biological reaction (both a Th2 cell and a Th9 cell, or any one of the Th cells), a Th1 biological reaction (a Th1 cell and a Tfh cell or a Th1 cytokine) and a cytokine are carried out sequentially to select the quantity of each of the Th agents and the period of administration of each of the Th agents, thereby formulating a therapeutic agent.

Priority: JP20090230019 Applic. Date: 2009-10-01; WO2010JP52394 Applic. Date: 2010-02-10

Inventor: KUWABARA MASATO [JP]; HONJOH MICHIO [JP]; KAWANABE MIKIKO [JP]


Publication No.: WO2011040823A1  Published: 07/Apr/2011

Title: SYNTHETIC MYOSTATIN PEPTIDE ANTAGONISTS

Applicant/Assignee: COVITA LIMITED

Application No.: NZ2010/000191   Filing Date: 29/Sep/2010

Abstract:The present invention relates to novel synthetic myostatin antagonists, comprising a synthetic mature myostatin peptide, wherein the peptide comprises at least two cysteine residues at positions 281 and 282 which are forced to bond and form a disulfide bond or a functional variant or fragment thereof and are useful in the treatment of myostatin related disorders.

Priority: US20090247821P Applic. Date: 2009-10-01

Inventor: BOWER ROBERT SYNDECOMBE [AU]; MOURA MONICA SENNA SALERNO DE [NZ]


Publication No.: WO2011041654A1  Published: 07/Apr/2011

Title: EXTRACTS OF PHYLLANTHUS NIRURI

Applicant/Assignee: JOHNSON & JOHNSON CONSUMER COMPANIES, INC

Application No.: US2010/051089   Filing Date: 01/Oct/2010

Abstract:A method of making a low molecular weight fraction of Phyllanthus niruri is provided. Such low molecular weight fraction is particularly useful for treating the skin, for example skin in need of treatment for signs of aging, for reducing inflammation, or for skin lightening.

Priority: US2009-572373 Applic. Date: 2009-10-02

Inventor: GARAY MICHELLE [US]; KAUR SIMARNA [US]; SOUTHALL MICHAEL [US]; WEN PING [US]; MAHMOOD KHALID [US]


Publication No.: WO2011041897A1  Published: 14/Apr/2011

Title: COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTIC AGENTS

Applicant/Assignee: ANGIOCHEM INC

Application No.: CA2010/001596   Filing Date: 05/Oct/2010

Abstract:The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a compostion capable of transporting an agent (e.g., a therapeutic agent). In certain cases, the polypeptides are directly conjugated to a lipid or polymeric vector to allow targeted application of a therapeutic agent to treat, for example, a cancer, a neurodegenerative disease, or a lysosomal storage disorder.

Priority: US20090249152P Applic. Date: 2009-10-06

Inventor: CASTAIGNE JEAN-PAUL [CA]; DEMEULE MICHEL [CA]; CHE CHRISTIAN [CA]; REGINA ANTHONY [CA]


Publication No.: WO2011042684A2  Published: 14/Apr/2011

Title: ANTIMICROBIAL COMPOSITION AND METHOD OF CONTROLLING CONTAMINATION OR INFECTIONS USING SAID COMPOSITION

Applicant/Assignee: UWS VENTURES LIMITED

Application No.: GB2010/001837   Filing Date: 01/Oct/2010

Abstract:The invention relates to an antimicrobial composition having the formula C5H11O2N, and salts or esters thereof, which is obtained, in particular from extracts of fly larvae.

Priority: GB20090017554 Applic. Date: 2009-10-08

Inventor: BEXFIELD ALYSON [GB]; BOND ALISON ELISABETH [GB]; DUDLEY EDWARD [GB]; NEWTON PETER RUSSEL [GB]; NIGAM YAMNI [GB]; RATCLIFFE NORMAN ARTHUR [GB]


Publication No.: WO2011043136A1  Published: 14/Apr/2011

Title: IMMUNOSUPPRESSING AGENT COMPRISING MESENCHYMAL STEM CELL DERIVED FROM ADIPOSE TISSUE, AND USE THEREOF

Applicant/Assignee: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY

Application No.: JP2010/064682   Filing Date: 30/Aug/2010

Abstract:Disclosed are: an immunosuppressing agent having a high therapeutic effect

and use of the immunosuppressing agent. An adipose-tissue-derived mesenchymal stem cell produced by low-serum culture is used as the immunosuppressing agent.

Priority: JP20090233991 Applic. Date: 2009-10-08

Inventor: MARUYAMA SHOICHI [JP]; OZAKI TAKENORI [JP]; SAKA YOSUKE [JP]; FURUHASHI KAZUHIRO [JP]; TSUBOI NAOTAKE [JP]


Publication No.: WO2011043212A1  Published: 14/Apr/2011

Title: CERAMIDE PRODUCTION ENHANCER AND MOISTURIZING AGENT

Applicant/Assignee: KAO CORPORATION

Application No.: JP2010/066698   Filing Date: 27/Sep/2010

Abstract:Disclosed are a ceramide production enhancer and a moisturizing agent, each containing at least one plant extract selected from the group consisting of Chenopodium hybridum, Melia toosendan, Indigofera tinctoria, Cirsium japonicum, Catalpa ovata and Tagetes erecta, or a compound represented by general formula (1) as an active ingredient. (In the formula, R represents an acyl group having 1-5 carbon atoms.)

Priority: JP20090231847 Applic. Date: 2009-10-05; JP20100103651 Applic. Date: 2010-04-28

Inventor: SHIMOTOYODOME YOSHIE [JP]; ITO SHOTARO [JP]; SUGAI YOSHIYA [JP]; HASHIMOTO HIROSHI [JP]; ISHIKAWA JUNKO [JP]


Publication No.: WO2011043359A1  Published: 14/Apr/2011

Title: PHARMACEUTICAL PRODUCT CONTAINING AROMATIC HETEROCYCLIC COMPOUND

Applicant/Assignee: KYOWA HAKKO KIRIN CO., LTD

Application No.: JP2010/067511   Filing Date: 06/Oct/2010

Abstract:Disclosed is a pharmaceutical product or the like, which contains an aromatic heterocyclic compound represented by formula (I) or the like as an active ingredient. (In the formula, Q1 represents a CR2 group (wherein R2 represents a hydrogen atom or the like) or the like

Q2 represents a CR3 group (wherein R3 represents a hydrogen atom or the like) or the like

Q3 represents a nitrogen atom or the like

R1 represents a -C(=O)OR16 group (wherein R16 represents a hydrogen atom or the like) or the like

R5 represents a hydrogen atom or the like

R6 represents an optionally substituted cycloalkyl group or the like

X and Y may be the same or different and each represents a CH group wherein H may be substituted by a substituent, or the like

and Z represents a nitrogen atom or the like.)

Priority: JP20090232201 Applic. Date: 2009-10-06; JP20100118474 Applic. Date: 2010-05-24

Inventor: TAKADA CHIE; SAEKI KOJI; KAWASAKI HIROKAZU; TAGAYA MIHO; KOMAI MASATO; IKEMURA TOSHIHIDE; YAMAGUCHI SHINPEI; IIDA KYOICHIRO


Publication No.: WO2011043371A1  Published: 14/Apr/2011

Title: OXAZOLE COMPOUND

Applicant/Assignee: ASTELLAS PHARMA INC

Application No.: JP2010/067541   Filing Date: 06/Oct/2010

Abstract:Disclosed is a novel and excellent prophylactic and/or therapeutic method for diseases associated with interleukin-1 receptor-associated kinase-4 (IRAK-4), which is based on an interleukin-1 receptor-associated kinase-4 (IRAK-4) inhibitory effect. Specifically disclosed is an oxazole carboxylic acid amide derivative which is characterized in that an oxazole that is substituted with a heteroaryl group at the 2-position is bonded to a heteroaryl ring via a carboxamide. The oxazole carboxylic acid amide derivative has a strong inhibitory effect on IRAK-4, and can serve as a prophylactic and/or therapeutic agent for diseases associated with IRAK-4 such as inflammatory diseases and autoimmune diseases.

Priority: JP20090233048 Applic. Date: 2009-10-07

Inventor: INAMI HIROSHI [JP]; MIZUTANI TSUYOSHI [JP]; MAEDA JUNKO [JP]; USUDA HIROYUKI [JP]; NAGASHIMA SHINYA [JP]; ITO TOMONORI [JP]; AOYAMA NAOHIRO [JP]; KONTANI TORU [JP]; HAYASHIDA HISASHI [JP]; TERASAWA TAKESHI [JP]; SEO RYUSHI [JP]; AKAMATSU MASAHIKO [JP]; ISHIKAWA TAKESHI [JP]; HAYASHI KAZUMI [JP]


Publication No.: WO2011043453A1  Published: 14/Apr/2011

Title: ACTIVATOR FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR

Applicant/Assignee: NIPPON CHEMIPHAR CO., LTD

Application No.: JP2010/067715   Filing Date: 08/Oct/2010

Abstract:Disclosed are: a compound represented by general formula (I) or a pharmacologically acceptable salt thereof

and an activator for a peroxisome proliferator activated receptor (PPAR), which contains the compound or salt as an active ingredient. (In the formula, R1 and R3 each represents a hydrogen atom, a halogen atom, an alkyl group having 1-8 carbon atoms, an alkyl group which is substituted by a halogen atom and has 1-8 carbon atoms, or the like

R2 represents a hydrogen atom, an alkyl group having 1-8 carbon atoms or the like

R4, R5, R6 and R7 each represents a hydrogen atom, an alkyl group having 1-8 carbon atoms or the like

X represents a nitrogen atom or the like

Y represents an oxygen atom or the like

Z represents an oxygen atom, a sulfur atom, a bonding hand or the like

p represents 1 or 2

m represents an integer of 1-4

and n represents an integer of 0-4.)

Priority: JP20090234600 Applic. Date: 2009-10-08

Inventor: SAKUMA SHOGO [JP]; KOBAYASHI KUNIO [JP]


Publication No.: WO2011044207A2  Published: 14/Apr/2011

Title: COMPOSITIONS CONTAINING A HIGH CONCENTRATION OF POLAR SPHINGOLIPID(S)

Applicant/Assignee: L'OREAL S.A

Application No.: US2010/051591   Filing Date: 06/Oct/2010

Abstract:The invention relates to compositions for topical application comprising a high concentration of polar sphingolipid(s).

Priority: US20090248973P Applic. Date: 2009-10-06

Inventor: BARBARAT PHILIPPE [US]; PHILIPPE MICHEL [FR]; MARTIN RICHARD [FR]


Publication No.: WO2011044367A1  Published: 14/Apr/2011

Title: METHODS AND COMPOSITIONS FOR SKIN REGENERATION

Applicant/Assignee: GENOGEN, INC

Application No.: US2010/051830   Filing Date: 07/Oct/2010

Abstract:Compositions and methods for inducing tissue differentiation and growth within a localized area of application in humans or other animals are provided. Compositions comprising a biological or pharmacologically active agent such as Insulin-like Growth Factor-1 (IGF-1) and sustained-release nanoparticle formulations comprising IGF-1 and a matrix forming component such as hyaluronan for use in skin repair and regeneration are provided. Nanoparticles of the invention activate endogenous stem cells in the local area of administration to produce new dermal cells and tissues.

Priority: US20090278576P Applic. Date: 2009-10-07; US20100380671P Applic. Date: 2010-09-07

Inventor: MIZE NANCY [US]


Publication No.: WO2011044587A2  Published: 14/Apr/2011

Title: CYTOPROTECTIVE OR THERAPEUTIC PLANT COMPOSITION

Applicant/Assignee: OREGON HEALTH & SCIENCE UNIVERSITY

Application No.: US2010/052375   Filing Date: 12/Oct/2010

Abstract:Embodiments herein provide plant compositions, and, more specifically, a plant composition including Allium vineale or an extract thereof. Other compositions are also provided, as well as methods of formulating the compositions, and methods of using the compositions to treat or prevent conditions such as cancer, allergies, and inflammation, or to promote cytoprotection or accelerate wound healing.

Priority: US20090250165P Applic. Date: 2009-10-09

Inventor: BOWMAN DONALD B [US]


Publication No.: WO2011044736A1  Published: 21/Apr/2011

Title: PHARMACEUTICAL COMPOSITION FOR TREATING SKIN INJURY, PREPARATION METHOD OF ITS OINTMENT AND USE THEREOF

Applicant/Assignee:

Application No.: CN2009/074713   Filing Date: 30/Oct/2009

Abstract:A pharmaceutical composition for treating skin injury, the preparation method of its ointment and use thereof. The composition consists of fresh leaves of Rosa cymosa, dried flowers of hibisci mutabilidis and Oleum Camelliae. The preparation method of its ointment includes: mixing fresh leaves of Rosa cymosa and dried flowers of hibisci mutabilidis together and turning it into slurry

then combining the slurry with Oleum Camelliae and manufacturing into ointment. The composition can be used to prepare medicine for treating skin injury.

Priority: CN20091112625 Applic. Date: 2009-10-12

Inventor: ZENG QINTAI [CN]; ZHANG YUNMAO [CN]; ZHENG XIULIAN [CN]


Publication No.: WO2011044737A1  Published: 21/Apr/2011

Title: USE OF CYCLOPHOSPHAMIDE FOR TREATING CONDYLOMA ACUMINATA

Applicant/Assignee: HUBEI CENTURY BIOTECHNOLOGY CO., LTD

Application No.: CN2009/074974   Filing Date: 17/Nov/2009

Abstract:The present invention provides the use of cyclophosphamide for treating condyloma acuminata.

Priority: CN20091272393 Applic. Date: 2009-10-13

Inventor: HUANG BO [CN]


Publication No.: WO2011044746A1  Published: 21/Apr/2011

Title: BAMBOO OR WOOD VINEGAR SOLUTION, PREPARATION METHOD AND USE THEREOF

Applicant/Assignee: ZHEJIANG JIANZHONG BAMBOO INDUSTRY & TECHNOLOGY CO., LTD

Application No.: CN2010/001086   Filing Date: 20/Jul/2010

Abstract:A bamboo or wood vinegar solution, preparation method and use thereof, said bamboo or wood vinegar solution comprises edible water 89-99%, organic acids 0.5-10%, flavonoids derived from bamboo leaves 0.05-0.20%, alcohols 0.05-1.6%, and water soluble flavors 0.05-0.20%. Impurities and toxic irritant substances and carcinogenic substances are removed from the bamboo or wood vinegar solution. The bamboo or wood vinegar solution has aroma.

Priority: CN20091153436 Applic. Date: 2009-10-12

Inventor: MA JIANYI [CN]; TONG SENMIAO [CN]; DING JIANZHONG [CN]


Publication No.: WO2011045593A1  Published: 21/Apr/2011

Title: NOVEL MACROCYLES AND METHODS FOR THEIR PRODUCTION

Applicant/Assignee: BIOTICA TECHNOLOGY LIMITED

Application No.: GB2010/051713   Filing Date: 12/Oct/2010

Abstract:There are provided compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein the variables R1-R3 are as described in the description, said compounds being useful as anti-inflammatory agents with reduced systemic effects.

Priority: GB20090017816 Applic. Date: 2009-10-12

Inventor: MOSS STEVEN JAMES [GB]; GREGORY MATTHEW ALAN [GB]; ZHANG MING-QIANG [CN]


Publication No.: WO2011045594A1  Published: 21/Apr/2011

Title: NOVEL MACROCYCLES AND METHODS FOR THEIR PRODUCTION

Applicant/Assignee: BIOTICA TECHNOLOGY LIMITED

Application No.: GB2010/051714   Filing Date: 12/Oct/2010

Abstract:There are provided compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein the variables R1-R4 and X are as described in the description, said compounds being useful as anti-inflammatory agents with reduced system effect.

Priority: GB20090017817 Applic. Date: 2009-10-12

Inventor: MOSS STEVEN JAMES [GB]; GREGORY MATTHEW ALAN [GB]; ZHANG MING-QIANG [CN]


Publication No.: WO2011045681A2  Published: 21/Apr/2011

Title: CARBOHYDRATE ENTRAPPED ACTIVE AGENT DELIVERY COMPOSITION AND ARTICLES USING THE SAME

Applicant/Assignee: KIMBERLY-CLARK WORLDWIDE, INC

Application No.: IB2010/053931   Filing Date: 01/Sep/2010

Abstract:Delivery compositions and substrates for imparting a volatile active agent to a surface are disclosed herein. To achieve the delivery of the volatile component, a delivery composition of a carbohydrate matrix and a volatile component is incorporated into the carbohydrate matrix to stabilize the volatile for extended periods of time. The delivery composition further comprises a self-generating expelling agent to expel the volatile component onto the contaminated surface or skin upon addition of a triggering agent.

Priority: US2009-578348 Applic. Date: 2009-10-13

Inventor: WENZEL SCOTT W [US]; KOENIG DAVID WILLIAM [US]; SEIDLING JEFFERY RICHARD [US]; CHEN MICHAEL MEIHAN [US]


Publication No.: WO2011045682A2  Published: 21/Apr/2011

Title: ACTIVE AGENT CONTAINING POLYMER NETWORK DELIVERY COMPOSITION AND ARTICLES USING THE SAME

Applicant/Assignee: KIMBERLY-CLARK WORLDWIDE, INC

Application No.: IB2010/053932   Filing Date: 01/Sep/2010

Abstract:Delivery compositions and substrates for imparting a volatile active agent to a surface are disclosed herein. To achieve the delivery of the volatile component, a delivery composition of a polymer network and a volatile component incorporated into the polymer network to stabilize the volatile for extended periods of time. The delivery composition may also be present on a substantially dry substrate to deliver the active agent. The dry substrate may be selected from facial tissue, bath tissue, paper towel, or dinner napkin. The substantially dry substrate may also be reusable.

Priority: US2009-578334 Applic. Date: 2009-10-13

Inventor: KOENIG DAVID WILLIAM [US]; WENZEL SCOTT W [US]; SEIDLING JEFFERY RICHARD [US]; CHEN MICHAEL MEIHAN [US]


Publication No.: WO2011045803A1  Published: 21/Apr/2011

Title: SORE RELIEF FORMULATION

Applicant/Assignee:

Application No.: IN2009/000574   Filing Date: 13/Oct/2009

Abstract:The present invention relates to sore relief formulations containing calamine, zinc oxide and boric acid as well as a method for preparing the same.

Priority:

Inventor: LUTHRIA AKSHAY [IN]; VIJAY LUTHRIA VANDANA [IN]


Publication No.: WO2011045823A1  Published: 21/Apr/2011

Title: COMPOSITION BASED ON MUSCARI COMOSUM AND ALOE VERA BARBADENSIS

Applicant/Assignee: NM TECH NANOMATERIALS AND MICRODEVICES TECHNOLOGYLTD

Application No.: IT2009/000470   Filing Date: 15/Oct/2009

Abstract:The present invention relates to a composition based on Muscari comosum and Aloe Vera barbadensis. In particular, the present invention relates to a composition based on Muscari comosum and Aloe Vera barbadensis, comprising a mixture of active ingredients composed of a Muscari comosum preparation and an Aloe Vera barbadensis preparation, and excipients or ingredients necessary to the completion of the composition. Jams, marmalades, or yoghurts containing the inventive composition are described, as well as capsules for oral administration in which the composition is contained in a freeze-dried form. The use of the inventive composition in the treatment of intestinal constipation and decubitus ulcers or other skin lesions is also described and claimed.

Priority:

Inventor: LOSACCO ANTONIO [GB]


Publication No.: WO2011045934A1  Published: 21/Apr/2011

Title: METHOD FOR PRODUCING REDUCED COENZYME Q10, METHOD FOR STABILIZING SAME, AND COMPOSITION COMPRISING SAME

Applicant/Assignee: KANEKA CORPORATION

Application No.: JP2010/006103   Filing Date: 14/Oct/2010

Abstract:Provided are a component, which not only has an ability to reduce oxidized coenzyme Q10 and an ability to stabilize reduced coenzyme Q10 but also contains nutrients and has a good taste and broad utility, and a method for using the same. Disclosed is a method for safely and easily producing reduced coenzyme Q10, which comprises reducing oxidized coenzyme Q10 by using one or more components selected from the group consisting of an acerola extract, a tea extract, a rosemary extract, a pine bark extract and a cowberry and/or lingoberry extract, each originating in a natural material and being safe to living organisms. Also disclosed are a method for stabilizing reduced coenzyme Q10 in the coexistence of a component originating in a natural material, and a stabilized composition. Since it can be expected that the aforesaid component originating in a natural material also exerts effects as nutrients, the composition is particularly beneficial as products that should exert various effects, for example, drugs, supplements, foods with nutrient function claims, foods for special health use, nutritious supplements, revitalizers, animal drugs, cosmetics, therapeutic agents and so on.

Priority: JP20090239741 Applic. Date: 2009-10-16

Inventor: YAMAGUCHI TAKAO [JP]; JOKIHARA TAKAAKI [JP]; KITAMURA SHIRO [JP]; UEDA YASUYOSHI [JP]


Publication No.: WO2011046199A1  Published: 21/Apr/2011

Title: METHOD FOR PRODUCING REDUCED COENZYME Q10, METHOD FOR STABILIZING SAME, AND COMPOSITION COMPRISING SAME

Applicant/Assignee: KANEKA CORPORATION

Application No.: JP2010/068155   Filing Date: 15/Oct/2010

Abstract:Provided are a component, which not only has an ability to reduce oxidized coenzyme Q10 and an ability to stabilize reduced coenzyme Q10 but also contains nutrients and has a good taste and broad utility, and a method for using the same. Disclosed is a method for producing reduced coenzyme Q10, which comprises reducing oxidized coenzyme Q10 by using specific amino acid(s). Also disclosed are a method for stabilizing reduced coenzyme Q10 in the coexistence of the specific amino acid(s), and a composition stabilized thereby.

Priority: JP20090239754 Applic. Date: 2009-10-16

Inventor: JIKIHARA TAKAAKI [JP]; YAMAGUCHI TAKAO [JP]; KITAMURA SHIRO [JP]; UEDA YASUYOSHI [JP]


Publication No.: WO2011046221A1  Published: 21/Apr/2011

Title: INTERFERON-a MODULATOR

Applicant/Assignee: THE RITSUMEIKAN TRUST, KANSAI MEDICAL UNIVERSITY, AMINO UP CHEMICAL CO., LTD

Application No.: JP2010/068209   Filing Date: 15/Oct/2010

Abstract:Disclosed are: an antisense nucleotide which contains a sequence complementary to IFN-a mRNA, especially a sequence complementary to a base sequence in the SL1 and/or SL2 region of IFN-a mRNA, and which is capable of enhancing the expression of IFN-a

an IFN-a expression enhancer and a prophylactic or therapeutic agent for viral infectious diseases or cancer, each containing the antisense nucleotide

a sense oligonucleotide which contains a sequence complementary to endogenous asRNA for IFN-a mRNA, especially a sequence homologous to a base sequence in the SL1 or SL2 region of IFN-a mRNA, and which is capable of modulating the expression of IFN-a

and an IFN-a expression modulator which contains the sense oligonucleotide.

Priority: JP20090239801 Applic. Date: 2009-10-16; JP20100107544 Applic. Date: 2010-05-07

Inventor: KIMURA TOMINORI [JP]; NISHIZAWA MIKIO [JP]; JIANG SHIWEN [JP]; NISHIKAWA MASAO [JP]


Publication No.: WO2011046267A1  Published: 21/Apr/2011

Title: SILVER/POLYDIGUANIDE COMPLEX, PREPARATION METHOD THEREOF, AND ANTIBACTERIAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT

Applicant/Assignee: SNU R&DB FOUNDATION

Application No.: KR2010/000717   Filing Date: 05/Feb/2010

Abstract:The present invention relates to a silver/polydiguanide complex and derivatives thereof including silver and polydiguanide having at least two biguanide moieties, wherein the silver is stabilized in an oxidation state of an integer of 0 to 4, a mole ratio between the silver and the polydiguanide is 1: 1-4, an average particle diameter of the complex is micrometer or nanometer, and zeta potential of the complex is greater than or equal to zero, a preparation method thereof, and an antibacterial composition for burns or wounds treatment including the same as an active ingredient. A silver/polydiguanide complex according to the present invention is different from conventional silver/polydiguanide complexes in carbon, hydrogen, and nitrogen contents as well as in structure of silver and polydiguanide, and solubility, is a material that exhibits a very good antibacterial activity due to a much lower minimal inhibitory concentration (MIC) value by 10 to 100 folds or more compared to silver sulfadiazine which is a conventional therapeutic agent for burns, and may be usefully used as an antibacterial composition for burns or wounds treatment.

Priority: KR20090099020 Applic. Date: 2009-10-17; KR20100001428 Applic. Date: 2010-01-07

Inventor: SONG JOON MYONG [KR]; PAL SUKDEB [KR]


Publication No.: WO2011046978A2  Published: 21/Apr/2011

Title: STEROIDAL COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF

Applicant/Assignee: NEW YORK UNIVERSITY

Application No.: US2010/052394   Filing Date: 12/Oct/2010

Abstract:Provided are steroidal compounds of formula I, for example, conessine, and the use of such compounds and compositions thereof to modulate (e.g., inhibit) melanogenesis and pigmentation. Also provided are plant extracts containing a compound of formula I, for example, conessine, and the use of such a plant extract to modulate (e.g., inhibit) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.

Priority: US2009-587882 Applic. Date: 2009-10-13

Inventor: ORLOW SETH J [US]; KOMATSU LI NI [US]


Publication No.: WO2011047173A2  Published: 21/Apr/2011

Title: PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION

Applicant/Assignee: XENON PHARMACEUTICALS INC

Application No.: US2010/052703   Filing Date: 14/Oct/2010

Abstract:This invention is directed to pharmaceutical compositions for oral administration to a mammal, wherein the pharmaceutical compositions comprise a spiro-oxindole compound, as a single stereoisomer or as a mixture thereof, or a pharmaceutically acceptable salt thereof. These pharmaceutical compositions are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Priority: US20090251340P Applic. Date: 2009-10-14

Inventor: WINTERS CONRAD STEWART [CA]; GAMMILL SHAUN LEE [US]


Publication No.: WO2011047345A2  Published: 21/Apr/2011

Title: METHODS OF TREATING DISEASES OF CONDITIONS USING MESENCHYMAL STEM CELLS

Applicant/Assignee:

Application No.: US2010/052953   Filing Date: 15/Oct/2010

Abstract:The present invention provides a method of treating or preventing a disease or condition in a patient comprising intravenously administering a therapeutically effective amount of mesenchymal stem cells to the patient, wherein the disease or condition is osteoarthritis, rheumatoid arthritis, multiple sclerosis, stroke, ulcerative colitis, psoriasis, Hashimoto's thyroiditis, atopic dermatitis, allergic rhinitis, chronic obstructive pulmonary disease with bronchial asthma or hearing loss.

Priority: US20090252129P Applic. Date: 2009-10-15

Inventor: YOO TAI JUNE [US]


Publication No.: WO2011047420A1  Published: 28/Apr/2011

Title: COSMETIC COMPOSITIONS

Applicant/Assignee: CHEMEQ LTD

Application No.: AU2010/001386   Filing Date: 19/Oct/2010

Abstract:A topical antimicrobial composition including (i) a polymer of 2-propenal, and (ii) a C3-10 alkanediol.

Priority: US20090252875P Applic. Date: 2009-10-19; AU20100100972 Applic. Date: 2010-09-06

Inventor: DUNLOP ROBERT WILLIAM [AU]


Publication No.: WO2011047432A1  Published: 28/Apr/2011

Title: FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS

Applicant/Assignee: FIBROTECH THERAPEUTICS PTY LTD

Application No.: AU2010/001398   Filing Date: 21/Oct/2010

Abstract:The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment disorders.

Priority: US20090253889P Applic. Date: 2009-10-22

Inventor: WILLIAMS SPENCER JOHN [AU]; ZAMMIT STEVEN [AU]; KELLY DARREN JAMES [AU]


Publication No.: WO2011048111A1  Published: 28/Apr/2011

Title: COMPOUNDS

Applicant/Assignee: RESPIVERT LIMITED

Application No.: EP2010/065746   Filing Date: 19/Oct/2010

Abstract:The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their 10 compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.

Priority: GB20090018249 Applic. Date: 2009-10-19

Inventor: KING-UNDERWOOD JOHN [GB]; ITO KAZUHIRO [GB]; MURRAY PETER JOHN [GB]; HARDY GEORGE [GB]; BROOKFIELD FREDERICK ARTHUR [GB]; BROWN CHRISTOPHER JOHN [GB]


Publication No.: WO2011048148A2  Published: 28/Apr/2011

Title: GLYCOSIDE DERIVATIVE AND USES THEREOF

Applicant/Assignee: NOVARTIS AG

Application No.: EP2010/065802   Filing Date: 20/Oct/2010

Abstract:This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.

Priority: IN2009DE02172 Applic. Date: 2009-10-20

Inventor: BEBERNITZ GREGORY RAYMOND [US]; BOCK MARK G [US]; BHUNIYA DEBNATH [IN]; DATRANGE LAXMIKANT [IN]; KURHADE SURESH EKNATH [IN]; PALLE P VENKATA [IN]; REDDY DUMBALA SRINIVAS [IN]


Publication No.: WO2011048409A1  Published: 28/Apr/2011

Title: CYCLIC AMINE DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY

Applicant/Assignee: ASTRAZENECA AB, PULMAGEN THERAPEUTICS (SYNERGY) LIMITED

Application No.: GB2010/051751   Filing Date: 18/Oct/2010

Abstract:Compounds of formula (I) having activities at muscarinic and ss2-receptors (MABAs) for use in therapy.

Priority: GB20090018322 Applic. Date: 2009-10-20; GB20100009803 Applic. Date: 2010-06-11

Inventor: DONALD DAVID KEITH [GB]; JENNINGS ANDREW STEPHEN ROBERT [GB]; RAY NICHOLAS CHARLES [GB]; ROUSSEL FABIEN [GB]; SUTTON JONATHAN MARK [GB]; TISSELLI PATRIZIA [GB]; WILSON MICHELLE [GB]


Publication No.: WO2011048554A2  Published: 28/Apr/2011

Title: COMBINATION OF A PROBIOTIC LYSATE AND A C-GLYCOSIDE DERIVATIVE

Applicant/Assignee: L'OREAL

Application No.: IB2010/054744   Filing Date: 20/Oct/2010

Abstract:The present invention relates to the cosmetic use of a combination including a lysate of at least one probiotic microorganism of the Bifidobacterium sp. genus having at least one C-glycoside derivative as an active agent that can be used for cosmetic treatment of keratin materials.

Priority: FR20090057374 Applic. Date: 2009-10-21; US20090272788P Applic. Date: 2009-11-03

Inventor: BRETON LIONEL [FR]


Publication No.: WO2011048936A1  Published: 28/Apr/2011

Title: AMINOTHIAZOLE DERIVATIVE

Applicant/Assignee: TAISHO PHARMACEUTICAL CO., LTD

Application No.: JP2010/067383   Filing Date: 04/Oct/2010

Abstract:A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase ? inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn's disease, irritable colitis, Sjoegren's syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.

Priority: JP20090240008 Applic. Date: 2009-10-19

Inventor: YABUUCHI TETSUYA [JP]; OKA YUSUKE [JP]; KURODA SHOICHI [JP]; OI TAKAHIRO [JP]; SEKIGUCHI YOSHINORI [JP]


Publication No.: WO2011049053A1  Published: 28/Apr/2011

Title: INTESTINAL MUCOSA-INHERENT MYELOID CELLS INHIBITING T CELL ACTIVATION AND UTILIZATION OF SAME

Applicant/Assignee: OSAKA UNIVERSITY

Application No.: JP2010/068305   Filing Date: 19/Oct/2010

Abstract:It was discovered that myeloid cells, which occurs in the lamina propria of healthy animals and are highly positive to Gr-1, positive to CD11b and positive to CD11c, can induce T cell apoptosis and, in its turn, inhibit T cell activation. These myeloid cells are highly useful as the active ingredient of an immunomodulator that is applicable to the prevention or treatment of inflammatory bowel disease and so on.

Priority: JP20090241034 Applic. Date: 2009-10-20

Inventor: TAKEDA KIYOSHI [JP]; KAYAMA HISAKO [JP]


Publication No.: WO2011049093A1  Published: 28/Apr/2011

Title: FILM-COATED TABLET WHICH IS SUPPRESSED IN DISCOLORATION AND ODOR

Applicant/Assignee: DAIICHI SANKYO HEALTHCARE CO., LTD

Application No.: JP2010/068398   Filing Date: 19/Oct/2010

Abstract:Disclosed is a tablet containing tranexamic acid, ascorbic acid and L-cysteine, which has excellent stability and is suppressed in discoloration and unpleasant odor. Specifically disclosed is a film-coated tablet that is obtained by providing a tablet, which contains tranexamic acid, ascorbic acid and L-cysteine, with a coating film that contains a polyvinyl alcohol copolymer.

Priority: JP20090241276 Applic. Date: 2009-10-20

Inventor: MATSUSHITA TAKESHI; MOCHIZUKI YUSUKE; MAFUNE EIICHI


Publication No.: WO2011049200A1  Published: 28/Apr/2011

Title: ANTIPRURITIC AGENT

Applicant/Assignee: UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, JAPAN

Application No.: JP2010/068695   Filing Date: 22/Oct/2010

Abstract:Provided is a faster-acting antipruritic agent which has little side effects and is efficacious in treating strongly itchy skin diseases such as atopic dermatitis, characterized by comprising, as the active ingredient, a cholecystokinin 2 acceptor agonist such as a peptide having an amino acid sequence that is homologous with a partial amino acid sequence consisting of 7 or more amino acids from the C-terminal side of a peptide having the amino acid sequence represented by SEQ ID NO:1. Val-Ser-Gln-Arg-Thr-Asp-Gly-Glu-Ser-Arg-Ala-His-Leu-Gly-Ala-Leu-Leu-Ala-Arg-Tyr-Ile-Gln-Gln-Ala-Arg-Lys-Ala-Pro-Ser-Gly-Arg-Met-Ser-Ile-Val-Lys-Asn-Leu-Gln-Asn-Leu-Asp-Pro-Ser-His-Arg-Ile-Ser-Asp-Arg-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 [SEQ ID NO:1]

Priority: JP20090244528 Applic. Date: 2009-10-23

Inventor: TOKURA YOSHIKI [JP]; FUKAMACHI AKIKO [JP]


Publication No.: WO2011050030A1  Published: 28/Apr/2011

Title: ALPHA ADRENERGIC RECEPTOR MODULATORS

Applicant/Assignee: ALLERGAN, INC

Application No.: US2010/053327   Filing Date: 20/Oct/2010

Abstract:Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor, in particular the alpha 2C receptor. The compounds can include N-(2,3-substituted phenyl)-3,4-dihydro-2Hpyrrol-5-amine derivatives. Methods of making, using and formulating these compounds are described

Priority: US20090253654P Applic. Date: 2009-10-21

Inventor: CHOW KEN [US]; WANG LIMING [US]; FANG WENKUI K [US]; CORPUZ EVELYN G [US]; GIL DANIEL W [US]


Publication No.: WO2011050099A2  Published: 28/Apr/2011

Title: THERAPEUTIC COMPOSITION

Applicant/Assignee:

Application No.: US2010/053427   Filing Date: 20/Oct/2010

Abstract:This application discloses a therapeutic composition, a method of preparing a therapeutic composition, and a method for treating skin with a therapeutic composition.

Priority: US20090253405P Applic. Date: 2009-10-20

Inventor: STONE DEBORAH [US]


Publication No.: WO2011050311A1  Published: 28/Apr/2011

Title: USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS

Applicant/Assignee: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Application No.: US2010/053831   Filing Date: 22/Oct/2010

Abstract:C-terminal endostatin polypeptides are disclosed herein. These polypeptides include or consist of at least at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2 or SEQ ID NO: 13 with at most 5 amino acid substitutions, wherein the polypeptide has anti-fibrotic activity and wherein the polypeptide does not comprise amino acids 1-92 of SEQ ID NO: 2 or SEQ ID NO: 13. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung. Also disclosed are methods of decreasing lysyl oxidase (LOX) production in a cell or increasing matrix metalloproteinase production in a cell involving contacting the cells with the polypeptides.

Priority: US20090261280P Applic. Date: 2009-11-13; US20090254143P Applic. Date: 2009-10-22

Inventor: FEGHALI-BOSTWICK CAROL A [US]; YAMAGUCHI YUKIE [JP]


Publication No.: WO2011050574A1  Published: 05/May/2011

Title: PHARMACEUTICAL COMPOSITION CONTAINING CYCLOMETALATED N-HETEROCYCLIC CARBENE COMPLEXES FOR CANCER TREATMENT

Applicant/Assignee: THE UNIVERSITY OF HONG KONG

Application No.: CN2010/001705   Filing Date: 27/Oct/2010

Abstract:The present invention discloses a pharmaceutical composition for treating cancers, comprising a cyclometalated N-heterocyclic carbene complex. Said cyclometalated N-heterocyclic carbene complex contains a gold (III) or platinum (II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase.

Priority: US20090255667P Applic. Date: 2009-10-28; US20100301752P Applic. Date: 2010-02-05

Inventor: CHE CHIMING [CN]; SUN WAIYIN RAYMOND [CN]; CHOW LOKFUNG [CN]; YAN JING [CN]


Publication No.: WO2011050590A1  Published: 05/May/2011

Title: POLYMORPH OF 3-(SUBSTITUTEDDIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND PHARMACEUTICAL COMPOSITIONS THEREOF

Applicant/Assignee: NANJING CAVENDISH BIO-ENGINEERING TECHNOLOGY CO.,LTD

Application No.: CN2010/001751   Filing Date: 02/Nov/2010

Abstract:The present invention provides polymorph of 3-(4-amino-1-oxo-1,3- dihydro-2H-isoindole-2-yl)-piperidine-2,6-dione, and also the preparing methods and pharmaceutical compositions thereof.

Priority: CN20091210392 Applic. Date: 2009-11-02

Inventor: YAN RONG [CN]; YANG HAO [CN]; XU YONGXIANG [CN]


Publication No.: WO2011050947A2  Published: 05/May/2011

Title: TAPE, IN PARTICULAR, ADHESIVE TAPE, FOR THE TREATMENT OF SKIN DISORDERS COMPRISING AT LEAST ONE HYPERKERATOSIS INHIBITOR AND/OR AT LEAST ONE KERATINOLYTIC AGENT

Applicant/Assignee: JOHNSON & JOHNSON GMBH

Application No.: EP2010/006554   Filing Date: 27/Oct/2010

Abstract:The present invention relates to a tape for the treatment of skin disorders comprising at least one base layer having a first surface facing away from the skin during use and a second surface facing towards the skin during use, and at least one carrier layer on the side of said second surface, having a first surface facing away from the skin during use and a second surface facing towards the skin during use, which covers at least part of the second surface of said base layer and which comprises at least one hyperkeratosis inhibitor and/or at least one keratinolytic agent.

Priority: EP20090013680 Applic. Date: 2009-10-30

Inventor: PEREZ ENCARNA [DE]; FERNANDEZ-KLEINLEIN ELENA [DE]


Publication No.: WO2011050948A1  Published: 05/May/2011

Title: TAPE, IN PARTICULAR ADHESIVE TAPE, FOR THE TREATMENT OF SKIN DISORDERS COMPRISING A FILM, IN PARTICULAR DISSOLVABLE FILM, CONTAINING AT LEAST ONE ENZYME

Applicant/Assignee: JOHNSON & JOHNSON GMBH

Application No.: EP2010/006555   Filing Date: 27/Oct/2010

Abstract:The present invention relates to a tape, in particular adhesive tape, for the treatment of skin disorders comprising at least one base layer having a first surface facing away from the skin during use and a second surface facing towards the skin during use, and at least one first film, in particular dissolvable film, on the side of said second surface, which covers at least part of the second surface of said base layer, said first film, in particular dissolvable film, having a first surface facing away from the skin during use and a second surface facing towards the skin during use and comprising at least one enzyme, in particular a proteolytic enzyme.

Priority: EP20090013681 Applic. Date: 2009-10-30

Inventor: PEREZ ENCARNA [DE]


Publication No.: WO2011051813A1  Published: 05/May/2011

Title: COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS

Applicant/Assignee:

Application No.: IB2010/003159   Filing Date: 13/Dec/2010

Abstract:Provided herein are methods of improving one or more symptoms of a dermatological condition in a patient. The methods comprise topically administering a topical composition to the patient comprising a branched chain amino acid, and an enzyme activator. Also provided are kits comprising the topical composition and optionally a topical steroid.

Priority: US2009-607470 Applic. Date: 2009-10-28

Inventor: PAUL HARBHAJAN S [US]


Publication No.: WO2011052668A1  Published: 05/May/2011

Title: TISSUE-REGENERATION PROMOTER USING RECRUITMENT OF BONE MARROW MESENCHYMAL STEM CELLS AND/OR PLURIPOTENT STEM CELLS IN BLOOD

Applicant/Assignee: GENOMIX CO., LTD, OSAKA UNIVERSITY

Application No.: JP2010/069133   Filing Date: 28/Oct/2010

Abstract:Intravenous administration of HMGB-1 and S100A8 was found to cause recruitment of bone-marrow-derived cells to a skin ulceration site and promote healing of the skin ulceration. Also, bone-marrow-derived cells expressing nerve cell markers were found in the brains of stroke model mice administered HMGB-1 intravenously after stroke inducement. In comparison with controls, mice administered HMGB-1 intravenously exhibited pronounced improvement in terms of stroke lesion contraction. Mice administered HMGB-1 intravenously had a higher post-stroke survival rate. Using mice, the involvement of bone-marrow pluripotent stem cells in the bone-fracture healing process was confirmed, which indicates that bone-marrow-derived cells far from the injury site moved to the bone-fracture area to repair injured tissue.

Priority: JP20090247143 Applic. Date: 2009-10-28

Inventor: TAMAI KATSUTO [JP]; KANEDA YASUFUMI [JP]; YAMAZAKI TAKEHIKO [JP]; CHINO TAKENAO [JP]; SAGA KOTARO [JP]; ENDO MAYUMI [JP]


Publication No.: WO2011052830A1  Published: 05/May/2011

Title: RASPBERRY EXTRACT FOR ENHANCING SKIN IMMUNITY, COMBINED PRESSURE EXTRACTION METHOD AND EXTRACT THEREFROM

Applicant/Assignee: UNIVERSITY-INDUSTRY COOPERATION FOUNDATION KANGWON NATIONAL UNIVERSITY

Application No.: KR2009/006378   Filing Date: 02/Nov/2009

Abstract:The present invention relates to an extraction method for raspberry extract which has a skin immunity enhancing effect, and the extract therefrom. The present invention overcomes the disadvantages found in known high pressure extraction methods by applying an effective, step-wise extraction process which targets raspberry extract. Further disclosed is an excellent raspberry extract which provides protection against skin aging. The present invention combines super-critical extraction with high pressure extraction at appropriate levels which is characterized by adding ethanol at an optimum rate during the initial super-critical extraction. The present invention will find wide use in cosmetics.

Priority:

Inventor: LEE HYEON-YONG [KR]; JEONG HYANG-SUK [KR]; HAN JAE-GUN [KR]; KIM SEUNG-SEOP [KR]; HA JI-HYE [KR]; OH SUNG-HO [KR]; JEONG MYOUNG-HOON [KR]; JIN LING [KR]; KWAK HYEONG-GEUN [KR]; HWANGBO YOUNG [KR]; NA CHUN-SU [KR]


Publication No.: WO2011053007A2  Published: 05/May/2011

Title: COMPOSITION FOR SUPPRESSING PORE SHRINKAGE OR SEBUM SECRETION WHICH COMPRISES POTENTILLA CHINENSIS EXTRACT

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: KR2010/007465   Filing Date: 28/Oct/2010

Abstract:The present invention relates to a composition for suppressing pore shrinkage or sebum secretion which comprises Potentilla chinensis extract as an active ingredient. The Potentilla chinensis extract which constitutes an active ingredient comprised in the composition according to the present invention has been confirmed to be able to inhibit the formation of complexes of SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) and to inhibit the release of neurotransmitters and can therefore suitably be used as an active ingredient in compositions for suppressing pore shrinkage or sebum secretion.

Priority: KR20090104415 Applic. Date: 2009-10-30

Inventor: KOH HYUN JU [KR]; KIM DO-HOON [KR]; PARK WON SEOK [KR]; KIM JEONG-HWAN [KR]; KIM HYOUNG JUN [KR]; SHIN HONG-JU [KR]; PARK JONG HEE [KR]; YI CHANG-GEUN [KR]; KWEON DAE-HYUK [KR]


Publication No.: WO2011053487A1  Published: 05/May/2011

Title: METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA

Applicant/Assignee: GALDERMA PHARMA S.A

Application No.: US2010/053198   Filing Date: 19/Oct/2010

Abstract:A method of treating or preventing acute erythema in a human in need thereof by topical administration of an effective amount of an alpha adrenergic receptor agonist or pharmaceutically acceptable salt thereof is claimed. The preferred alpha adrenergic receptor agonist is brimonidine. A method of preventing secondary inflammation caused by acute erythema by topical administration of an effective amount of an alpha adrenergic receptor agonist or a pharmaceutically acceptable salt thereof is also claimed.

Priority: US20090254805P Applic. Date: 2009-10-26

Inventor: ANDRES PHILIPPE [FR]; LOESCHE CHRISTIAN [FR]; GRAEBER MICHAEL [US]


Publication No.: WO2011053571A1  Published: 05/May/2011

Title: PHYTOESTROGENIC FORMULATIONS FOR ALLEVIATION OR PREVENTION OF HAIR LOSS

Applicant/Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA

Application No.: US2010/054046   Filing Date: 26/Oct/2010

Abstract:Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with hair loss or prostate cancer/prostate hypertrophy are described herein. These select phytoestrogen formulations are preferably composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERss over ERa and agonist activity in non- reproductive tissues including brain.

Priority: US2009-606006 Applic. Date: 2009-10-26

Inventor: BRINTON ROBERTA DIAZ [US]; ZHAO LIQIN [US]


Publication No.: WO2011054090A1  Published: 12/May/2011

Title: COMPOSITIONS COMPRISING EXTRACTS OF BOSWELLIA, TEA TREE, ALOE AND LAVENDER OIL AND METHODS OF TREATING WOUNDS, BURNS AND SKIN INJURIES THEREWITH

Applicant/Assignee: NUTRIQUINE N.V

Application No.: CA2010/001740   Filing Date: 02/Nov/2010

Abstract:Compositions for the treatment of sores, wounds, burns and other traumatized dermal tissues and skin injuries comprising Boswellia gum, gel, resin or extract, Tea Tree oil (Melaleuca oil), an Aloe gel, resin, latex or extract and Lavender oil. The composition may be incorporated into a medical device such as a wound dressing or bandage, or formulated into a topical preparation such as an ointment, lotion or cream.

Priority: CA20092684258 Applic. Date: 2009-11-03

Inventor: CHAMBERLAND GUY [CA]; BOLLEN PETER [BE]


Publication No.: WO2011054301A1  Published: 12/May/2011

Title: USE OF DANSHENSU, NOTOGINSENOSIDE R1 OR THEIR COMBINATION IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING DISEASES CAUSED BY MICROCIRCULATION DISORDER

Applicant/Assignee: TIANJIN TASLY PHARMACEUTICAL CO., LTD

Application No.: CN2010/078411   Filing Date: 04/Nov/2010

Abstract:Use of danshensu, notoginsenoside R1 or their combination in the preparation of medicaments for preventing and treating diseases caused by microcirculation disorder.

Priority: CN20091071163 Applic. Date: 2009-11-05

Inventor: HAN JINGYAN [CN]; GUO JUN [CN]; YANG JIYING [CN]; SUN KAI [CN]; WANG MINGXIA [CN]; ZHANG YU [CN]; LIU YUYING [CN]


Publication No.: WO2011054805A1  Published: 12/May/2011

Title: SUBSTITUTED 3-(PHENOXYMETHYL) BENZYL AMINES AND PERSONAL CARE COMPOSITIONS

Applicant/Assignee: UNILEVER PLC, UNILEVER N.V, HINDUSTAN UNILEVER LIMITED

Application No.: EP2010/066607   Filing Date: 02/Nov/2010

Abstract:Certain novel substituted 3-(phenoxymethyl) benzyl amines and personal care compositions comprising such, which are particularly beneficial for skin lightening and achieving evenness of color, especially for face and underarm skin.

Priority: US2009-614731 Applic. Date: 2009-11-09

Inventor: ROSA JOSE GUILLERMO [US]; HARICHIAN BIJAN [US]; BAJOR JOHN STEVEN [US]; BOSKO CAROL ANNETTE [US]; DRENNAN DIANA JEAN [US]; NIP JOHN CHUN-SING [US]


Publication No.: WO2011054837A2  Published: 12/May/2011

Title: BIFUNCTIONAL PRODRUGS AND DRUGS

Applicant/Assignee: GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENLICHEN RECHTS

Application No.: EP2010/066688   Filing Date: 03/Nov/2010

Abstract:The present invention relates to novel compounds, more precisely to novel bifunctional prodrugs and drugs. In a further aspect, the invention relates to pharmaceutical compositions comprising said prodrugs and drugs, and to the use thereof as cytostatic agents in tumor therapy. The compounds according to the invention thereby are based on CC- 1065 analogously.

Priority: DE200910051799 Applic. Date: 2009-11-03

Inventor: TIETZE LUTZ [DE]; VON HOF JAN MARIAN [DE]


Publication No.: WO2011055032A2  Published: 12/May/2011

Title: USE OF A COMPOSITION COMPRISING A NON-FERMENTED RICE PEPTIDE HYDROLYSATE FOR STIMULATING HAIR GROWTH

Applicant/Assignee: ISP INVESTMENTS INC

Application No.: FR2010/000722   Filing Date: 02/Nov/2010

Abstract:The invention relates to the use of a composition comprising at least one non-fermented rice peptide hydrolysate as an active agent that can slow down and limit hair loss, and/or stimulate hair growth. Said composition is used to protect the follicular adult stem cells and the specific micro-environment thereof. Furthermore, the composition according to the invention enables the control of ageing, especially photo-ageing of hair. The invention also relates to a plurality of non-therapeutic treatment methods using said composition.

Priority: FR20090005256 Applic. Date: 2009-11-03

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Publication No.: WO2011055033A2  Published: 12/May/2011

Title: USE OF A CORN PEPTIDE HYDROLYSATE AS AN ACTIVE AGENT STIMULATING HAIR GROWTH

Applicant/Assignee: ISP INVESTMENTS INC

Application No.: FR2010/000723   Filing Date: 02/Nov/2010

Abstract:The invention relates to the use of a composition comprising at least one corn peptide hydrolysate (Zea mays L.), as an active agent, for stimulating and/or restoring hair growth or preventing hair from falling out. The invention also relates to the use of said novel active agent for producing a dermato-pharmaceutical composition, for stimulating and restoring hair growth or limiting the amount of hair falling out. The invention further relates to a cosmetic treatment method for preventing or fighting signs of hair ageing.

Priority: FR20090005258 Applic. Date: 2009-11-03

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Publication No.: WO2011055034A1  Published: 12/May/2011

Title: USE OF YEAST PEPTIDE HYDROLYSATE AS AN ACTIVE AGENT FOR STRENGTHENING HAIR

Applicant/Assignee: ISP INVESTMENTS INC

Application No.: FR2010/000724   Filing Date: 02/Nov/2010

Abstract:The invention relates to the use of a composition including at least one yeast peptide hydrolysate (Saccharomyces cerevisiae) as an active agent for strengthening hair and improving hair health. The invention also relates to the use of said novel active agent for producing a dermatopharmacological composition for stimulating hair growth or controlling hair loss. The invention also relates to a cosmetic treatment method for stimulating hair growth or controlling hair loss and for controlling exterior factors affecting the hair.

Priority: FR20090005257 Applic. Date: 2009-11-03

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Publication No.: WO2011055139A2  Published: 12/May/2011

Title: FORMULATIONS

Applicant/Assignee: SYNTOPIX GROUP PLC

Application No.: GB2010/051824   Filing Date: 01/Nov/2010

Abstract:An antimicrobial and/or anti-acne formulation containing either usnic acid or an usnate, together with (a) a primary solvent or solvent system in which the usnic acid or usnate is at least partially dissolved

(b) a glycol

and (c) a hydrophobic fatty acid, fatty alcohol or derivative thereof. The formulation may also contain (d) an alkylene glycol derivative.

Priority: GB20090019210 Applic. Date: 2009-11-03

Inventor: DAVIS ADRIAN [GB]; DONOGHUE GAVIN [GB]; EADY ELIZABETH [GB]


Publication No.: WO2011055270A1  Published: 12/May/2011

Title: INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS

Applicant/Assignee: WYETH LLC

Application No.: IB2010/054845   Filing Date: 26/Oct/2010

Abstract:Disclosed are compounds of Formula (I): which are useful as antagonists of the CRTH2 receptors. Pharmaceutical compositions containing compounds of Formula (I) and the use of compounds of Formula (I) to treat diseases or disorders that are responsive to inhibition of the binding of endogenous ligands to the CRTH2 receptor are also disclosed. Methods for preparing and using these compounds are further described.

Priority: US20090257975P Applic. Date: 2009-11-04

Inventor: FOLLOWS BRUCE CHRISTOPHER [US]; HUANG ADRIAN [US]; JANZ KRISTIN MARIE [US]; KAILA NEELU [US]; LOWE MICHAEL DENNIS [US]; MANSOUR TAREK SUHAYL [US]; MORETTO ALESSANDRO FABIO [US]; SAIAH EDDINE [US]; THOMASON JENNIFER ROMANIC [US]; WILLIAMS CARA MARGARET MAY [US]


Publication No.: WO2011055550A1  Published: 12/May/2011

Title: THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES OR ALLERGY, AND METHOD FOR SCREENING FOR THE THERAPEUTIC AGENT

Applicant/Assignee: OSAKA UNIVERSITY

Application No.: JP2010/006527   Filing Date: 05/Nov/2010

Abstract:Disclosed is a therapeutic agent for cellular immune diseases, which comprises a substance capable of inhibiting the binding between a Neuropilin-1/Plexin-A1 hetero receptor and Sema3A as an active ingredient. The substance is, for example, a Sema3A-neutralizing antibody, a Neuropilin-1-neutralizing antibody, Neuropilin-1 in a soluble form, or a derivative of any one of the aforementioned substances. Also disclosed is a method for screening for a therapeutic agent for cellular immune diseases by employing a signal produced upon the interaction among Neuropilin-1, Plexin-A1 and Sema3A as a measure.

Priority: JP20090254108 Applic. Date: 2009-11-05

Inventor: KUMANOGOH ATSUSHI [JP]


Publication No.: WO2011055561A1  Published: 12/May/2011

Title: PROTEIN CROSSLINKING INHIBITOR AND USE THEREOF

Applicant/Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY

Application No.: JP2010/058411   Filing Date: 19/May/2010

Abstract:Disclosed are: a ketone compound which is represented by general formula (1), (2) or (3) and has transglutaminase inhibitory activity

a protein crosslinking inhibitor which contains the compound

and a composition for prevention or treatment of diseases that are caused by crosslinking of proteins, said composition containing the compound or the protein crosslinking inhibitor. (In the formulae, R1 represents a substituted or unsubstituted aryl group or heterocyclic group

R2, R3 and R4 each represents a hydrogen atom

n represents 2

X represents a halogen atom

and R5 and R6 each independently represents a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl group, aryl group or aralkyl group. In this connection, R5 and R6 are not hydrogen atoms at the same time, and R5 and R6 may combine together to form a saturated or unsaturated, substituted or unsubstituted heterocyclic group that contains a nitrogen atom (N).)

Priority: JP20090255518 Applic. Date: 2009-11-06

Inventor: MIKOSHIBA KATSUHIKO [JP]; HAMADA KOZO [JP]; TERAUCHI AKIKO [JP]; OZAKI SHOUICHIROU [JP]; GOTO JUN-ICHI [JP]; EBISUI ETSUKO [JP]; SUZUKI AKINOBU [JP]


Publication No.: WO2011055838A1  Published: 12/May/2011

Title: COMPOUND FOR INHIBITING BIOSYNTHESIS OF TESTOSTERONE

Applicant/Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED

Application No.: JP2010/069879   Filing Date: 02/Nov/2010

Abstract:Disclosed are use and the like of a compound represented by formula (I), a salt thereof or a solvate thereof, for the purpose of inhibiting the biosynthesis of testosterone.

Priority: JP20090252735 Applic. Date: 2009-11-04

Inventor: HARADA KOICHIRO [JP]; KUBO HIDEKI [JP]; ABE JUN [JP]


Publication No.: WO2011056017A2  Published: 12/May/2011

Title: MASS PROPAGATION METHOD FOR HAIR FOLLICLE STEM CELLS

Applicant/Assignee: RNL BIO CO., LTD

Application No.: KR2010/007794   Filing Date: 05/Nov/2010

Abstract:The present invention relates to a method for propagating hair follicle stem cells with a high yield rate, and more particularly, to a method which uses a specific culture medium with a Rho-associated kinase (ROCK) inhibitor at a specific concentration during the cultivation of hair follicle stem cells, in order to mass-produce hair follicle stem cells. The present invention also relates to the culture medium used for the method. The culture medium for culturing hair follicle stem cells according to the present invention can propagate hair follicle stem cells separated from scalp tissues in an amount sufficient for application to clinical treatment, and therefore the hair follicle stem cells can be effectively used as therapeutic agents for promoting hair growth for those with alopecia, atrichia, and the like.

Priority: KR20090107184 Applic. Date: 2009-11-06

Inventor: RA JEONG CHAN [KR]; KANG SUNG KEUN [KR]; WOO SANG KYU [KR]; KIM MI AE [KR]; YOON EUN JI [KR]


Publication No.: WO2011056056A2  Published: 12/May/2011

Title: ANTI-CYTOKINE VHNAR DOMAINS

Applicant/Assignee: LABORATORIOS SILANES, S.A. DE C.V

Application No.: MX2010/000122   Filing Date: 04/Nov/2010

Abstract:The invention relates to selected sequences of variable regions called VHNAR from antigen receptor IgNAR-type immunoglobulins from elasmobranchs with a specificity for cytokines. The invention also relates to pharmaceutical compositions containing recombinant vNAR proteins, encoded by the VHNAR sequences, to be used in the topical or systemic treatment of ailments depending on the action of cytokines for inhibiting its activity, especially that of interleukins 1 and 6 (IL-I, IL- 6) of the tumoral necrosis factor (TNF) and the vascular endothelial growth factor (VEGF).

Priority: US20090258118P Applic. Date: 2009-11-04

Inventor: LICEA NAVARRO ALEXEI FEDOROVISH [MX]; CAMACHO VILLEGAS TANYA AMANDA [MX]; SANCHEZ CASTREJON EDNA [MX]; MATA GONZALEZ MARIA TERESA [MX]; GARCIA HUBBELOHDE WALTER J [MX]; OLGUIN JIMENEZ ARACELI [MX]; PANIAGUA SOLIS JORGE F [MX]


Publication No.: WO2011056116A1  Published: 12/May/2011

Title: COMPOSITION FOR PROMOTING WOUND HEALING

Applicant/Assignee: LIPIDOR AB

Application No.: SE2010/000269   Filing Date: 03/Nov/2010

Abstract:A lipid layer forming wound healing promoting composition comprising volatile silicone oil, polar lipid, C2 - C4 aliphatic alcohol, and a wound healing agent, in particular a low to medium size natural or synthetic peptide. Also disclosed is a method of forming the lipid layer on a wound and a medical patch provided with the composition.

Priority: SE20090001408 Applic. Date: 2009-11-03; SE20100000022 Applic. Date: 2010-01-12

Inventor: CARLSSON ANDERS [SE]; HOLMBAECK JAN [SE]


Publication No.: WO2011056382A1  Published: 12/May/2011

Title: ANGIOGENESIS PROMOTED BY CAGED GROWTH FACTORS

Applicant/Assignee: EMPIRE TECHNOLOGY DEVELOPMENT LLC, GLITTER TECHNOLOGY LLP

Application No.: US2010/052817   Filing Date: 15/Oct/2010

Abstract:The present disclosure relates to controlling the release of growth factors for the promotion of angiogenesis. The growth factors or a polymer matrix are modified by photoactive compounds, such that the growth factors are not released into an active form until they are irradiated with light. The disclosure also relates to tissue engineering scaffolds comprising one or more polymers and at least two growth factors.

Priority: US2009-605744 Applic. Date: 2009-10-26

Inventor: MILLER SETH ADRIAN [US]


Publication No.: WO2011056497A1  Published: 12/May/2011

Title: ACTIVIN RECEPTOR TYPE IIB COMPOSITIONS AND METHODS OF USE

Applicant/Assignee: GENENTECH, INC, F. HOFFMANN-LA ROCHE AG

Application No.: US2010/053918   Filing Date: 25/Oct/2010

Abstract:Disclosed herein are methods and compositions for treating disorders associated with angiogenesis or lymphangiogenesis using ACVR2B antagonists.

Priority: US20090254990P Applic. Date: 2009-10-26

Inventor: YAN MINHONG [US]; NIESSEN KYLE [US]


Publication No.: WO2011056502A1  Published: 12/May/2011

Title: BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE II COMPOSITIONS AND METHODS OF USE

Applicant/Assignee: GENENTECH, INC, F. HOFFMANN-LA ROCHE AG

Application No.: US2010/053933   Filing Date: 25/Oct/2010

Abstract:Disclosed herein are methods and compositions for treating disorders associated with angiogenesis or lymphangiogenesis using BMPR2 antagonists.

Priority: US20090254995P Applic. Date: 2009-10-26

Inventor: YAN MINHONG [US]; NIESSEN KYLE [US]


Publication No.: WO2011056667A2  Published: 12/May/2011

Title: ROSACEA TOPICAL SKIN TREATMENT METHOD AND FORMULATION

Applicant/Assignee:

Application No.: US2010/054322   Filing Date: 27/Oct/2010

Abstract:A method for topical treatment of rosacea comprising application of a formulation to the affected area is disclosed. The formulation comprises one or more iron chelators. Omadine, a bispyrithione salt, and kojic acid are the preferred iron chelators. The formulation also comprises one or more false substrates for arachidonic acid. The preferred false substrates for arachidonic acid are alpha-linoleic acid and gamma dihomo-linolenic acid. The formulation further comprises an inhibitor of stratum corneum tryptic enzyme (SCTE). A preferred stratum corneum tryptic enzyme inhibitor is zinc. The formulation also preferably includes one or more medium-chain saturated fatty acid monoester. The preferred medium-chain fatty acid monoesters are glycerol monolaurate and glycerol monocaprylate.

Formulation components are solubilized in a suitable carrier base which includes emollient, humectant, antioxidant and sunscreen components. The method preferably comprises application of a leave-on formulation. Alternatively, a pre-step of application of a rinse-off formulation containing a higher concentration of an iron chelator may be employed in the regimen.

Priority: US20090255556P Applic. Date: 2009-10-28

Inventor: GUTHERY EUGENE B [US]


Publication No.: WO2011057269A2  Published: 12/May/2011

Title: COMPOSITIONS FOR ENHANCING HAIR GROWTH

Applicant/Assignee: ALLERGAN, INC

Application No.: US2010/056036   Filing Date: 09/Nov/2010

Abstract:Methods and compositions for stimulating the growth of hair are disclosed wherein emulsions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal.

Priority: US20090259368P Applic. Date: 2009-11-09; US20090260163P Applic. Date: 2009-11-11

Inventor: GORE ANURADHA [US]; WARNER KEVIN S [US]


Publication No.: WO2011057471A1  Published: 19/May/2011

Title: METHODS AND COMPOSITIONS FOR TREATING DISEASE OR CONDITION RELATED TO OREXIN RECEPTOR 1, OREXIN RECEPTOR 2, SOMATOSTATIN RECEPTOR 2 OR DOPAMINE D2L RECEPTOR

Applicant/Assignee: CENTER LABORATORIES, INC

Application No.: CN2010/001681   Filing Date: 25/Oct/2010

Abstract:The present invention discloses methods and compositions for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine D2L receptor. The method comprises administering a composition comprising an effective amount of verapamil and a pharmaceutically acceptable excipient to a subject, wherein the verapamil is capable of binding to at least one of receptors selected from the group consisting of orexin receptor 1, orexin receptor 2, somatostatin receptor 2 and dopamine D2L receptor of the subject.

Priority: US20090259688P Applic. Date: 2009-11-10

Inventor: LEE HUAI-CHENG [CN]; SHANE GUANG-TZUU [CN]; WANG HSI-CHIEH [CN]; LIN RONGJIN [CN]


Publication No.: WO2011058423A2  Published: 19/May/2011

Title: IDENTIFICATION AND CHARACTERIZATION OF NATURAL CHEMICAL ENTITIES BY LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRY LC-MS/MS AND USES THEREOF

Applicant/Assignee: AVESTHAGEN LIMITED

Application No.: IB2010/002886   Filing Date: 12/Nov/2010

Abstract:The present invention further relates to extracts which are isolated from Deschampsia antarctica plant, the preparation of such extracts, the medicaments containing said extracts, and the use of these extracts and constituents for the preparation of a medicament.

Priority: IN2009CH02800 Applic. Date: 2009-11-13

Inventor: PATELL VILLOO MORAWALA [IN]; JAIN RENUKA [IN]; SHINDE MANOHAR [IN]; SETTU LAKSMI [IN]


Publication No.: WO2011059021A1  Published: 19/May/2011

Title: 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE

Applicant/Assignee: DAINIPPON SUMITOMO PHARMA CO., LTD

Application No.: JP2010/070095   Filing Date: 11/Nov/2010

Abstract:Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A represents a group that is represented by formula (A-1)

R1a and R1b may be the same or different and each independently represents a C1-6 alkyl group which may be substituted by one to three halogen atoms

m and n each independently represents an integer of 0-5

X1 represents a hydroxyl group or an aminocarbonyl group

Z1 represents a single bond or the like

and R2 represents an optionally substituted C1-6 alkyl group, an optionally substituted C6-10 aryl group or the like.)

Priority: JP20090258451 Applic. Date: 2009-11-11; JP20100156263 Applic. Date: 2010-07-08

Inventor: HORIUCHI YOSHIHIRO [JP]; SAWAMURA KIYOTO [JP]; FUJIWARA HIROAKI [JP]


Publication No.: WO2011059110A1  Published: 19/May/2011

Title: THERAPEUTIC AGENT FOR PSORIASIS OR ATOPIC DERMATITIS

Applicant/Assignee: KABUSHIKI KAISHA SAIWAI MEDIX

Application No.: JP2010/070627   Filing Date: 12/Nov/2010

Abstract:Disclosed is a therapeutic agent for psoriasis or atopic dermatitis, which comprises an anti-Staphylococcus aureus antibody as an active ingredient. Specifically disclosed is a therapeutic agent for psoriasis or atopic dermatitis, which comprises, as an active ingredient, a comprehensive anti-Staphylococcus aureus surface antibody including an antibody against the entire of a protein molecule that is expressed on the surface of Staphylococcus aureus and is produced through the steps of: (a) treating Staphylococcus aureus cells with a protein-crosslinking/immobilizing reagent to immobilize a protein expressed on the surfaces of the Staphylococcus aureus cells by means of intermolecular crosslinking

(b) administering the Staphylococcus aureus cells that have been immobilized with the protein-crosslinking/immobilizing reagent to an animal as an immunogen

and (c) obtaining the antibody from the animal.

Priority: JP20090260031 Applic. Date: 2009-11-13

Inventor: SHICHIRI MASAYOSHI [JP]


Publication No.: WO2011059776A2  Published: 19/May/2011

Title: PROPHYLAXIS OF SKIN CANCER WITH RETINAMIDES

Applicant/Assignee: REVISION THERAPEUTICS, INC

Application No.: US2010/054575   Filing Date: 28/Oct/2010

Abstract:Provided in certain embodiments herein are methods of prophylaxis of skin cancer in individuals having a heightened risk of skin cancer with a fenretinide agent.

Priority: US20090255739P Applic. Date: 2009-10-28; US20100372821P Applic. Date: 2010-08-11

Inventor: BUTLER BARRY SCOTT [US]; MATA NATHAN L [US]; VOGEL ROGER [US]; PETERSON CARYN E [US]


Publication No.: WO2011059866A2  Published: 19/May/2011

Title: COMPOSITION AND METHODS FOR IMPROVING SKIN APPEARANCE

Applicant/Assignee: SYTHEON LTD

Application No.: US2010/055357   Filing Date: 04/Nov/2010

Abstract:Skin conditioning compositions comprising a C4 to C30 monoaikyi-, diaikyi, monoalkanoyl- or dialkanoyl- substituted isohexide are found to exhibit a marked effect on skin hydration and barrier function homeostasis thereby improving skin appearances.

Priority: US2010-938743 Applic. Date: 2010-11-03; US20090260846P Applic. Date: 2009-11-13

Inventor: CHAUDHURI RATAN K [US]


Publication No.: WO2011060354A2  Published: 19/May/2011

Title: COLORING COMPOSITION CONTAINING AN AROMATIC COMPOUND AND AN INITIATOR

Applicant/Assignee: WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC, JOHN MASTERS ORGANIC HAIR CARE, INC

Application No.: US2010/056695   Filing Date: 15/Nov/2010

Abstract:A natural coloring composition for coloring materials, and methods of its use. The coloring composition comprises a natural precursor aromatic ring molecule such as L-DOPA that is oxidatively oligomerized or polymerized in the presence of an activator, such as a salt or an enzyme, to form colored compounds that dye a material. The natural coloring composition can also include a buffer, colorant, stabilizer, and/or thickening agent, and can comprise one or two inactive solutions that are combined to form an active coloring composition.

Priority: US20090261287P Applic. Date: 2009-11-13; US20090261290P Applic. Date: 2009-11-13

Inventor: WARNER JOHN C [US]; STOLER EMILY J [US]


Publication No.: WO2011060390A2  Published: 19/May/2011

Title: ADVANCED FUNCTIONAL BIOCOMPATIBLE FOAM USED AS A HEMOSTATIC AGENT FOR COMPRESSIBLE AND NON-COMPRESSIBLE ACUTE WOUNDS

Applicant/Assignee: UNIVERSITY OF MARYLAND, COLLEGE PARK

Application No.: US2010/056758   Filing Date: 15/Nov/2010

Abstract:A sprayable polymeric foam hemostat for both compressible and non-compressible (intracavitary) acute wounds is disclosed. The foam comprises hydrophobically-modified polymers, such as hm-chitosan, or other amphiphilic polymers that anchor themselves within the membrane of cells in the vicinity of the wound. By rapidly expanding upon being released from a canister pressurized with liquefied gas propellant, the foam is able to enter injured body cavities and staunch bleeding. The seal created is strong enough to substantially prevent the loss of blood from these cavities. Hydrophobically-modified polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The amphiphilic polymers form solid gel networks with blood cells to create a physical clotting mechanism that prevent loss of blood.

Priority: US20090261194P Applic. Date: 2009-11-13

Inventor: DOWLING MATTHEW [US]; RAGHAVAN SRINIVASA R [US]


Publication No.: WO2011061119A1  Published: 26/May/2011

Title: HUMANIZED ANTIBODIES AGAINST HUMAN IL-22RA

Applicant/Assignee: MERCK SERONO S.A

Application No.: EP2010/067332   Filing Date: 12/Nov/2010

Abstract:The invention relates to humanized antibodies against human IL-22RA and to their use in the treatment of psoriasis and other immune-mediated diseases such as psoriatic arthritis and atopic dermatitis.

Priority: EP20090176525 Applic. Date: 2009-11-19; US20090262998P Applic. Date: 2009-11-20

Inventor: BECKMANN ROLAND [AT]; JOHNSON-LEGER CAROLINE [FR]


Publication No.: WO2011061252A2  Published: 26/May/2011

Title: COMBINATION THERAPY FOR TREATING OR PREVENTING AN INFLAMMATORY SKIN DISORDER

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: EP2010/067749   Filing Date: 18/Nov/2010

Abstract:Methods and compositions for improved treatment and prevention of an inflammatory skin disorder or a sign and/or symptom associated with the skin disorder are described. The methods involve topical application to the skin a combination of a therapeutically effective amount of an a2 adrenergic receptor agonist, such as brimonidine, and a therapeutically effective amount of a non-steroidal anti-inflammatory agent, such as diclofenac.

Priority: EP20090176392 Applic. Date: 2009-11-18

Inventor: JOMARD ANDRE [FR]; DELAMADELEINE FRANCOISE [FR]


Publication No.: WO2011061747A1  Published: 26/May/2011

Title: ANTIFUNGAL AND ANTI PARASITIC CONJUGATES OF AMPHOTERICIN B DERIVATIVES

Applicant/Assignee: CONJUGATE LTD

Application No.: IL2010/000981   Filing Date: 23/Nov/2010

Abstract:This invention relates to conjugates of polysaccharides and active drug components and uses thereof in a variety of therapies, such as antifungal and antileishmanial therapies.

Priority: US20090263559P Applic. Date: 2009-11-23

Inventor: DOMB ABRAHAM J [IL]; POLACHECK ITZHACK [IL]


Publication No.: WO2011061932A1  Published: 26/May/2011

Title: CERAMIDE AND COLLAGEN SYNTHESIS PROMOTER AND COLLAGEN SACCHARIFICATION INHIBITOR

Applicant/Assignee: LOTTE CO., LTD

Application No.: JP2010/006752   Filing Date: 17/Nov/2010

Abstract:Disclosed is an oral preparation that is capable of enhancing skin barrier functions such as moisture retention by accelerating the synthesis of ceramide in the skin, and furthermore increases the level of collagen in the skin, prevents skin wrinkles and sagging by inhibiting the saccharification of collagen, and can be safely ingested. Specifically disclosed are a ceramide synthesis promoter, a collagen synthesis promoter, and a collagen saccharification inhibitor, which involve the oral ingestion of xylitol, that have an excellent ceramide synthesis promoting effect, collagen level increasing effect, and collagen saccharification inhibiting effect, and can be safely ingested.

Priority: JP20090262951 Applic. Date: 2009-11-18

Inventor: ICHIKAWA TOMOYA [JP]; YOSHIDA KEISHIRO [JP]; SHIMURA SUSUMU [JP]; OISHI YUICHI [JP]


Publication No.: WO2011062253A1  Published: 26/May/2011

Title: NOVEL FUSED PYRIMIDINE DERIVATIVE

Applicant/Assignee: DAINIPPON SUMITOMO PHARMA CO., LTD

Application No.: JP2010/070651   Filing Date: 19/Nov/2010

Abstract:Disclosed is a prophylactic and/or therapeutic agent for diseases associated with autoimmunity, immune deficiency diseases or neurodegenerative diseases, said prophylactic and/or therapeutic agent containing a novel fused pyrimidine derivative. Particularly disclosed is a prophylactic and/or therapeutic agent for sepsis.

Priority: JP20090264612 Applic. Date: 2009-11-20

Inventor: ASANO SHIGEHIRO [JP]; KUBOTA KATSUMI [JP]; KASAI MAI [JP]; ISOBE YOSHIAKI [JP]


Publication No.: WO2011062443A2  Published: 26/May/2011

Title: PHARMACEUTICAL COMPOSITION FOR TREATING ATOPIC DERMATITIS, CONTAINING LACTOBACILLUS, AND PHARMACEUTICAL COMPOSITION CONTAINING GOLD CULTURED TOGETHER WITH SAID BACTERIUM

Applicant/Assignee: ACTSBIO

Application No.: KR2010/008202   Filing Date: 19/Nov/2010

Abstract:The present invention relates to a pharmaceutical composition for preventing and treating atopic dermatitis, containing Lactobacillus, which is administered into the skin, and a pharmaceutical composition containing gold cultured together with said bacterium. The composition according to the present invention can plan to prevent and treat atopic dermatitis and to relieve the symptom thereof by fundamental change in the immune system in the body if administered into the skin. In addition, side effects of known chemical formulation such as tolerance and the like can prevented and safety is secured by using microorganism strains harmless to the human body.

Priority: KR20090112888 Applic. Date: 2009-11-20

Inventor: YOON WON SUCK [KR]


Publication No.: WO2011063102A1  Published: 26/May/2011

Title: APREMILAST FOR THE TREATMENT OF SARCOIDOSIS

Applicant/Assignee: CELGENE CORPORATION

Application No.: US2010/057200   Filing Date: 18/Nov/2010

Abstract:Provided herein are methods of treating, preventing and/or managing sarcoidosis by the administration of (+)-2-[ 1 -(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-4- acetylaminoisoindolin-l,3-dione, alone or in combination with other therapeutics.

Priority: US20090262907P Applic. Date: 2009-11-19

Inventor: ZELDIS JEROME B [US]


Publication No.: WO2011063320A2  Published: 26/May/2011

Title: RECOMBINANT FILAGGRIN POLYPEPTIDES FOR CELL IMPORTATION

Applicant/Assignee: RESEARCH DEVELOPMENT FOUNDATION

Application No.: US2010/057592   Filing Date: 22/Nov/2010

Abstract:Disclosed are recombinant polypeptides that include (a) a f?laggrin amino acid sequence and (b) a cell importation signal sequence that includes a motif of two to fifteen amino acids, wherein the motif includes at least one arginine residue and at least one methionine residue. Also disclosed are nucleic acids encoding the recombinant polypeptides of the present invention, and compositions that include the recombinant polypeptides and nucleic acids of the present invention. Methods of treating or preventing a skin disease or skin disorder using the compositions of the present invention are also included, as well as kits that include a sealed containing that includes a recombinant polypeptide of the present invention.

Priority: US20090263604P Applic. Date: 2009-11-23

Inventor: STOUT TIMOTHY J [US]; APPUKUTTAN BINOY [US]; MCFARLAND TREVOR [US]


Publication No.: WO2011063475A1  Published: 03/Jun/2011

Title: METHODS OF PREPARING HYDROGELS BY ENZYME CATALYSIS AND SUBSEQUENT INACTIVATION

Applicant/Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION

Application No.: AU2010/001611   Filing Date: 30/Nov/2010

Abstract:This invention provides a method for forming a self-assembled hydrogel structure of a self-assembling peptide building block, the method including contacting a precursor peptide and an enzyme that catalyses the conversion of the precursor peptide to the self-assembling peptide building block, under conditions suitable for the self-assembled hydrogel to form from the self-assembling peptide building block, and subsequently inactivating the enzyme-catalysed conversion. The invention also provides a self-assembled hydrogel comprised of a self-assembling peptide building block, the self-assembling peptide building block having been converted by enzymic catalysis from a peptide precursor, and a method of culturing cells by seeding the self-assembled hydrogel with cells to be cultured.

Priority: US20090264993P Applic. Date: 2009-11-30

Inventor: WILLIAMS RICHARD [AU]; HARTLEY PATRICK GORDON [AU]; MCLEAN KEITH MICHAEL [AU]


Publication No.: WO2011063477A1  Published: 03/Jun/2011

Title: FIBRONECTIN: GROWTH FACTOR CHIMERAS

Applicant/Assignee: QUEENSLAND UNIVERSITY OF TECHNOLOGY

Application No.: AU2010/001613   Filing Date: 30/Nov/2010

Abstract:Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, EGF, bFGF, or KGF and fibronectin, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of fibronectin. These protein complexes include synthetic proteins where the growth factor and fibronectin sequences are joined by a linker sequence. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement, skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer.

Priority: US2009-627647 Applic. Date: 2009-11-30; US2010-793386 Applic. Date: 2010-06-03

Inventor: UPTON ZEE [AU]; VAN LONKHUYZEN DEREK [AU]


Publication No.: WO2011063921A1  Published: 03/Jun/2011

Title: ACCELERATION OF WOUND HEALING BY A TISSUE INHIBITOR OF METALLOPROTEINASES (TIMP) LINKED TO GLYCOSYLPHOSPHATIDYLINOSITOL (GPI)-ANCHORS

Applicant/Assignee: LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN, GMG BERATUNGS- UND BETEILIGUNGS VERWALTUNGS GMBH

Application No.: EP2010/007069   Filing Date: 22/Nov/2010

Abstract:The present invention relates to fusion constructs of glycosylphosphatidylinositol (GPI)- anchored tissue inhibitors of metalloproteinases (TIMPs) and their use for the treatment of cancer and in regenerative medicine. By this approach, the GPI-anchored TIMP proteins are incorporated into the surface membrane of cells. The fusion constructs of the present invention are effective agents in accelarating wound healing.

Priority: EP20090014652 Applic. Date: 2009-11-24

Inventor:


Publication No.: WO2011064401A2  Published: 03/Jun/2011

Title:

Applicant/Assignee: LABORATOIRES EXPANSCIENCE

Application No.: EP2010/068573   Filing Date: 30/Nov/2010

Abstract:The invention relates to a composition containing an extract of seeds of Vigna unguiculata. Advantageously the composition is cosmetic, pharmaceutical, dermatological or nutraceutical. The invention also relates to a method for extracting a Vigna unguiculata seed extract, as well as to the resulting extract. The invention further relates to one such composition or one such extract for use in the prevention or treatment of disorders and diseases affecting the skin, mucosae or appendages, for use in the prevention or treatment of vascular disorders and for use in the prevention or treatment of adipose tissue alterations. Moreover, the invention relates to a method for cosmetic care of the skin, appendages and mucosae in order to improve the condition or appearance thereof, comprising the administration of one such composition or one such extract.

Priority: FR20090058529 Applic. Date: 2009-11-30

Inventor: MSIKA PHILIPPE [FR]; SAUNOIS ALEX [FR]; LECLERE-BIENFAIT SOPHIE [FR]; BAUDOIN CAROLINE [FR]


Publication No.: WO2011064402A2  Published: 03/Jun/2011

Title: ACACIA MACROSTACHYA SEED EXTRACT AND COMPOSITIONS CONTAINING SAME

Applicant/Assignee: LABORATOIRES EXPANSCIENCE

Application No.: EP2010/068574   Filing Date: 30/Nov/2010

Abstract:The invention relates to a composition containing an extract of seeds of Acacia macrostachya. Advantageously the composition is cosmetic, pharmaceutical, dermatological or nutraceutical. The invention also relates to a method for extracting a Acacia macrostachya seed extract, as well as to the resulting extract. The invention further relates to one such composition or one such extract for use in the prevention or treatment of disorders and diseases affecting the skin, mucosae or appendages, for use in the prevention or treatment of vascular disorders and for use in the prevention or treatment of adipose tissue alterations. Moreover, the invention relates to a method for cosmetic care of the skin, appendages and mucosae in order to improve the condition or appearance thereof, comprising the administration of one such composition or one such extract.

Priority: FR20090058525 Applic. Date: 2009-11-30

Inventor: MSIKA PHILIPPE [FR]; SAUNOIS ALEX [FR]; LECLERE-BIENFAIT SOPHIE [FR]; BAUDOIN CAROLINE [FR]


Publication No.: WO2011064508A1  Published: 03/Jun/2011

Title: USE OF A DIPYRIDYL COMPOUND FOR TREATING ROSACEA

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: FR2010/052543   Filing Date: 26/Nov/2010

Abstract:The present invention relates to a compound with the following formula (I), or any of the pharmaceutically acceptable salts thereof, to be used in the treatment of rosacea.

Priority: FR20090058478 Applic. Date: 2009-11-30

Inventor: SAFONOVA IRINA [FR]; PIERRET JEAN-DOMINIQUE [FR]


Publication No.: WO2011064524A1  Published: 03/Jun/2011

Title: DERMATOLOGICAL COMPOSITIONS COMPRISING A FAT OR OIL OF AN ESSENTIAL FATTY ACID TRIGLYCERIDE

Applicant/Assignee: CRODA INTERNATIONAL PLC

Application No.: GB2010/002043   Filing Date: 09/Nov/2010

Abstract:The present invention relates to a human beta-defensin inducing agent that comprises at least one fat or oil of an essential fatty acid triglyceride or a derivative thereof as the main active ingredient. It also relates to cosmetic, dermatological and pharmacological formulations comprising the at least one fat or oil.

Priority: GB20090020846 Applic. Date: 2009-11-27

Inventor: WAITE ALAN GEOFFREY [GB]; RAWLINGS ANTHONY VINCENT [GB]; JONES DEBRA LOUISE [GB]


Publication No.: WO2011064657A2  Published: 03/Jun/2011

Title: QUINAZOLIN-4(3A)-ONE DERIVATIVES AND METHODS OF USE THEREOF

Applicant/Assignee: PROTEOLOGICS, LTD

Application No.: IB2010/003048   Filing Date: 26/Nov/2010

Abstract:Provided are quinazolin-4(3A)-one derivatives, which are inhibitors of the ubiquitin ligase activity of a human polypeptide, particularly to POSH inhibitors, and to compositions and methods for the treatment RING E3 ubiquitin ligase related diseases.

Priority: US20090264741P Applic. Date: 2009-11-27

Inventor: EREZ OMRI [IL]; NAKACHE PHILIPPE [IL]


Publication No.: WO2011065335A1  Published: 03/Jun/2011

Title: PREVENTING OR AMELIORATING AGENT FOR HYPERSENSITIVITY IN SENSITIVE SKIN

Applicant/Assignee: KAO CORPORATION

Application No.: JP2010/070830   Filing Date: 22/Nov/2010

Abstract:Provided is a preventing or ameliorating agent for hypersensitivity in sensitive skin which can be easily used and is highly safe. The preventing or ameliorating agent for hypersensitivity in sensitive skin comprises, as the active ingredient, Thujopsis dolabrata or an extract thereof.

Priority: JP20090269677 Applic. Date: 2009-11-27

Inventor: MORI KATSURA [JP]; NOJIRI HIROSHI [JP]; NAKAMURA TADASHI [JP]


Publication No.: WO2011065657A2  Published: 03/Jun/2011

Title: COMPOUND COMPRISING EXTRACTS OR FRACTIONS OF CHRYSANTHEMUM BOREALE MAKINO HAVING ANTI-INFLAMMATION ACTIVITY

Applicant/Assignee: WOONGJIN COWAY CO., LTD, UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY

Application No.: KR2010/006651   Filing Date: 30/Sep/2010

Abstract:The present invention relates to a composition having an anti-inflammatory activity, comprising extracts or fractions of Chrysanthemum boreale Makino. Since the composition show the prophylactic and therapeutic effects on inflammatory diseases, in particular, atopic dermatitis, it can be used as a pharmaceutical composition, and also applied to various fields, including quasi-drugs, cosmetic compositions, foods, and water softeners.

Priority: KR20090116247 Applic. Date: 2009-11-27; KR20100033965 Applic. Date: 2010-04-13; KR20100069145 Applic. Date: 2010-07-16

Inventor: HAN CHANG SOO [KR]; KIM WON TAE [KR]; CHOI HO-YOUNG [KR]; HAM INHYE [KR]; YANG GABSIK [KR]; BANG CHANSUNG [KR]


Publication No.: WO2011065719A2  Published: 03/Jun/2011

Title: TOPICAL COMPOSITION FOR SKIN CONTAINING POLYSACCHARIDE EXTRACT OF RED GINSENG

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: KR2010/008272   Filing Date: 23/Nov/2010

Abstract:The present invention relates to a topical composition for skin for reducing skin wrinkles, enhancing skin elasticity and preventing skin aging, and more specifically, to a topical composition for skin which contains a polysaccharide extract of red ginseng having a molecular weight of less than 10,000 as an active ingredient, which increases the expression of enzymes in the mitochondrial electron transport system of human keratinocytes and improves the activity of skin cells, thereby reducing skin wrinkles, enhancing skin elasticity and preventing skin aging.

Priority: KR20090116466 Applic. Date: 2009-11-30

Inventor: KIM JI SEONG [KR]; YEOM MYEONG HUN [KR]; KWON SUN SANG [KR]; KIM DUCK HEE [KR]; KIM HAN KON [KR]


Publication No.: WO2011066506A1  Published: 03/Jun/2011

Title: 2-METHYLENE-19,26-NOR-(20S)-1a-HYDROXYVITAMIN D3

Applicant/Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION

Application No.: US2010/058208   Filing Date: 29/Nov/2010

Abstract:Compounds of formula I are provided where X1 and X2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.

Priority: US20090264990P Applic. Date: 2009-11-30

Inventor: DELUCA HECTOR F [US]; GRZYWACZ PAWEL [US]; PLUM LORI A [US]; CLAGETT-DAME MARGARET [US]


Publication No.: WO2011066604A1  Published: 09/Jun/2011

Title: ACNE TREATMENT

Applicant/Assignee: BRANDS WORLDWIDE HOLDINGS I.P. PTY LIMITED

Application No.: AU2010/001605   Filing Date: 30/Nov/2010

Abstract:A kit and method for a two-step acne treatment regimen. The kit comprises a wash composition and a cream treatment composition. The method comprising the steps of: using a wash composition to clean acne affected skin of an individual

and applying a cream treatment composition to the acne affected skin.

Priority: US2009-629033 Applic. Date: 2009-12-01

Inventor: SHER STEVEN [AU]; SAHA AMIT [AU]


Publication No.: WO2011066656A1  Published: 09/Jun/2011

Title: COMPOSITIONS COMPRISING IGF1 AGONISTS AND USES THEREOF

Applicant/Assignee:

Application No.: CA2010/001925   Filing Date: 03/Dec/2010

Abstract:Pharmaceutical compositions and methods for improving functional capacity of tissues and organs in both healthy and pathologic disease states for: reducing unwanted cosmetic effects of aging on the skin to reduce wrinkles, to increase collagen and water content, thicken and increase skin volume and to maintain a youthful appearance to age and sun damaged skin, to treat diseases of skin and tissues caused by ischemia of venous congestion and arterial insufficiency, to accelerate healing of tendons, ligaments, joints, cartilage, nerves, bones or neuromuscular injuries or diseases, to improve and restore the functional capacity of specific tissues and organs of the body, and to treat hair loss comprising an effective amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatmedin-C)

and analogue LR3 IGF1 in admixture with a pharmaceutically-acceptable diluent or carrier.

Priority: CA20092687012 Applic. Date: 2009-12-03

Inventor: ADAMS KENNETH W [CA]


Publication No.: WO2011068147A1  Published: 09/Jun/2011

Title: ENHANCEMENT OF MELANIN SYNTHESIS AND ACTIVATION OF TYROSINASE

Applicant/Assignee: SHALOM CO., LTD

Application No.: JP2010/071548   Filing Date: 02/Dec/2010

Abstract:Disclosed is a novel technique by which melanin synthesis can be enhanced. Specifically disclosed is a method for producing a melanin synthesis enhancer. One embodiment of the method comprises: a drying/pulverization step (S100) in which plant tissues of stevia serving as a starting material are dried and pulverized

a fermentation step (S102) in which the dried stevia powder obtained in the drying/pulverization step (S100) is fermented

an extraction step (S104) in which extraction from the fermented stevia powder (hereinafter referred to as "fermented stevia") is carried out using an aqueous ethanol solution, thereby obtaining a liquid extract

a first fractionation step (S106) in which the liquid extract of the fermented stevia is fractionated, thereby obtaining an ethanol-soluble fraction

and a second fractionation step (S108) in which the ethanol-soluble fraction is further fractionated, thereby obtaining a lipid-soluble fraction.

Priority: JP20090275375 Applic. Date: 2009-12-03; JP20100017510 Applic. Date: 2010-01-28

Inventor: SUGIBAYASHI KENJI [JP]; TOKUDOME YOSHIHIRO [JP]; KON TATSUHIKO [JP]


Publication No.: WO2011068171A1  Published: 09/Jun/2011

Title: BICYCLIC NITROGEN-CONTAINING SATURATED HETEROCYCLIC DERIVATIVES

Applicant/Assignee: DAIICHI SANKYO COMPANY,LIMITED

Application No.: JP2010/071608   Filing Date: 02/Dec/2010

Abstract:Provided are compounds having prophylactic and/or therapeutic effect on chronic rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn diseases and ulcerative colitis, autoimmune diseases typified by psoriasis, rejection of a transplanted organ, allergic diseases and so on

medicinal compositions comprising these compounds

and a method for preventing or treating an autoimmune disease characterized by comprising administering an effective amount of a medicinal composition to a mammal. A compound represented by general formula (I) or a pharmacologically acceptable salt of the same.

Priority: JP20090275880 Applic. Date: 2009-12-03

Inventor: HAYAKAWA ICHIRO; WATANABE JUN; MOMOSE TAKAYUKI; TOMISATO WATARU


Publication No.: WO2011068303A2  Published: 09/Jun/2011

Title: HYALURONIC ACID DERIVATIVE EFFECTIVE AGAINST ATOPIC DERMATITIS, AND METHOD FOR MANUFACTURING SAME

Applicant/Assignee: CELLINBIO CO., LTD

Application No.: KR2010/006214   Filing Date: 13/Sep/2010

Abstract:Disclosed are a hyaluronic acid derivative effective against atopic dermatitis, and a method for manufacturing same. The method for manufacturing the hyaluronic acid derivative of the present invention comprises: a first step of chlorinating ascorbic acid

a second step of producing a tetrabutylammonium hydroxide (TBA) salt of hyaluronic acid

and a third step of conjugating the ascorbic acid chlorinated in the first step and the TBA salt of hyaluronic acid produced in the second step. The hyaluronic acid derivative can effectively reduce the substances causing skin lesions, can contribute toward the remission of atopic diseases, and is effective in skin renewal.

Priority: KR20090117962 Applic. Date: 2009-12-01

Inventor: LEE DONG HEE [KR]; SONG JUN SIK [KR]; JUNG HA NA [KR]; CHA SANG DO [KR]; LEE DA YEA [KR]; KIM CHEOL MIN [KR]; PARK JONG CHUL [KR]


Publication No.: WO2011069987A1  Published: 16/Jun/2011

Title: INFANT FORMULA WITH PROBIOTICS AND MILK FAT GLOBULE MEMBRANE COMPONENTS

Applicant/Assignee: NESTEC S.A

Application No.: EP2010/069016   Filing Date: 07/Dec/2010

Abstract:A nutritional composition is proposed comprising a probiotic and milk fat globule membrane (MFGM) wherein the MFGM and the probiotics mutually potentiate their respective effects and promote complementary beneficial protective mechanisms that reflect physiological synergy. The nutritional composition can be an infant formula, infant cereals, baby food or health care nutritional product. The synergistic effect can include promoting immune maturation and/or immune education and/or reducing inflammation and/or treating or preventing disease or infections.

Priority: EP20090178339 Applic. Date: 2009-12-08

Inventor: BENYACOUB JALIL [CH]; BLUM-SPERISEN STEPHANIE [CH]; BOSCO MOHAMED NABIL [CH]; BOVETTO LIONEL JEAN RENE [FR]; BUREAU-FRANZ ISABELLE [FR]; DONNET-HUGHES ANNE [CH]; SCHIFFRIN EDUARDO [CH]; FAVRE LAURENT [CH]


Publication No.: WO2011070080A1  Published: 16/Jun/2011

Title: 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: EP2010/069195   Filing Date: 08/Dec/2010

Abstract:The present invention concerns novel 4-(azacycloalkyl)-benzene-1,3-diol compounds with the following general formula (I): to compositions containing them, to a process for their preparation and to their use in pharmaceutical or cosmetic compositions for the treatment or prevention of pigmentary disorders.

Priority: US20090282064P Applic. Date: 2009-12-10; FR20090058829 Applic. Date: 2009-12-10

Inventor: BOITEAU JEAN-GUY [FR]; LUZY ANNE-PASCALE


Publication No.: WO2011070168A1  Published: 16/Jun/2011

Title: PHARMACEUTICAL COMPOSITION FOR TREATING CUTANEOUS BURNS

Applicant/Assignee:

Application No.: EP2010/069412   Filing Date: 10/Dec/2010

Abstract:The present invention relates to a pharmaceutical composition characterized in that said composition contains at least 4 wt% relative to the total weight of the composition of an active principle selected from among cetearyl octanoate and hexanoic acid, beeswax and optionally one or more pharmaceutically acceptable excipient(s), as well as to the use thereof for the treatment of cutaneous pre-burns or burns and for reducing pain following a thermal shock.

Priority: BE20090000780 Applic. Date: 2009-12-11

Inventor: DEBETENCOURT JEAN-JACQUES [GB]


Publication No.: WO2011070278A2  Published: 16/Jun/2011

Title: COSMETIC OR DERMATOLOGICAL COMPOSITION BASED ON EVERLASTING FLOWER ESSENTIAL OIL- AND MYRTLE ESSENTIAL OIL AND THE USE THEREOF

Applicant/Assignee: L'OCCITANE

Application No.: FR2010/052615   Filing Date: 06/Dec/2010

Abstract:The present invention relates to a cosmetic or dermatological composition and to the use thereof for controlling skin aging effects while improving skin nutrition and regeneration, increasing cell life, and moreover improving skin brightness as well as evenness of skin tone and appearance of pigment spots. The present invention also relates to a cosmetic treatment method including a step of applying an effective amount of the composition onto the skin of a patient.

Priority: FR20090005904 Applic. Date: 2009-12-07

Inventor: MILLOU YVES [FR]; PIERRISNARD JEAN-LOUIS [FR]; FONTES KATIA [FR]; TOUREL CECILE [FR]


Publication No.: WO2011070415A1  Published: 16/Jun/2011

Title: NOVEL THERAPEUTIC METHODS FOR TREATING INFLAMMATION AND IMMUNE SYSTEM DISORDERS

Applicant/Assignee: PURAPHARM INTERNATIONAL (HK) LIMITED, VERSITECH LIMITED

Application No.: IB2010/003050   Filing Date: 08/Nov/2010

Abstract:A method for treating inflammatory and immune conditions by modulating TNF-a and nitric oxide production is provided. Said [method comprises administering a compound having the following formula (I):

Priority: US20090263517P Applic. Date: 2009-11-23

Inventor: LAU ALLAN SY [CN]; YANG LAI HUNG CINDY [CN]; OR CHO TSUN [CN]; LAW HING YEE [CN]


Publication No.: WO2011070539A1  Published: 16/Jun/2011

Title: CYSTEINE PROTEASE INHIBITORS

Applicant/Assignee: MEDIVIR UK LIMITED

Application No.: IB2010/055732   Filing Date: 10/Dec/2010

Abstract:Compounds of Formula (II) wherein R1a is H

and R1b is C1-C6alkyl, Carbocyclyl or Het

or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms

R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl

R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or -CH2C3-C7 cycloalkyl

R4' is C1-C6alkyl, C1-C6haloalkyl or oxetany-3-yl. for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

Priority: SE20090050951 Applic. Date: 2009-12-10; GB20100010084 Applic. Date: 2010-06-16

Inventor: AYESA SUSANA [SE]; ERSMARK KAROLINA [SE]; GRABOWSKA URSZULA [GB]; HEWITT ELLEN [GB]; JOENSSON DANIEL [SE]; KAHNBERG PIA [SE]; KLASSON BJOERN [SE]; LIND PETER [SE]; LUNDGREN STINA [SE]; ODEN LOURDES [SE]; PARKES KEVIN [GB]; WIKTELIUS DANIEL [SE]


Publication No.: WO2011070541A1  Published: 16/Jun/2011

Title: CYSTEINE PROTEASE INHIBITORS

Applicant/Assignee: MEDIVIR UK LIMITED

Application No.: IB2010/055738   Filing Date: 10/Dec/2010

Abstract:Compounds of the formula (I) wherein R1a is H

and R1b is C1-C6alkyl, Carbocyclyl or Het

or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms

R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl

R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or -CH2C3-C7 cycloalkyl

R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkylamino or C1-C6dialkylamino

for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

Priority: SE20090050951 Applic. Date: 2009-12-10; GB20100010084 Applic. Date: 2010-06-16

Inventor: AYESA SUSANA [SE]; CARLQUIST PETER [SE]; ERSMARK KAROLINA [SE]; GRABOWSKA URSZULA [GB]; HEWITT ELLEN [GB]; JOENSSON DANIEL [SE]; KAHNBERG PIA [SE]; KLASSON BJOERN [SE]; LIND PETER [SE]; ODEN LOURDES [SE]; PARKES KEVIN [GB]; WIKTELIUS DANIEL [SE]


Publication No.: WO2011070568A1  Published: 16/Jun/2011

Title: METHOD FOR TREATING PSORIASIS

Applicant/Assignee: NIKKEN SOHONSHA CORPORATION, TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD

Application No.: IL2010/001026   Filing Date: 05/Dec/2010

Abstract:A method for treating psoriasis in a subject suffering from psoriasis comprising orally administering to the subject a pharmaceutically effective amount of crude Dunaliella powder.

Priority: US20090285358P Applic. Date: 2009-12-10

Inventor: SHAISH AVIV [IL]; HARATS DROR [IL]; GREENBERGER SHOSHANA [US]


Publication No.: WO2011070767A1  Published: 16/Jun/2011

Title: PROPHYLACTIC AGENT FOR ATOPIC DERMATITIS

Applicant/Assignee: LOTTE CO., LTD

Application No.: JP2010/007099   Filing Date: 07/Dec/2010

Abstract:Disclosed are: a prophylactic agent for atopic dermatitis

and a food containing the prophylactic agent. Extensive studies have been carried out, and it is found that atopic dermatitis can be prevented through the oral ingestion of collagen. Specifically disclosed are: a prophylactic agent for atopic dermatitis, which comprises collagen

and a food or beverage containing the prophylactic agent for atopic dermatitis.

Priority: JP20090280606 Applic. Date: 2009-12-10

Inventor: HIGUCHI HIROAKI [JP]; NARISE ATSUSHI [JP]; OSAWA KENJI [JP]; SHIMIZU KATSUMASA [JP]; ITO MASANORI [JP]


Publication No.: WO2011070970A1  Published: 16/Jun/2011

Title: OVEREXPRESSION INHIBITOR OF THYMIC STROMAL LYMPHOPOIETIN

Applicant/Assignee: SAPPORO MEDICAL UNIVERSITY, SAPPORO BREWERIES LIMITED

Application No.: JP2010/071595   Filing Date: 02/Dec/2010

Abstract:Provided is an overexpression inhibitor of thymic stromal lymphopoietin (TSLP) which contains, as the active ingredient, a water extract of hop, a water-soluble fraction thereof, a water-soluble polymer fraction thereof or a water-soluble polymeric polyphenol fraction thereof. The aforesaid overexpression inhibitor of TSLP enables the fundamental prevention and/or treatment of allergic diseases and improvement of allergic predisposition. This overexpression inhibitor of TSLP can be taken daily and continuously and is usable not only as an ingredient of medicines but also as a starting material of foods, drinks and so on.

Priority: JP20090277906 Applic. Date: 2009-12-07

Inventor: SAWADA NORIMASA [JP]; KOJIMA TAKASHI [JP]; FUCHIMOTO JUN [JP]; KOBAYASHI NAOYUKI [JP]


Publication No.: WO2011072103A2  Published: 16/Jun/2011

Title: GLYCERINE BASED JELLY COMPOSITIONS

Applicant/Assignee:

Application No.: US2010/059634   Filing Date: 09/Dec/2010

Abstract:The present disclosure describes a replacement for petroleum jelly as a base for products which is suitable for most any application for which petroleum jelly can be used. The jelly is a glycerine based jelly composition comprising, vegetable derived glycerine and an emulsifier, wherein the emulsifier can be any known and / or commercially available glucoside containing emulsifier. Other suitable emulsifiers together with glycerine and essential or vegetable based oils with or without inorganic fillers may also be added to the jelly to impart fragrance, color, UVA and UVB sun protection factor(s), immuno-enhancing aromatherapeutics, as well as free radical scavenging constituents. In addition, temperature stabilizers and stiffening agents such as waxes and other inorganic fillers including silica and clays may also be added during manufacture as required.

The glycerine is preferably present in the range of 50-95%. Other ingredients which may be added include vitamins and provitamins, carotenoids, as well as aloe vera gel or juice.

Priority: US20090285298P Applic. Date: 2009-12-10; US20100345383P Applic. Date: 2010-05-17

Inventor: GRUNE GUERRY L [US]


Publication No.: WO2011072216A2  Published: 16/Jun/2011

Title: TREATMENT METHODS UTILIZING STEM CELL MOBILIZERS AND IMMUNOSUPPRESSIVE AGENTS

Applicant/Assignee: THE JOHNS HOPKINS UNIVERSITY

Application No.: US2010/059877   Filing Date: 10/Dec/2010

Abstract:The present invention relates to the field of organ transplantation. In one aspect, the present invention provides methods of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.

Priority: US20090285602P Applic. Date: 2009-12-11; US20100316180P Applic. Date: 2010-03-22

Inventor: SUN ZHAOLI [US]; WILLIAMS GEORGE MELVILLE [US]


Publication No.: WO2011072287A2  Published: 16/Jun/2011

Title: METHOD FOR LATE INTRODUCTION OF THE (8R)-HYDROXYL GROUP IN CARBAPENEM BETA-LACTAM ANTIBIOTIC SYNTHESIS

Applicant/Assignee: THE JOHNS HOPKINS UNIVERSITY

Application No.: US2010/060081   Filing Date: 13/Dec/2010

Abstract:The presently disclosed subject matter demonstrates that ThnG and ThnQ enzymes encoded by the thienamycin gene cluster in Streptomyces cattleya oxidize the C-2 and C-6 moieties of carbapenems, respectively. ThnQ stereospecifically hydroxylates PS-5 giving N-acetyl thienamycin. ThnG catalyzes sequential desaturation and sulfoxidation of PS-5, giving PS-7 and its sulfoxide. The ThnG and ThnQ enzymes are relatively substrate selective, but give rise to the oxidative diversity of carbapenems produced by S. cattleya, and orthologues likely function similarly in allied streptomyces.

Priority: US20090285608P Applic. Date: 2009-12-11

Inventor: TOWNSEND CRAIG ARTHUR [US]; BODNER MICAH JEFFREY [US]; PHELAN RYAN MARTIN [US]; FREEMAN MICHAEL FRANCIS [US]


Publication No.: WO2011072394A1  Published: 23/Jun/2011

Title: METHOD OF TREATING SCARS AND ss-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS

Applicant/Assignee: THE HOSPITAL FOR SICK CHILDREN

Application No.: CA2010/002014   Filing Date: 15/Dec/2010

Abstract:Methods of treating disorders mediated by ss-catenin comprising administration of Nefopam compounds are provided In particular, the treatment of disorders arising from excessive or undesired expression of ss- catenin is contemplated Said compounds include Nefopam, analogues thereof, prodaigs thereof, and salts and solvates of Nefopam The ss-catenin mediated disorders are preferably selected from the group consisting of fibroproliferative disorders (such as scars, aggressive fibramtoses, and fibroses) and cancer (such as colon cancer, melanoma, liver cancer, ovarian cancer, endometrial cancer, medullobalstoma pilomatricomas, and prostate cancer)

Priority: US20090286633P Applic. Date: 2009-12-15

Inventor: ALMAN BENJAMIN A [CA]; POON RAYMOND [CA]; HONG HELEN [CA]


Publication No.: WO2011073248A1  Published: 23/Jun/2011

Title: USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SKIN DISORDERS

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: EP2010/069739   Filing Date: 15/Dec/2010

Abstract:Use compounds in the treatment or prevention of skin disorders The invention relates to the use of a compound of following formula (I) or one of its pharmaceutically acceptable salts, pharmaceutically acceptable solvates or hydrates in the preparation of a medicament intended to prevent and/or treat inflammatory skin pathologies.

Priority: US20090282109P Applic. Date: 2009-12-17

Inventor: AUBERT JEROME [FR]


Publication No.: WO2011073281A1  Published: 23/Jun/2011

Title: COMPOSITION CONTAINING AT LEAST ONE C7 SUGAR FOR ALOPECIA TREATMENT, COSMETIC TREATMENT OF HAIR AND NAILS, AND CARE OF HAIR, EYELASHES, OR NAILS

Applicant/Assignee: LABORATOIRES EXPANSCIENCE

Application No.: EP2010/069806   Filing Date: 15/Dec/2010

Abstract:The present invention relates to a composition including at least one C7 sugar, or derivative from esterification of said sugar, and a pharmaceutically acceptable carrier for treating alopecia. The present invention also relates to a method for cosmetically treating hair and nails, said method being intended to stimulate the growth thereof and/or slow the loss thereof. According to said method, a cosmetic composition including at least one C7 sugar, or derivative from esterification of said sugar, is administered. The present invention finally relates to a method for cosmetic care of hair and/or eyelashes and/or nails.

Priority: FR20090059075 Applic. Date: 2009-12-16

Inventor: BAUDOUIN CAROLINE [FR]; MSIKA PHILIPPE [FR]


Publication No.: WO2011073419A1  Published: 23/Jun/2011

Title: NEW STEROID INHIBITORS OF PGP FOR USE FOR INHIBITING MULTIDRUG RESISTANCE

Applicant/Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Application No.: EP2010/070141   Filing Date: 17/Dec/2010

Abstract:The present invention relates to a compound of formula (I) for its use for reversing or inhibiting multidrug resistance.

Priority: EP20090306282 Applic. Date: 2009-12-18

Inventor: GRENOT CATHERINE [FR]; CUILLERON CLAUDE [FR]


Publication No.: WO2011073437A2  Published: 23/Jun/2011

Title: BACTERIOCIN- AND PREBIOTIC-BASED COSMETIC OR DERMATOLOGICAL COMPOSITIONS

Applicant/Assignee: L'OREAL

Application No.: EP2010/070167   Filing Date: 17/Dec/2010

Abstract:The invention relates to compositions containing, in a physiologically acceptable medium, the combination of at least one bacteriocin and at least one prebiotic. The invention also relates to the cosmetic uses and methods that implement the combination of a bacteriocin with a prebiotic.

Priority: FR20090059154 Applic. Date: 2009-12-17; US20090290988P Applic. Date: 2009-12-30

Inventor: GAVILLON ROXANNE [FR]; SIMONNET JEAN-THIERRY [FR]


Publication No.: WO2011073961A1  Published: 23/Jun/2011

Title: PROCESS FOR OBTAINING A STANDARDISED EXTRACT OF QUERCETIN AND 3-0-METHYLQUERCETIN FROM FLOWERS OF MACELA (ACHYROCLINE SATUREIOIDES), AND COSMETIC AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID EXTRACT

Applicant/Assignee: NATURA COSMETICOS S.A

Application No.: IB2011/000015   Filing Date: 06/Jan/2011

Abstract:It describes an extraction process for obtaining a standardized extract of quercetin and 3-0-methylquercetin from inflorescences of macela- do-campo (Achyrocline satureioides) characterized by comprising of the following steps: A) grinding the inflorescences of Achyrocline satureioides to obtain a material of ground plant

B) submitting the ground plant to at least four sequential stages of hydro-alcoholic extraction at a temperature from 60 DEG C to 80 DEG C1 for 3 to 4 hours for each stage, in order to obtain 4 intermediary hydro-alcoholic extracts

C) combining the 4 intermediary hydro-alcoholic extracts

D) concentrating the intermediary hydro-alcoholic extracts mixture

in order to obtain up to a maximum of 20% of the initial mass of the intermediary hydro-alcoholic extracts

E) drying the material obtained in (D). It also describes cosmetic, pharmaceutical and veterinary compositions containing the aforesaid extract of macela-do-campo, destined for the prevention and treatment of the damages arising from inflammatory, microbial and oxidation/lypoperoxidation reactions. The use and method of application of the aforesaid extract of macela are also described.

Priority: FR20090059012 Applic. Date: 2009-12-15

Inventor: MOURA SA ROCHA VANESSA DE [BR]; DELARCINA JUNIOR SERGIO [BR]; FIGUEREDO BEDA DEBORA [BR]; LORENCINI MARCIO [BR]; COSTA BEBER TIAGO [BR]; PASSERO ALAN [BR]


Publication No.: WO2011074275A1  Published: 23/Jun/2011

Title: SKIN BARRIER FUNCTION PROMOTER

Applicant/Assignee: FUJI CHEMICAL INDUSTRY CO.,LTD

Application No.: JP2010/050470   Filing Date: 18/Jan/2010

Abstract:Disclosed are a preparation for external application and a preparation for internal application both of which are effective on the promotion of a skin barrier function. Also disclosed is a combination of the preparation for external application and the preparation for internal application. The preparation for external application and the preparation for internal application are characterized by comprising one or both of tocopherol and a glyceride represented by general formula (1) and astaxanthin. (In the formula, R1, R2 and R3 may be the same as or different from one another and independently represent a linear or branched saturated or unsaturated alkyl group having 8 to 22 carbon atoms.)

Priority: JP20090287231 Applic. Date: 2009-12-18

Inventor: TOMINAGA KUMI [JP]; HONGO NOBUKO [JP]; YAMASHITA EIJI [JP]


Publication No.: WO2011074643A1  Published: 23/Jun/2011

Title: PROPHYLACTIC OR AMELIORATING AGENT FO PIGMENTATION

Applicant/Assignee: POLA CHEMICAL INDUSTRIES INC

Application No.: JP2010/072689   Filing Date: 16/Dec/2010

Abstract:Disclosed is an external preparation for skin, which is suitable for the prevention or amelioration of pigmentation. Specifically disclosed are: a prophylactic or ameliorating agent for pigmentation, comprising a compound represented by general formula (1) or an isomer and/or a pharmacologically acceptable salt thereof

and an external preparation for skin, containing the component. [In the formula, R1 represents a unsubstituted aromatic group or an aromatic group having a substituent

R2 represents a hydrogen atom, a linear or branched C1-4 alkyl group, or an acyl group having a linear or branched C1-4 alkyl chain

and R3 represents a hydrogen atom, or a linear or branched C1-4 alkyl group.]

Priority: JP20090285001 Applic. Date: 2009-12-16

Inventor: SAITOH YUKO [JP]; KONDO CHIHIRO [JP]; YAMASAKI TAKASHI [JP]


Publication No.: WO2011074921A2  Published: 23/Jun/2011

Title: COMPOSITION FOR ALLEVIATING ATOPIC DERMATITIS AND A PREPARATION METHOD OF THE SAME

Applicant/Assignee:

Application No.: KR2010/009089   Filing Date: 17/Dec/2010

Abstract:The present invention relates to a composition for alleviating atopic dermatitis and a method for preparing the same. More specifically, the present invention relates to a composition and a preparation method for alleviating atopic dermatitis, which has a moisturizing and an antimicrobial function that suppress an induction of atopic dermatitis and prevent and cure atopic dermatitis, and which is able to activate skin by forming an oil coating on skin as well. The present invention is characterized by comprising: 11 (approx.) 15 wt% of pleuropterus multiflorus heated three times in honey at 80 C for 90 minutes

15 (approx.) 21 wt% of angelica gigantis radix heated two times in rice water at 80 C for 90 minutes

5 (approx.) 7 wt% of Cnidium officinale heated submerged in Japanese apricot concentrate for 24 hours

11 (approx.) 15 wt% of Chaenomeles sinensis

5 (approx.) 7 wt% of Crataegi fructus heated in milk at 80 C for 90 minutes

0.5 (approx.) 1 wt% of Eucommia ulmoides oliver roasted for 5 minutes

0.5 (approx.) 1 wt% of earthworm

a small amount of sugar.

Priority: KR20090127555 Applic. Date: 2009-12-18; KR20100129795 Applic. Date: 2010-12-17

Inventor: HA KYOUNG-YOON [KR]


Publication No.: WO2011075267A1  Published: 23/Jun/2011

Title: USE OF ALPHA 2 ADRENERGIC RECEPTOR AGONISTS FOR TREATING OR PREVENTING PSORIASIS

Applicant/Assignee: GALDERMA LABORATORIES LP

Application No.: US2010/057184   Filing Date: 18/Nov/2010

Abstract:Methods and kits for treating or preventing psoriasis or a symptom associated with psoriasis in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of an a2 adrenergic receptor agonist, such as brimonidine.

Priority: US2009-621942 Applic. Date: 2009-11-19

Inventor: DEJOVIN JACK A [US]


Publication No.: WO2011075628A1  Published: 23/Jun/2011

Title: HETEROCYCLIC COMPOUNDS AND THEIR USES

Applicant/Assignee: AMGEN INC

Application No.: US2010/060978   Filing Date: 17/Dec/2010

Abstract:Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Priority: US20090287827P Applic. Date: 2009-12-18

Inventor: CUSHING TIMOTHY D [US]; GONZALEZ LOPEZ DE TURISO FELIX [US]; HAO XIAOLIN [US]; SHIN YOUNGSOOK [US]


Publication No.: WO2011076206A1  Published: 30/Jun/2011

Title: PHARMACEUTICAL COMPOSITION COMPRISING VITAMIN D ANALOGUE AND COSOLVENT-SURFACTANT MIXTURE

Applicant/Assignee: LEO PHARMA A/S

Application No.: DK2009/000266   Filing Date: 22/Dec/2009

Abstract:A topical pharmaceutical composition which is an oil-in-water-oil emulsion comprising a vitamin D derivative or analogue dissolved in a mixture of a non-ionic surfactant and a lower alkanol. The topical pharmaceutical composition may be used in the treatment of dermal conditions, such as psoriasis.

Priority:

Inventor: PETERSSON KARSTEN [DK]


Publication No.: WO2011076708A1  Published: 30/Jun/2011

Title: NEW AMINOTETRALINE DERIVATIVES

Applicant/Assignee:

Application No.: EP2010/070194   Filing Date: 20/Dec/2010

Abstract:The present application relates to compounds of formula (I): and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds in producing medicaments for the treatment of various diseases and conditions, such as of the central nervous system.

Priority: EP20090015827 Applic. Date: 2009-12-22

Inventor: GMEINER PETER [DE]; RUBERG MIRIAM [DE]; HUEBNER HARALD [DE]


Publication No.: WO2011077043A2  Published: 30/Jun/2011

Title: NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: FR2010/052871   Filing Date: 22/Dec/2010

Abstract:The invention relates to novel compounds having formula (I) and the cosmetic or pharmaceutical use thereof.

Priority: US20090282153P Applic. Date: 2009-12-23; FR20090059475 Applic. Date: 2009-12-23

Inventor: POINSARD CEDRIC [FR]; COLLETTE PASCAL [FR]; MAUVAIS PASCALE [FR]; LINGET JEAN-MICHEL [FR]; RETHORE SANDRINE [FR]


Publication No.: WO2011077587A1  Published: 30/Jun/2011

Title: COMPOSITION FOR INHIBITING ALLERGIC DISEASES

Applicant/Assignee: KINJIRUSHI CO., LTD

Application No.: JP2009/071824   Filing Date: 21/Dec/2009

Abstract:Disclosed is a composition for inhibiting allergic diseases, which is capable of inhibiting or ameliorating various symptoms of allergic diseases. Specifically disclosed is a composition for inhibiting allergic diseases, which contains an isothiocyanate and a fragrance material as active ingredients. The composition for inhibiting allergic diseases is characterized in that the isothiocyanate is composed of one or more substances selected from the group consisting of ?-methylthioalkyl isothiocyanate, ?-methylsulfinylalkyl isothiocyanate, ?-methylsulfonylalkyl isothiocyanate and ?-alkenyl isothiocyanate, and the fragrance material is composed of one or more substances selected from the group consisting of indoles, ethers, esters, ketones, fatty acids, aliphatic higher alcohols, aliphatic higher aldehydes, aliphatic higher hydrocarbons, thioethers, thiols, terpene hydrocarbons, phenol ethers, phenols, furfurals, aromatic aldehydes, aromatic alcohols, lactones, furans and natural fragrance materials.

Priority:

Inventor: NAGAI MASASHI [JP]; ICHIKAWA YOSHINOBU [JP]


Publication No.: WO2011077701A1  Published: 30/Jun/2011

Title: ANTI-ANDROGENIC AGENT, SEBUM SECRETION BLOCKER, HAIR GROWTH STIMULANT, AND FOOD OR BEVERAGE

Applicant/Assignee: LOTTE CO., LTD

Application No.: JP2010/007396   Filing Date: 21/Dec/2010

Abstract:Disclosed are: an anti-androgenic agent having a high anti-androgenic activity, has few adverse side effects, and has excellent safety performance

and a sebum secretion blocker and a hair growth stimulant, each of which comprises the anti-androgenic agent as an active ingredient. Specifically disclosed are: an anti-androgenic agent characterized by comprising lactoferrin

a sebum secretion blocker characterized by comprising the anti-androgenic agent as an active ingredient

a hair growth stimulant characterized by comprising the anti-androgenic agent as an active ingredient

and a food or beverage containing the anti-androgenic agent that comprises lactoferrin as an active ingredient.

Priority: JP20090292651 Applic. Date: 2009-12-24

Inventor: KODAMA YUSHI [JP]; HIGUCHI HIROAKI [JP]; NARISE ATSUSHI [JP]; SAKURAI KOJI [JP]


Publication No.: WO2011077800A1  Published: 30/Jun/2011

Title: HYPERLIPEMIA-AMELIORATING AGENT, ANEMIA-AMELIORATING COMPOSITION, URIC-ACID-LEVEL-REDUCING COMPOSITION, AND FOODS AND BEVERAGES

Applicant/Assignee: LION CORPORATION

Application No.: JP2010/067058   Filing Date: 30/Sep/2010

Abstract:A neutral fat level control agent, a cholesterol level control agent, a free fatty acid level control agent and an anti-obesity agent, each characterized by comprising at least one of protopanaxatriol, panaxatriol, protopanaxadiol and panaxadiol which are aglycons of dammrane-type saponins

and a hyperlipemia-ameliorating agent characterized by comprising at least one of the neutral fat level control agent, the cholesterol level control agent, the free fatty acid level control agent and the anti-obesity agent.

Priority: JP20090289798 Applic. Date: 2009-12-21; JP20100131169 Applic. Date: 2010-06-08

Inventor: KAMBAYASHI HIROAKI [JP]; KITAMURA KUMIKO [JP]; IWASAKI HIDEAKI [JP]


Publication No.: WO2011078134A1  Published: 30/Jun/2011

Title: DIACYLGLYCEROLE ACYLTRANFERASE GENE, AND USE THEREOF

Applicant/Assignee: SUNTORY HOLDINGS LIMITED

Application No.: JP2010/072930   Filing Date: 20/Dec/2010

Abstract:Disclosed are a diacylglycerole acyltranferase, and a polynucleotide which codes for same. Provided are: a polynucleotide containing a base sequence represented by SEQ ID NO: 1 or 4

a polynucleotide which codes for a protein comprising an amino acid sequence represented by SEQ ID NO: 2

an expression vector and transformant containing said polynucleotide

a method for producing an aliphatic acid or a lipid using said transformant

and food containing the aliphatic acid or lipid which were produced by means of said method.

Priority: JP20090289287 Applic. Date: 2009-12-21

Inventor: OCHIAI MISA [JP]


Publication No.: WO2011078143A1  Published: 30/Jun/2011

Title: PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

Applicant/Assignee: SHIONOGI & CO. LTD

Application No.: JP2010/072951   Filing Date: 21/Dec/2010

Abstract:Disclosed is a novel compound which has histamine H4 receptor modulating activity. Specifically disclosed is a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the compound or salt. (In the formula, ring A represents an aromatic heterocyclic ring

-B1 represents a group represented by -X-(CR8aR8b)m-Y

X represents a group represented by N(R7c) or the like

R7c represents a hydrogen atom, a substituted or unsubstituted alkyl group or the like

R8a and R8b each independently represents a hydrogen atom, a halogen atom or the like

m represents an integer of 0-5

Y represents a substituted or unsubstituted cycloalkylthio group or the like

and -B2 represents a group represented by formula (II) (wherein R10s each independently represents a substituted or unsubstituted alkyl group or the like

R11 represents a hydrogen atom, a substituted or unsubstituted alkyl group or the like

and p represents an integer of 0-4) or the like.)

Priority: JP20090290033 Applic. Date: 2009-12-22; JP20100081490 Applic. Date: 2010-03-31

Inventor: MASUDA TSUTOMU [JP]; TACHIBANA YUKI [JP]; MIYAGAWA MASAYOSHI [JP]; HASEGAWA TSUYOSHI [JP]; TOBINAGA HIROYUKI [JP]


Publication No.: WO2011078221A1  Published: 30/Jun/2011

Title: IMIDAZOPYRIDAZINE COMPOUNDS

Applicant/Assignee: AJINOMOTO CO., INC

Application No.: JP2010/073126   Filing Date: 22/Dec/2010

Abstract:By making a search for many various compounds having inhibitory activity against IL-12/IL-23 production, provided are medicinal compositions that contain the compounds and therapeutic or prophylactic agents that contain the compounds and that are efficacious against diseases associated with IL-12/IL-23 overproduction. Disclosed are: imidazopyridazine compounds represented by general formula (I), which have inhibitory activity against IL-12/IL-23 production

pharmaceutically acceptable salts thereof

and useful medicinal compositions and therapeutic or prophylactic agents for diseases associated with IL-12/IL-23 overproduction, characterized by containing the compounds or the pharmaceutically acceptable salts. In general formula (I), A and E are each an optionally substituted aryl group, or the like

U, V, X and Y are each a single bond or the like

T is N=C(Rd) (wherein Rd is a hydrogen atom or the like) or the like

m and n are each 0, 1 or 2

p and q are each 0 or 1

R1 is a hydrogen atom or the like

R2 is a hydrogen atom or the like

R3 is a hydrogen atom or the like

R4 is a hydrogen atom or the like

R5 is a hydrogen atom or the like

R6, R7, R8 and R9 are each a hydrogen atom or the like

and the W-containing group is a 4- to 6-membered cyclic amino group (wherein W is O or the like).

Priority: JP20090293145 Applic. Date: 2009-12-24; JP20100146436 Applic. Date: 2010-06-28

Inventor: YAMAMOTO TAKASHI [JP]; ANDOU AYATOSHI [JP]; HAYAKAWA NOBUHIKO [JP]; NOGUCHI MASATSUGU [JP]; NISHIO HIKARU [JP]; EVIRYANTI AGUNG [JP]; YOKOYAMA RYOHEI [JP]; KAGEYAMA SHUNSUKE [JP]; KURIBAYASHI KANNA [JP]


Publication No.: WO2011078413A1  Published: 30/Jun/2011

Title: SEVEN-MEMBERED RING COMPOUND AND PHARMACEUTICAL USE THEREFOR

Applicant/Assignee: DAIICHI SANKYO COMPANY, LIMITED

Application No.: JP2010/073879   Filing Date: 24/Dec/2010

Abstract:Provided is a compound that has a nitrogen-containing seven-membered ring skeleton represented by formula (I) and is useful in the prevention or treatment of pathological conditions in which chymase is involved. Also provided is a drug, containing the aforementioned compound, for prevention or treatment of disorders in which chymase is involved.

Priority: JP20090296113 Applic. Date: 2009-12-25

Inventor: MUTO TSUYOSHI [JP]; TANAKA TAISAKU [JP]; FUTAMURA JUNKO [JP]; IMAJO SEICHI [JP]; SUGAWARA HAJIME [JP]


Publication No.: WO2011078590A2  Published: 30/Jun/2011

Title: ULTRAVIOLET PROTECTION COMPOSITION COMPRISING A BLT2 INHIBITOR

Applicant/Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Application No.: KR2010/009242   Filing Date: 23/Dec/2010

Abstract:The present invention relates to an ultraviolet protection composition comprising a BLT2 inhibitor, and more particularly, to an ultraviolet protection composition which can be used in skin care formulations, anti-inflammatory agents for the skin, ultraviolet-screening protective formulations for the sking, and the like. According to the present invention, it has been identified that BLT2, which is a cell membrane protein, the ligands thereof, the synthetases thereof, etc. are overexpressed by ultraviolet rays irradiated thereto, and thus induce apoptotic cell death by generating reactive oxygen species and activating MAP kinases. It has also been identified that an inhibitor for inhibiting the expression of said protein can effectively protect the skin, the hair, and the like from ultraviolet rays.

Priority: KR20090130869 Applic. Date: 2009-12-24

Inventor: KIM JAE HONG [KR]; RYU HO CHEOL [KR]


Publication No.: WO2011078795A1  Published: 30/Jun/2011

Title: BRIDGED MORPHOLINO SUBSTITUTED PURINES

Applicant/Assignee: S*BIO PTE LTD

Application No.: SG2010/000474   Filing Date: 16/Dec/2010

Abstract:The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative conditions or disorders including tumours and cancers as well as other disorders or conditions related to or associated with PI3K and/or mTOR kinases.

Priority: US20090288365P Applic. Date: 2009-12-21

Inventor: BLANCHARD STEPHANIE [SG]; DIZHONG CHEN [SG]; HARISH KUMAR MYSORE NAGARAJ [SG]; MEREDITH WILLIAMS [SG]


Publication No.: WO2011079051A1  Published: 30/Jun/2011

Title: FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: US2010/061146   Filing Date: 17/Dec/2010

Abstract:Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

Priority: US20090289969P Applic. Date: 2009-12-23; US20100386964P Applic. Date: 2010-09-27

Inventor: ARIKAWA YASUYOSHI [US]; JONES BENJAMIN [US]; LAM BETTY [US]; NIE ZHE [US]; SMITH CHRISTOPHER [US]; TAKAHASHI MASASHI [US]; DONG QING [US]; FEHER VICTORIA [US]


Publication No.: WO2011079091A1  Published: 30/Jun/2011

Title: (METHYLSULFONYL) ETHYL BENZENE ISOINDOLINE DERIVATIVES AND THEIR THERAPEUTICAL USES

Applicant/Assignee: CELGENE CORPORATION

Application No.: US2010/061420   Filing Date: 21/Dec/2010

Abstract:Provided are (methylsulfonyl)ethyl benzene isoindoline compounds, and pharmaceutically acceptable salts, solvates, or stereoisomers thereof. Methods of use and pharmaceutical compositions of these compounds are also disclosed.

Priority: US20090289356P Applic. Date: 2009-12-22

Inventor: SCHAFER PETER H [US]; FRANK ANTHONY J [US]; MAN HON-WAH [US]; SHANKAR SAI L [US]


Publication No.: WO2011079103A1  Published: 30/Jun/2011

Title: SPIROPIPERIDINE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS

Applicant/Assignee: SANOFI

Application No.: US2010/061464   Filing Date: 21/Dec/2010

Abstract:The present invention discloses and claims a series of substituted spiropiperidine benzylamines of formula (I) wherein R is as described herein. More specifically, the compounds of this invention are inhibitors of ss-tryptase and are, therefore, useful as pharmaceutical agents for treating joint inflammation, including arthritis, rheumatoid arthritisand other arthritic condition such as rheumatoid spondylitis, gouty arthptis, traumatic arthritis, rubella arthritis, psoriatic arthritis, osteoarthritis or other chronic inflammatory joint disease, or diseases of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, interstitial lung diseases, fibrosis, sceleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofibromas, hypertrophic scars, various dermatological conditions, for example, atopic dermatitis and psoriasis, myocardial infarction, stroke, angina or other consequences of atherosclerotic plaque rupture, as well as periodontal disease, diabetic retinopathy, macular degeneration, acute macular degeneration, wet macular degeneration, tumour growth, anaphylaxis, multiple sclerosis, peptic ulcers, or a syncytial viral infection.

Priority: US20090289611P Applic. Date: 2009-12-23; FR20100057200 Applic. Date: 2010-09-10

Inventor: CHOI-SLEDESKI YONG MI [US]; LIANG GUYAN [US]; POLI GREGORY B [US]


Publication No.: WO2011079308A2  Published: 30/Jun/2011

Title: COMPOSITIONS COMPRISING TNF-ALPHA AND IL-6 ANTAGONISTS AND METHODS OF USE THEREOF

Applicant/Assignee: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC

Application No.: US2010/062081   Filing Date: 23/Dec/2010

Abstract:The present disclosure relates to compositions and methods for treating autoimmune diseases including rheumatoid arthritis. In particular, the present disclosure relates to compositions comprising IL-6 antagonists (e.g., anti-IL6 or anti-IL6R or anti-hyperIL6) and TNF-Alpha antagonists (e.g., (anti-TNF or etanercept) and methods of using same in the treatment of rheumatoid arthritis.

Priority: US20090289929P Applic. Date: 2009-12-23

Inventor: MISHER LYNDA E [US]; LOFQUIST ALAN KEITH [US]


Publication No.: WO2011080220A1  Published: 07/Jul/2011

Title: AN AGENT FOR STIMULATING THE EXPRESSION OF LOXL

Applicant/Assignee: BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S

Application No.: EP2010/070662   Filing Date: 23/Dec/2010

Abstract:The present invention concerns a novel agent which is capable of stimulating the expression of LOXL and of increasing quality and functionality of collagen fibres and has anti-oxidizing, anti- elastase, anti-MMP properties as well as its use in producing cosmetic or pharmaceutical compositions, especially dermatological compositions, or food compositions.

Priority: US20100292225P Applic. Date: 2010-01-05; FR20090059682 Applic. Date: 2009-12-31

Inventor: CENIZO VALERIE [FR]; ABDUL MALAK NABIL [FR]; ANDRE VALERIE [FR]


Publication No.: WO2011080722A2  Published: 07/Jul/2011

Title: USE OF SKIN PERMEATION AND RETENTION ENHANCER COMPOUND IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS AND COSMETIC AND PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUND

Applicant/Assignee: NATURA COSMETICOS S.A

Application No.: IB2011/000018   Filing Date: 06/Jan/2011

Abstract:The present invention relates to the use of a compound of general formula: wherein X is a CiO-24 carbon chain with "n" unsaturations wherein "n" is an integer from zero to 3 for the preparation of a cosmetic composition and a pharmaceutical composition to increase the skin permeation and retention of active ingredients. The present invention is suitable for cosmetic and pharmaceutical products the activity of which is enhanced with increased permeation and retention of active ingredients in the skin as a treatment for cellulite and fat accumulation, acne treatment, skin whitening amongst others.

Priority: FR20090059634 Applic. Date: 2009-12-29

Inventor: TEIXEIRA TAGE BIAGGIO ROSA MARIA [BR]; PEDROSO DE OLIVEIRA ANA PAULA [BR]; GESZTESI JEAN-LUC [BR]; JESUS LEDA FERNANDA [BR]; NAKAMURA MARY SANAE [BR]


Publication No.: WO2011080825A1  Published: 07/Jul/2011

Title: ANTI-ALLERGIC AGENT

Applicant/Assignee: NISSHIN PHARMA INC, SHIZUOKA PREFECTURE PUBLIC UNIVERSITY CORPORATION

Application No.: JP2009/071769   Filing Date: 28/Dec/2009

Abstract:Disclosed is an agent which can be produced readily, is easy to ingest, and has an anti-allergic activity. An extract of green soybean with a solvent can be used as an anti-allergic agent. The extract of green soybean with a solvent has an inhibitory activity on the production of IgE and an activity of deflecting the Th1-Th2 balance in the Th1 side direction, and is therefore useful as an anti-allergic agent.

Priority:

Inventor: ISEMURA MAMORU [JP]; KANEKO AKIHIRO [JP]; YASUI KENSUKE [JP]


Publication No.: WO2011080887A1  Published: 07/Jul/2011

Title: SEBUM SECRETION-BLOCKING COMPOSITION, AND FOOD OR BEVERAGE CONTAINING SAME

Applicant/Assignee: LOTTE CO., LTD

Application No.: JP2010/007370   Filing Date: 20/Dec/2010

Abstract:Disclosed are a sebum secretion-blocking composition and a food or beverage containing the sebum secretion-blocking composition. Extensive studies have been made, and it is found that the secretion of sebum can be blocked when a collagen peptide produced by hydrolyzing collagen is ingested orally. Thus, specifically disclosed are: an oral sebum secretion-blocking composition containing a collagen hydrolysate

and a food or beverage containing the composition.

Priority: JP20090297848 Applic. Date: 2009-12-28

Inventor: ITO MASANORI [JP]; YUGI MASAYUKI [JP]; SHIMIZU KATSUMASA [JP]; TAKAMATSU CHIHARU [JP]; OTANI ERIKO [JP]; HASHIZUME TAKAYA [JP]


Publication No.: WO2011081173A1  Published: 07/Jul/2011

Title: TETRACYCLIC COMPOUND

Applicant/Assignee: KYOWA HAKKO KIRIN CO., LTD

Application No.: JP2010/073681   Filing Date: 28/Dec/2010

Abstract:A tetracyclic compound represented by formula (I) (wherein Q represents -O- or the like

X represents CH or the like

R1 represents a lower alkyl group or the like

R2 and R3 independently represent a hydrogen atom or the like

and R4 and R5 independently represent a lower alkyl group which may have a substituent, or the like) or a pharmaceutically acceptable salt thereof, which has a glucocorticoid receptor regulation activity and the like

and others.

Priority: JP20090299077 Applic. Date: 2009-12-29

Inventor: UCHIDA KENJI; ERA TOMOHIRO; NAKASATO YOSHISUKE


Publication No.: WO2011081715A1  Published: 07/Jul/2011

Title: TOPICAL ACYL GLUTATHIONE PSORIASIS FORMULATIONS

Applicant/Assignee:

Application No.: US2010/055955   Filing Date: 09/Nov/2010

Abstract:Topical compositions to treat inflammatory skin conditions such as psoriasis comprise an effective amount of S-acyl glutathione derivative and a carrier. Methods for treating inflammatory skin conditions such as psoriasis comprise applying a composition containing S-acyl glutathione derivative in a dermatologically acceptable carrier to skin tissue. The acyl group is a saturated or unsaturated aliphatic C12-C24 group, preferably an unsaturated C16 - C24 group, most preferably an unsaturated C18 group. In particularly preferred embodiments, the acyl group is a linoleoyl group.

Priority: US2009-647622 Applic. Date: 2009-12-28

Inventor: PERRICONE NICHOLAS V [US]


Publication No.: WO2011081716A1  Published: 07/Jul/2011

Title: TOPICAL ACYL GLUTATHIONE FORMULATIONS

Applicant/Assignee: N.V. PERRICONE LLC

Application No.: US2010/055969   Filing Date: 09/Nov/2010

Abstract:Topical compositions to prevent and to treat skin aging comprise an effective amount of S-acyl glutathione derivative and a carrier. Methods for preventing and treating skin aging comprise applying a composition containing S-acyl glutathione derivative in a dermatologically acceptable carrier to skin tissue. The acyl group is a saturated or unsaturated aliphatic C12-C24 group, preferably an unsaturated C16 - C24 group, most preferably an unsaturated C18 group. In particularly preferred embodiments, the acyl group is a linoleoyl group.

Priority: US2009-647629 Applic. Date: 2009-12-28; US2010-718706 Applic. Date: 2010-03-05

Inventor: PERRICONE NICHOLAS V [US]


Publication No.: WO2011082732A1  Published: 14/Jul/2011

Title: SPHINGOSINE KINASE INHIBITORS

Applicant/Assignee: MERCK PATENT GMBH

Application No.: EP2010/007003   Filing Date: 18/Nov/2010

Abstract:The invention relates to compounds of formula (I), where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, M1, M2, M3, M4, Y1, Y2, V, W, n, m and o have the meanings specified herein, and to the physiologically compatible salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including the mixtures thereof in all ratios, for use in the treatment of diseases that are influenced by inhibiting sphingosine kinase 1.

Priority: EP20090015631 Applic. Date: 2009-12-17

Inventor: STIEBER FRANK [DE]; WIENKE DIRK [DE]


Publication No.: WO2011083738A1  Published: 14/Jul/2011

Title: DNA DAMAGE REPAIR PROMOTER FOR ORAL APPLICATION, AND ELASTASE ACTIVITY INHIBITOR FOR ORAL APPLICATION

Applicant/Assignee: KABUSHIKI KAISHA YAKULT HONSHA

Application No.: JP2010/073796   Filing Date: 28/Dec/2010

Abstract:Disclosed are a DNA damage repair promoter for oral application and an elastase activity inhibitor for oral application. Specifically disclosed are a DNA damage repair promoter for oral application and an elastase activity inhibitor for oral application, each of which comprises a bacterium belonging to the genus bifidobacterium as an active ingredient.

Priority: JP20100001576 Applic. Date: 2010-01-06; JP20100001550 Applic. Date: 2010-01-06

Inventor: SUGIMOTO SAHO [JP]; SONE TOSHIRO [JP]; CHIBA KATSUYOSHI [JP]


Publication No.: WO2011083853A1  Published: 14/Jul/2011

Title: ANTI-ATOPIC DERMATITIS AGENT

Applicant/Assignee: MARUDAI FOOD CO., LTD

Application No.: JP2011/050199   Filing Date: 07/Jan/2011

Abstract:Disclosed is an anti-atopic dermatitis agent which ameliorate and treat the conditions of atopic dermatitis, can be used continuously for a long period, has less risk of adverse side effects, and can be applied to pregnant women, infants and the like. Specifically disclosed is an anti-atopic dermatitis agent comprising a sphingomyelin-containing material derived from a chicken skin as an active ingredient. The anti-atopic dermatitis agent comprises, as an active ingredient, a sphingomyelin-containing material derived from a chicken skin that has been eaten conventionally as a food. Therefore, the anti-atopic dermatitis agent is highly safe and has less adverse side effect even when used continuously for a long period.

Priority: JP20100003092 Applic. Date: 2010-01-08

Inventor: SUGIYAMA MASAAKI [JP]; KODAMA YOSHIROU [JP]; FUCHU HIDETAKA [JP]; FUJINO TAKEHIKO [JP]; YUNOKI KEITA [JP]


Publication No.: WO2011085013A2  Published: 14/Jul/2011

Title: VITAMIN C COMPOSITION FOR USE IN THE PREVENTION AND TREATMENT OF STRETCH MARKS, RADIATION DERMATITIS, AND OTHER SKIN CONDITIONS AND METHODS OF USING THE SAME

Applicant/Assignee:

Application No.: US2011/020238   Filing Date: 05/Jan/2011

Abstract:A formulation for a stable ascorbic acid composition which, in a simplified form, is comprised of ascorbic acid in solution with a hygroscopic compound (i.e., a substance with the ability to attract water molecules from the surrounding environment through either absorption or adsorption). Also disclosed herein are methods for the production of such compounds and methods of using such compounds in the prevention, inhibition and treatment of striae gravidarum, radiation dermatitis, rhytids, lentigoes, dyschromia, sun-damage induced hyperpigmentation, cellulite, scars and purpura, among other skin diseases or conditions.

Priority: US20100292365P Applic. Date: 2010-01-05

Inventor: KAPLAN DAVID L [US]


Publication No.: WO2011085276A2  Published: 14/Jul/2011

Title: METHODS AND KITS TO PREDICT PROGNOSTIC AND THERAPEUTIC OUTCOME IN SMALL CELL LUNG CANCER

Applicant/Assignee: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, SCOTTSDALE HEALTHCARE

Application No.: US2011/020612   Filing Date: 08/Jan/2011

Abstract:Disclosed herein are methods used in the identification of cancer patients likely or unlikely to respond to systemic chemotherapy, methods of treating cancer patients based upon the identification, and kits that facilitate the identification. The methods and kits involve detecting the expression of specific microRNA.

Priority: US20100293634P Applic. Date: 2010-01-09

Inventor: WEISS GLEN


Publication No.: WO2011085278A2  Published: 14/Jul/2011

Title: TOPICAL SCAR TREATMENT COMPOSITION

Applicant/Assignee: C & H SCIENTIFIC, LLC

Application No.: US2011/020614   Filing Date: 08/Jan/2011

Abstract:An anhydrous topical scar treatment product having a water activity of less than 0.50, the product being comprised of (i) a silicone elastomer, (ii) a non-volatile, anhydrous carrier vehicle, (iii) L-ascorbic acid in the form of fine powder, at a concentration of concentration of from 7.5% to 15% by weight, based on the total weight of the anhydrous topical scar treatment product, and (iv) an oil-soluble Vitamin C derivative at a concentration of from 5% to 10% by weight, based on the total weight of the anhydrous topical scar treatment product.

Priority: US20100293456P Applic. Date: 2010-01-08

Inventor: CHRYSOPOULO MINAS; HOFFMAN ROLAND; GOLDSBERRY SUSAN


Publication No.: WO2011085356A2  Published: 14/Jul/2011

Title: POVIDONE-IODINE AND SUCROSE WOUND HEALING DRESSING

Applicant/Assignee: A2 BIOSCIENCE PTE LTD

Application No.: US2011/020800   Filing Date: 11/Jan/2011

Abstract:The present invention relates to a composition and wound dressing for delivering a composition comprising povidone-iodine and sucrose mixture. The composition is gelled and, in one embodiment, is impregnated on a gauze or other like material for application to an exuding or non-exuding wound.

Priority: US2010-685370 Applic. Date: 2010-01-11

Inventor: GILMAN MILES E [US]; BERTINO JOSEPH S [US]


Publication No.: WO2011085484A1  Published: 21/Jul/2011

Title: ANTIMICROBIAL NITRIC OXIDE COMPOSITIONS

Applicant/Assignee: NITRIC SOLUTIONS INC

Application No.: CA2011/000042   Filing Date: 13/Jan/2011

Abstract:The present disclosure relates to gels comprising from about 100 [mu]M to about 10 mM of nitric oxide. The gels have an antimicrobial effect. The present gels may have a pH of from about 3 to about 6 and a viscosity at 21 DEG C is from about 5 mPa.s to about 100,000 mPa.s.

Priority: US20100294623P Applic. Date: 2010-01-13

Inventor: MILLER CHRISTOPHER [CA]; REGEV-SHOSHANI GIIIY [CA]; AV-GAY YOSSEF [CA]


Publication No.: WO2011085701A1  Published: 21/Jul/2011

Title: STABLE PROTEIN KINASE ACTIVATORS, PREPARATION METHODS AND USES THEREOF

Applicant/Assignee: UNITEDHEALTH (BEIJING) PHARMACEUTICAL TECHNOLOGY CO., LTD

Application No.: CN2011/070355   Filing Date: 18/Jan/2011

Abstract:Protein kinase activators, hydrates of adenosine cyclophosphate salt, preparation methods and uses thereof are disclosed. The hydrates of adenosine cyclophosphate salt have excellent storage stability and are not liable to absorb moisture. Furthermore, the hydrates of adenosine cyclophosphate salt are useful for treating or preventing diseases such as stenocardia, cardiac failure, myocardial infarction, myocarditis, arrhythmia, cardiogenic shock, acute leukemia, nerve system diseases, respiratory system diseases, senile chronic bronchitis, hepatitis and psoriasis, and for improving symptoms of cardiopalmus, shortness of breath, chest distress and the like of rheumatic heart disease.

Priority: CN20101029032 Applic. Date: 2010-01-18

Inventor: LIU LI [CN]


Publication No.: WO2011086053A1  Published: 21/Jul/2011

Title: TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Applicant/Assignee: F. HOFFMANN-LA ROCHE AG

Application No.: EP2011/050239   Filing Date: 11/Jan/2011

Abstract:The invention provides novel compounds of formula (I) having the general formula, wherein R1, R2, R3, X and Y are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.

Priority: US20100294404P Applic. Date: 2010-01-12; US20100366785P Applic. Date: 2010-07-22

Inventor: BABU SRINIVASAN [US]; BERGERON PHILLIPPE [US]; DRAGOVICH PETER [US]; DYKE HAZEL JOAN [GB]; GIBBONS PAUL [US]; GRADL STEFAN [US]; HANAN EMILY [US]; HURLEY CHRISTOPHER [GB]; JOHNSON TONY [GB]; KOEHLER MICHAEL [US]; KULAGOWSKI JANUSZ JOSEF [GB]; LABADIE SHARADA SHENVI [US]; LYSSIKATOS JOSEPH P [US]; MENDONCA ROHAN [US]; PULK REBECCA [US]; WARD STUARD [GB]; WASZKOWYCZ BOHDAN [GB]; ZAK MARK [US]


Publication No.: WO2011086532A1  Published: 21/Jul/2011

Title: NEW LIPO-PHOSPHATED OR LIPO-SULPHATED COMPOUND, COMPOSITIONS COMPRISING IT AND TOPICAL USES THEREOF

Applicant/Assignee: SEDERMA, PESCHARD, OLIVIER

Application No.: IB2011/050196   Filing Date: 17/Jan/2011

Abstract:The compound according to the invention has the following developed fomula IX: Wherein: X = PO(OH)2, SO2(OH)

PO(OH)(Xaa)m or SO2(Xaa)m

A = H

OH

NH2 or akyl (1-6C)

n = 1 to 4

Y= -CO- OR2

-CO-NR3R4, -0-CO-R2, -C=CR2

R2 = an alkyl, aryl, aralkyl, acyl, sulfonyl, sugar or alkoxy chain of 1 to 24 carbon atoms, linear, branched or cyclic, with or without substitutions, saturated or not, hydroxylated or not, sulfurated or not

R5 = OH, O-alk (1-6C), (Xaa)m, NH2 or NH-alkyl(l-6C)

Xaa = peptide of m aminoacids Xaa with m from 1 to 10

The compound is preferably phosphated, obtained from malic acid and having the following developed formula: A cosmetic composition comprising the compound of the present invention can improve the general condition of the skin, for example hydration, lightening and mechanical properties.

Priority: FR20100050306 Applic. Date: 2010-01-18

Inventor: FOURNIAL ARNAUD [FR]; MONDON PHILIPPE [FR]


Publication No.: WO2011087006A1  Published: 21/Jul/2011

Title: PIGMENTATION-PREVENTING OR -AMELIORATING AGENT

Applicant/Assignee: POLA CHEMICAL INDUSTRIES INC

Application No.: JP2011/050314   Filing Date: 12/Jan/2011

Abstract:Disclosed are: a pigmentation-preventing or -ameliorating agent having a novel base structure

and an external preparation for skin, which comprises the component. Specifically disclosed are: a pigmentation-preventing or -ameliorating agent comprising a compound represented by general formula (1) or an isomer and/or a pharmacologically acceptable salt thereof

and an external preparation for skin, which comprises the component. [In the formula, R1 represents a hydrogen atom, or a linear or branched alkyl group having 1 to 8 carbon atoms

R2 represents a hydrogen atom, or an aliphatic hydrocarbon group having 1 to 8 carbon atoms, an aromatic group having 5 to 12 carbon atoms, a polycyclic fused aromatic group or a heterocyclic group which is unsubstituted or has a substituent

R3 represents an aromatic group having 5 to 15 carbon atoms, a polycyclic fused aromatic group or a heterocyclic group which is unsubstituted or has a substituent

n represents an integer of 1 or 2

and m represents an integer of 0 to 3.]

Priority: JP20100003785 Applic. Date: 2010-01-12

Inventor: YAMASAKI TAKASHI [JP]; SAITOH YUKO [JP]; KONDO CHIHIRO [JP]


Publication No.: WO2011088120A1  Published: 21/Jul/2011

Title: ANTIBODY FORMULATION AND THERAPEUTIC REGIMENS

Applicant/Assignee: AMGEN INC

Application No.: US2011/020985   Filing Date: 12/Jan/2011

Abstract:The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.

Priority: US20100295387P Applic. Date: 2010-01-15; US20100422059P Applic. Date: 2010-12-10

Inventor: LIU DINGJIANG [US]; HUANG HOLLY ZHUOHONG [US]; MARTIN DAVID ANDREW [US]; RUSSELL CHRISTOPHER BOYD [US]; SALINGER DAVID H [US]; BAUMGARTNER SCOTT WALTER [US]; ENDRES CHRISTOPHER J [US]


Publication No.: WO2011088137A2  Published: 21/Jul/2011

Title: BAD PATHWAY GENE SIGNATURE

Applicant/Assignee: H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE

Application No.: US2011/021013   Filing Date: 12/Jan/2011

Abstract:The invention provides materials and methods for prognosing cancer, and predicting an individual's responsiveness to cancer treatments, methods of treating cancer, and materials and methods for obtaining BAD pathway gene expression profiles useful in carrying out the methods of the invention.

Priority: US20100294168P Applic. Date: 2010-01-12

Inventor: LANCASTER JOHNATHAN M [US]; CHEN DUNG TSA [US]; XIONG YIN [US]


Publication No.: WO2011088209A2  Published: 21/Jul/2011

Title: 1-DEOXY ANALOGS OF VITAMIN D-RELATED COMPOUNDS

Applicant/Assignee: CYTOCHROMA INC, JOHNS HOPKINS UNIVERSITY

Application No.: US2011/021129   Filing Date: 13/Jan/2011

Abstract:This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.

Priority: US20100294741P Applic. Date: 2010-01-13

Inventor: POSNER GARY H [US]; HESS LINDSEY C [US]; KALINDA ALVIN S [US]; SLACK RACHEL D [US]; SAHA UTTAM [CA]; PETKOVICH P MARTIN [CA]


Publication No.: WO2011088413A2  Published: 21/Jul/2011

Title: LYOPHILIZED CAKE FORMULATIONS

Applicant/Assignee: LITHERA, INC

Application No.: US2011/021424   Filing Date: 14/Jan/2011

Abstract:Provided herein are lyophilized cake forms of fluticasone, salmeterol, or a pharmaceutically acceptable salt or a combination thereof which provides room temperature stablility for an extended period of time. Upon reconstitution with an acceptable solvent (e.g., a carrier or diluent), the reconstituted pharmaceutical or cosmetic formulation provides a sterile, non-suspension form suitable for parenteral injectable administration, including subcutaneous injection.

Priority: US20100295646P Applic. Date: 2010-01-15

Inventor: DOBAK JOHN DANIEL [US]; KEMMERER CHRIS [US]; LOCKE KENNETH WALTER [US]


Publication No.: WO2011089161A1  Published: 28/Jul/2011

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING LIGNANS AND THEIR DERIVATIVES FOR THE MEDICAL MANAGEMENT OF ANGIOGENESIS AND HYPOVASCULARITY

Applicant/Assignee: MEDIZINISCHE UNIVERSITAET WIEN, UNIVERSITAET INNSBRUCK, MEDIZINISCHE UNIVERSITAET INNSBRUCK

Application No.: EP2011/050701   Filing Date: 19/Jan/2011

Abstract:The present invention relates to a pharmaceutical composition for stimulating angiogenesis and/or the treatment or prevention of hypovasc?larity and/or the prevention and/or treatment of an angiogenic disorder/disease, whereby the composition comprises specific compounds which may be obtained from Leontopodium alpinum Cass, (Edelweiss). These compounds relate to lignan compounds as shown in herein disclosed formula 1. A preferred compound in this context is leologin - IUPAC name [(2S,3R,4R)-4-(3,4-dimethoxybenzyl)-2-(3,4- dimethoxyphenyl)tetxahydrofuran-3-yl]methyl (2Z)-2-methylbut-2-enoat], and even more particularly 5-methoxy-leoligin (IUPAC name: [(25,3R,4R)-4-(3,4-dimethoxybenzyl)-2- (3,4,5-trimethoxyphenyl)tetrahydrofuran-3-yl]methyl-(2Z)-2-methylbut-2-enoat) and derivatives thereof. Corresponding means and methods in respect of medical uses of these compounds are described. The compounds provided herein may particularly be useful in the treatment of wound healing, in particular traumatic wounds (like, but not limited to surface and skin wounds), non-diabetic retinopathy, vascular obliteration. The compounds derived from Leontopodium alpinum Cass. (Edelweiss) as described herein are also useful in the re-vascularization of tissue after amputation as well during or after transplantation of tissues or organs. These compounds are also useful in the medical intervention of arterio- and veno-microvasculopathy of blood vessels, in particular retinal microvasculopathy, arterio- and veno-microangiopathy that preferably cannot be treated by surgery, in ischemic diseases or ischemic disorders or in the treatment or prevention of necrosis/necrotic events, in particular of ischemic diseases or necrosis/necrotic events that cannot be treated by surgery. These compounds may also be used in the treatment or prevention of stable angina abdominalis, vascular dementia, impotence or penile dysfunction and the like and they may be employed in the reactivation of necrotisising tissue or in the reactivation of hibernating tissue.

Priority: US20100336288P Applic. Date: 2010-01-19; EP20100151086 Applic. Date: 2010-01-19

Inventor: BERNHARD DAVID [AT]; STUPPNER HERMANN [AT]; SCHWAIGER STEFAN [AT]; WIEDEMANN DOMINIK [AT]; UNTERGASSER GEROLD [AT]


Publication No.: WO2011089173A1  Published: 28/Jul/2011

Title: HYDROGEL OF MICROSPHERES

Applicant/Assignee: BIOPHARMEX HOLDING LIMITED

Application No.: EP2011/050727   Filing Date: 20/Jan/2011

Abstract:The Invention relates to an injectable composition intended for tissue induction of the soft tissues by a system of immediate and prolonged progressive release. In particular, the invention relates to a composition comprising a gel of at least one first biodegradable polymer forming a first agent for filling soft tissues in an animal, and a suspension in this gel of microspheres with an average diameter between 5 and 50 micrometres, said microspheres comprising 50 to 90 wt.% of at least one biodegradable polysaccharide relative to the total weight of the microspheres, said microspheres inducing a second filling by tissue induction and containing at least one second biodegradable polymer forming at least one third filling of the soft tissues in an animal.

Priority: US20100303094P Applic. Date: 2010-02-10; FR20100050355 Applic. Date: 2010-01-20

Inventor: LAUGIER ELIZABETH [CH]


Publication No.: WO2011090062A1  Published: 28/Jul/2011

Title: PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT

Applicant/Assignee: TAIHO PHARMACEUTICAL CO., LTD

Application No.: JP2011/050840   Filing Date: 19/Jan/2011

Abstract:Disclosed are a piperazine compound represented by formula (1) and a salt thereof. (In the formula, X represents CH or a N atom, R1 represents a C1-6 alkyl group

R2 represents any of a C1-6 alkyl group optionally having a substituted base, a C2-6 alkenyl group optionally having a substituted base, a -(C=O)-N(R3)(R4) group, or a -(C=O)-OR5 group

R3 and R4 can be the same or different and represent a hydrogen atom, or a C1-6 alkyl group optionally having a substituted group

or, R3 and R4, together with the nitrogen atom bound to each, may optionally form a saturated heterocyclic group

and R5 represents a hydrogen atom, or a C1-6 alkyl group or an aralkyl group optionally having a substituted group.)

Priority: JP20100012501 Applic. Date: 2010-01-22

Inventor: URADE YOSHIHIRO [JP]; KITADE MAKOTO [JP]; SHIGENO KAZUHIKO [JP]; YAMANE KEIKO [JP]; TANAKA KATSUNAO [JP]


Publication No.: WO2011090926A1  Published: 28/Jul/2011

Title: NUTRITIONAL FORMULAS CONTAINING SYNBIOTICS

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: US2011/021506   Filing Date: 18/Jan/2011

Abstract:The present disclosure relates to a synbiotic composition comprising the probiotic Lactobacillus rhamnosus HNOO1 and a carbohydrate-based prebiotic such as fructooligosaccharides, galactooligosaccharides, human milk oligosaccharides, or combinations thereof, and the use of the composition for the prevention and/or treatment of allergic disease. In one embodiment, the symbiotic composition comprising the probiotic and prebiotic may be included in a nutritional composition or infant formula.

Priority: US20100296217P Applic. Date: 2010-01-19

Inventor: THOMAS DEBRA L [US]; BUCK RACHAEL H [US]


Publication No.: WO2011091084A2  Published: 28/Jul/2011

Title: STABILIZED PROTEASES FOR USE IN SKIN CARE

Applicant/Assignee: BASF CORPORATION

Application No.: US2011/021773   Filing Date: 19/Jan/2011

Abstract:Disclosed is an invention which relates to synthesizing immobilized and crosslinked proteases derived from plants for use as skin care agents. The resulting stabilized protease will minimally penetrate the skin because of its immobilized nature. It will retain activity because of its crosslinked nature and, in certain embodiments, due to its stabilization via physical additives. The present invention relates in particular to a linked papain product used in topical skin applications.

Priority: US20100296052P Applic. Date: 2010-01-19

Inventor: CHAVAN MANASI [US]

Clck to enlarge and view details
World  Patents Published  in 2012
World  Patents Published  in 2011 Page 2
World  Patents Published  in 2010
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..